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Background: Atrial fibrillation (AF) is the most common type of cardiac arrhythmia and is associated
with an increased risk of stroke and congestive heart failure. Lead-I electrocardiogram (ECG) devices are
handheld instruments that can be used to detect AF at a single time point in people who present with
relevant signs or symptoms.
Objective: To assess the diagnostic test accuracy, clinical impact and cost-effectiveness of using single
time point lead-I ECG devices for the detection of AF in people presenting to primary care with relevant
signs or symptoms, and who have an irregular pulse compared with using manual pulse palpation (MPP)
followed by a 12-lead ECG in primary or secondary care.
Data sources: MEDLINE, MEDLINE Epub Ahead of Print and MEDLINE In-Process & Other Non-Indexed
Citations, EMBASE, PubMed, Cochrane Databases of Systematic Reviews, Cochrane Central Database of
Controlled Trials, Database of Abstracts of Reviews of Effects and the Health Technology Assessment
Database.
Methods: The systematic review methods followed published guidance. Two reviewers screened the
search results (database inception to April 2018), extracted data and assessed the quality of the included
studies. Summary estimates of diagnostic accuracy were calculated using bivariate models. An economic
model consisting of a decision tree and two cohort Markov models was developed to evaluate the
cost-effectiveness of lead-I ECG devices.
Results: No studies were identified that evaluated the use of lead-I ECG devices for patients with signs or
symptoms of AF. Therefore, the diagnostic accuracy and clinical impact results presented are derived from
an asymptomatic population (used as a proxy for people with signs or symptoms of AF). The summary
sensitivity of lead-I ECG devices was 93.9% [95% confidence interval (CI) 86.2% to 97.4%] and summary
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specificity was 96.5% (95% CI 90.4% to 98.8%). One study reported limited clinical outcome data.
Acceptability of lead-I ECG devices was reported in four studies, with generally positive views. The de novo
economic model yielded incremental cost-effectiveness ratios (ICERs) per quality-adjusted life-year (QALY)
gained. The results of the pairwise analysis show that all lead-I ECG devices generated ICERs per QALY
gained below the £20,000–30,000 threshold. Kardia Mobile (AliveCor Ltd, Mountain View, CA, USA) is
the most cost-effective option in a full incremental analysis.
Limitations: No published data evaluating the diagnostic accuracy, clinical impact or cost-effectiveness of
lead-I ECG devices for the population of interest are available.
Conclusions: Single time point lead-I ECG devices for the detection of AF in people with signs or
symptoms of AF and an irregular pulse appear to be a cost-effective use of NHS resources compared with
MPP followed by a 12-lead ECG in primary or secondary care, given the assumptions used in the base-case
model.
Future work: Studies assessing how the use of lead-I ECG devices in this population affects the number
of people diagnosed with AF when compared with current practice would be useful.
Study registration: This study is registered as PROSPERO CRD42018090375.
Funding: The National Institute for Health Research Health Technology Assessment programme.
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Cost-effectiveness analysis An economic analysis that converts effects into health terms and describes
the costs per additional health gain.
Decision modelling A theoretical construct that allows the comparison of the relationship between the
costs and outcomes of alternative health-care interventions.
Decision tree A model of a series of related choices and their possible outcomes.
False negative An incorrect negative test result in an affected individual with a negative test result.
False positive An incorrect positive test result in an unaffected individual with a positive test result.
Incremental cost-effectiveness ratio The difference in the mean costs of two interventions in the
population of interest divided by the difference in the mean outcomes in the population of interest.
Index test The test whose performance is being evaluated.
Markov model An analytical method particularly suited to modelling repeated events or the progression
of a chronic disease over time.
Meta-analysis A statistical technique used to combine the results of two or more studies and obtain a
combined estimate of effect.
Negative predictive value The probability that people with a negative test result truly do not have the
disease.
Opportunity cost The cost of forgone outcomes that could have been achieved through alternative
investments.
Positive predictive value The probability that people with a positive test result truly have the disease.
Probabilistic sensitivity analysis A method of quantifying uncertainty in a mathematical model, such as
a cost-effectiveness model.
Receiver operating characteristic curve A graph that illustrates the trade-offs between sensitivity and
specificity that result from varying the diagnostic threshold.
Reference standard The best currently available diagnostic test against which the index test is compared.
Sensitivity The proportion of people with the target disorder who have a positive test result.
Specificity The proportion of people without the target disorder who have a negative test result.
True negative A correct negative test result in an unaffected individual with a negative test result.
True positive A correct positive test result in an affected individual with a positive test result.
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CVE cardiovascular event
DADS directly accessed diagnostic
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DARE Database of Abstracts of
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HRG Healthcare Resource Group
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NICE National Institute for Health
and Care Excellence
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OAC oral anticoagulant
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A trial fibrillation (AF) is the most common type of abnormal heart rhythm. People with AF are morelikely to have a serious stroke or die than people without the condition. Many people go to their
general practitioner (GP) with the signs or symptoms commonly linked to AF, such as feeling dizzy, being
short of breath, feeling tired and having heart palpitations. GPs check for AF by taking the patient’s pulse
by hand. If the GP thinks that the patient might have AF, a 12-lead electrocardiogram (ECG) test is
arranged. Lead-I (i.e. one lead) ECGs are handheld electronic devices that could detect AF more accurately
than a manual pulse check. If GPs were to routinely use lead-I ECG devices, people with suspected AF
could receive treatment while waiting for the AF diagnosis to be confirmed by a 12-lead ECG. This study
aimed to assess whether or not the use of lead-I ECGs in GP surgeries could benefit these patients and
offer good value for money to the NHS. All studies that examined how well lead-I ECGs identified people
with AF were reviewed, and the economic value of using these devices was assessed. No evidence was
found that examined the use of lead-I ECGs for people with signs or symptoms of AF. As an alternative,
evidence for the use of lead-I ECGs for people with no symptoms of AF was searched for and these data
were used to assess value for money. The study found that using a manual pulse check followed by a lead-I
ECG offers value for money when compared with a manual pulse check followed by a 12-lead ECG. This is
mostly because patients with AF can begin treatment earlier when a GP has access to a lead-I ECG device.
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Atrial fibrillation (AF) is the most common type of cardiac arrhythmia and is associated with conditions
such as hypertension, heart failure, coronary artery disease, valvular heart disease, obesity, diabetes
mellitus and chronic kidney disease. The National Institute for Health and Care Excellence (NICE) clinical
guideline CG180 [NICE. Atrial Fibrillation: Management. Clinical Guideline CG180. 2014. URL: www.nice.
org.uk/guidance/cg180/chapter/Introduction (accessed January 2018)] recommends that, after positive
manual pulse palpation (MPP), the diagnosis of AF should be confirmed based on the results of an
electrocardiogram (ECG). People who present to primary care with signs or symptoms of the condition
(e.g. palpitations, dizziness, shortness of breath and tiredness) and who have an irregular pulse should
receive a referral for a 12-lead ECG in the days following their initial primary care appointment if a 12-lead
ECG is not available in the practice. Lead-I ECG devices are handheld instruments that can be used in
primary care to detect AF at a single time point in people who present with relevant signs or symptoms
and who have an irregular pulse.
Objectives
The aim of this study was to assess the diagnostic test accuracy (DTA), the clinical impact and the cost-
effectiveness of using single time point lead-I ECG devices for the detection of AF in people presenting to
primary care with signs or symptoms of the condition and who have an irregular pulse compared with
using MPP followed by a 12-lead ECG in primary or secondary care (prior to initiation of anticoagulation
therapy). To achieve this aim we:
l conducted systematic reviews of the diagnostic accuracy and clinical impact of lead-I ECG devices for
(1) detecting AF in people presenting to primary care with signs or symptoms of the condition, or,
if evidence was not available for this population/setting, for (2) detecting AF in an asymptomatic
population, defined as people presenting to any setting without symptoms of AF, with or without a
previous diagnosis of AF
l developed an economic model to assess the cost-effectiveness of using single time point lead-I ECG
devices compared with using MPP followed by a 12-lead ECG in primary or secondary care (prior to
initiation of anticoagulation therapy) in people presenting to primary care with signs or symptoms of AF
who have an irregular pulse.
Methods: assessment of clinical impact and diagnostic test accuracy
Electronic databases [MEDLINE, MEDLINE Epub Ahead of Print and MEDLINE In-Process and Other
Non-Indexed Citations, EMBASE, PubMed, Cochrane Databases of Systematic Reviews (CDSR), Cochrane
Central Database of Controlled Trials (CENTRAL), Database of Abstracts of Reviews of Effects (DARE) and the
Health Technology Assessment Database] were searched from inception up to March 2018. Eligible studies
assessed the diagnostic accuracy or clinical impact of specified lead-I ECG devices [i.e. imPulse (Plessey
Semiconductors Ltd, Ilford, UK), Kardia Mobile (AliveCor Inc., Mountain View, CA, USA), MyDiagnostick
(MyDiagnostick Medical B.V., Maastricht, the Netherlands), RhythmPad GP (Cardiocity, Lancaster, UK)
and Zenicor ECG (Zenicor Medical Systems AB, Stockholm, Sweden)] in people presenting with signs or
symptoms of AF and who have an irregular pulse. Studies that assessed the diagnostic accuracy of lead-I
ECG devices used at a single time point to detect AF in an asymptomatic population were considered
for inclusion owing to the non-existence of studies in symptomatic populations. We considered an
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asymptomatic population to comprise people not presenting with symptoms of AF, with or without a
previous diagnosis of AF.
Two reviewers independently screened the search results, extracted data and assessed the methodological
quality of the included diagnostic accuracy studies using the QUality Assessment of Diagnostic Accuracy
Studies–2 (QUADAS-2) tool. The methodological quality of cross-sectional and case–control studies
evaluating the clinical impact of lead-I ECG devices was assessed using the Newcastle–Ottawa quality
assessment scale.
The sensitivity and specificity of each index test were summarised in forest plots and plotted in receiver
operating characteristic space. Pooled estimates of sensitivity and specificity with 95% confidence intervals
(CIs) were obtained using bivariate models. When there were few studies, the bivariate model was reduced
to two univariate random-effects logistic regression models by assuming no correlation between sensitivity
and specificity across studies. Judgement of heterogeneity, and hence the choice of more simple hierarchical
models, was informed by the visual appearance of forest plots and summary receiver operating characteristic
plots, in addition to clinical judgement regarding potential sources of heterogeneity. The analyses were
stratified by whether a diagnosis of AF was made by a trained health-care professional interpreting the
lead-I ECG trace, or by the lead-I ECG algorithm. For both sets of analyses, the reference standard was an
interpretation of the 12-lead ECG trace by a trained health-care professional. When studies reported data
for two types of lead-I ECG device and two different interpreters, one data set was chosen and sensitivity
analyses were performed using the alternative data sets. Clinical impact outcomes were synthesised
narratively.
Methods: assessment of cost-effectiveness
The literature was reviewed to identify published economic evaluations on the use of lead-I ECG devices
for the detection of AF in people presenting to primary care with signs or symptoms of the condition and
who had an irregular pulse. Electronic databases (MEDLINE, MEDLINE Epub Ahead of Print and MEDLINE
In-Process and Other Non-Indexed Citations, EMBASE, PubMed, EconLit and the NHS Economic Evaluation
Database) were searched from inception up to April 2018. Additional searches were carried out to identify
supporting information on costs and health state utility data.
A de novo economic analysis was undertaken that followed the diagnostic pathway for patients presenting
to primary care with signs or symptoms indicative of AF and an irregular pulse. The sensitivity and specificity
of the different lead-I ECG devices were taken from the results of the review DTA. The probabilistic
sensitivity analysis results were presented to reflect uncertainty in the model inputs; extensive deterministic
sensitivity analysis and scenario analysis were also undertaken to assess the impact of uncertainty in model
assumptions. This study reports the total costs of the annual number of symptomatic patients with positive
MPP seen by a single general practitioner (GP), total quality-adjusted life-years (QALYs) for these patients,
incremental costs and QALYs, and incremental cost-effectiveness ratios (ICERs). Several scenario analyses
were undertaken to investigate the impact of varying some of the base-case assumptions on the size of the
ICER per QALY gained. Costs and outcomes of future years over a lifetime time horizon were discounted at
an annual rate of 3.5%.
Results
The electronic database searches identified 1151 citations (915 unique records). No studies were identified
for the population of interest (i.e. people with signs or symptoms relevant to AF with an irregular pulse).
Therefore, all of the studies included in the systematic reviews assessed the diagnostic accuracy and the
clinical impact of using lead-I ECG devices at a single time point to detect AF in an asymptomatic population.
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Diagnostic test accuracy
A total of 13 publications reporting on nine studies were identified. In these studies, the index test
(lead-I ECG device) was interpreted by the device algorithm or by a trained health-care professional;
trained health-care professionals included cardiologists, electrophysiologists and GPs. All studies used a
12-lead ECG device interpreted by a trained health-care professional as the reference standard.
Interpreter of lead-I electrocardiogram: trained health-care professional
Data from four studies contributed to the meta-analyses (two studies of Kardia Mobile alone, one study
of Zenicor-ECG and one study of MyDiagnostick and Kardia Mobile). The main meta-analysis (AF cases,
n = 118; total patients, N = 580) indicated that the pooled sensitivity of lead-I ECG devices was 93.9%
(95% CI 86.2% to 97.4%) and the pooled specificity was 96.5% (95% CI 90.4% to 98.8%). Across the
sensitivity analyses, the numerical results were similar; the pooled sensitivity values ranged from 88.0% to
96.2% and the pooled specificity values ranged from 94.4% to 97.4%.
Interpreter of lead-I electrocardiogram: algorithm
Data from four studies were included in the meta-analyses (two studies of MyDiagnostick alone, one study
of Kardia Mobile alone and one study of MyDiagnostick and Kardia Mobile). The meta-analysis (AF cases,
n = 219; total patients, N = 842) showed a pooled sensitivity of 96.2% (95% CI 86.0% to 99.0%) and
pooled specificity of 95.2% (95% CI 92.9% to 96.8%). The numerical results were similar across the
sensitivity analyses; the pooled sensitivity values ranged from 88.0% to 95.2% and the pooled specificity
values ranged from 94.4% to 97.2%.
Clinical impact
A total of 24 publications reporting on 19 studies with a total of 33,993 participants were identified. The
index tests that were evaluated included imPulse (one study), Kardia Mobile alone (12 studies), MyDiagnostick
alone (four studies), Zenicor ECG (one study) and MyDiagnostick and Kardia Mobile (one study). Test failure
rate was reported in nine studies and ranged from 0.1% to 9%. The results for test failure rate included
both the failure of the lead-I ECG algorithm to produce a result and the poor quality of the lead-I ECG trace.
Diagnostic yield was reported in 13 studies. The percentage of new patients diagnosed with AF ranged
from 0.4% to 5.8%. Data for this outcome were considered too heterogeneous for a pooled estimate to
be clinically meaningful. Only one study reported the concordance between different lead-I ECG devices
(Kardia Mobile and MyDiagnostick) and observed no difference in agreement. Two studies reported a change
in treatment management following the use of the Kardia Mobile lead-I ECG in new patients diagnosed
with AF. The acceptability of lead-I ECG devices was reported in four studies, with generally positive views.
Cost-effectiveness
None of the studies identified assessed the cost-effectiveness of using single time point lead-I ECG devices
compared with using MPP followed by a 12-lead ECG in people presenting to primary care with signs or
symptoms of AF who had an irregular pulse.
A decision tree and two cohort Markov models were built in Microsoft Excel® (Microsoft Corporation,
Redmond, WA, USA). The decision tree describes the pathway followed by a patient presenting to primary
care with signs or symptoms of AF and an irregular pulse during the initial GP consultation. The first Markov
model captures the differences in the costs and benefits of treatment (standard diagnostic pathway vs.
lead-I ECG pathway) during the first 3 months after the initial GP appointment. During this period, some
patients will have a diagnosis of AF and start the relevant treatment and other patients will have further
tests to diagnose, or to rule out, AF (where ‘rule out’ means no diagnosis of AF is recorded in the patient’s
notes and no treatment for AF is started). The second Markov model captured the differences in lifetime
costs and benefits after patients have either received a diagnosis of AF or have had AF ruled out.
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The de novo economic model yielded ICERs per QALY gained. The results of the pairwise analysis show
that all lead-I ECG devices generate ICERs below the £20,000–30,000 threshold usually considered to be
cost-effective by NICE. Kardia Mobile appears to be the most cost-effective option in a full incremental
analysis and dominates both the standard pathway and the other lead-I ECG devices (costing less and
generating more QALYs). The only exception to this is the generic lead-I ECG device, which generates a
very small QALY gain but at a cost that produces an ICER well above £30,000 per QALY gained.
Conclusions
There is no evidence available to support the use of single time point lead-I ECG devices for the detection of
AF in people presenting with signs or symptoms of AF and an irregular pulse. The results of this assessment,
using data from asymptomatic patients as a proxy, suggest that the use of lead-I ECG devices is more
cost-effective than MPP followed by a 12-lead ECG in primary or secondary care.
Currently, the standard pathway for the diagnosis of AF indicates that patients with signs or symptoms of
AF and an irregular pulse are advised to have a 12-lead ECG test. The benefits accumulated during the
time interval between the lead-I ECG tests and the confirmatory 12-lead ECG tests are sufficiently large for
lead-I ECG devices to be considered as cost-effective in this specific population.
Study registration
This study is registered as PROSPERO CRD42018090375.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Background
Description of the target condition
Atrial fibrillation (AF) refers to a disturbance in heart rhythm (arrhythmia) that is caused by abnormal
electrical activity in the upper chambers of the heart (atria).1 The arrhythmia reduces the efficiency of the
heart to move blood into the ventricles, increasing the risk of blood clots and consequent stroke.1 AF is
associated with conditions such as hypertension, heart failure, coronary artery disease, valvular heart
disease, obesity, diabetes mellitus and chronic kidney disease.2
Types of atrial fibrillation
Three types of AF (based on presentation and duration of the arrhythmia) are described in Table 1.
Atrial fibrillation can be categorised as valvular or non-valvular for the purposes of choosing the most
suitable treatment. Categorisation as valvular or non-valvular refers to the underlying condition causing AF
(i.e. whether or not there is valve disease present) rather than the duration of AF episodes. Both valvular
AF and non-valvular AF can be paroxysmal, persistent or permanent. Patients diagnosed with paroxysmal
AF can develop persistent or permanent AF.2 It is also possible, but most unusual, for patients with
persistent AF to revert to normal sinus rhythm.2
Symptoms of atrial fibrillation
Patients with AF may experience palpitations, dizziness, shortness of breath and tiredness. However,
AF can be asymptomatic and may be identified only during medical appointments for other conditions.
Because the symptoms are intermittent, many cases of paroxysmal AF remain undiagnosed.2 Cases of
paroxysmal AF may be detected only after a prolonged monitoring period, rather than from a single
examination.2
Epidemiology
Atrial fibrillation is the most common type of cardiac arrhythmia. Estimates from 2010 suggest that,
worldwide, 20.9 million men and 12.6 million women are living with AF.2 Higher rates of AF are recorded
in developed countries than in undeveloped countries; however, this may be explained by differences
in reporting.2 Higher rates of AF are recorded in people living in Western countries (estimated incidence
rate of 9.03 per 1000 patient-years)4 than in people living in Asian countries (estimated incidence rate of
5.38 per 1000 patient-years).5 Despite a higher exposure to potential AF risk factors, such as hypertension
and obesity, African American people were found to have a lower age- and sex-adjusted risk of being
diagnosed with AF than white American people.6
In the 2016 European Society of Cardiology (ESC) guidelines,2 the prevalence of AF in the European Union
was reported to be 3%.The ESC also notes that one in four middle-aged people in Europe and the USA
will develop AF.2 The prevalence of AF in Europe is projected to increase over time because of the ageing
TABLE 1 Types of AF
Type of AF Description
Paroxysmal (intermittent) Intermittent episodes that usually last < 7 days and stop without treatment
Persistent Episodes that last > 7 days and do not stop without treatment
Permanent Present all the time
Contains information sourced from NICE CG180.3
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population, an increase in incidence of conditions associated with AF and the improvements in the
detection of AF.2
The overall age-adjusted incidence of AF per 1000 patient-years in the primary care setting in the UK has
increased from 1.11 [95% confidence interval (CI) 1.09 to 1.13] in 1998–2001 to 1.33 (95% CI 1.31 to 1.35)
in 2007–10, with a constant increase in incidence reported in people aged ≥ 75 years.7
In the NHS Quality and Outcomes Framework for 2015–16,8 the prevalence of AF in England is estimated
to be 1.7%, which equates to 985,000 people. However, as noted, AF can be asymptomatic, which
suggests that 1.7% may be an underestimate of the true prevalence.9 Based on a reference population
in a region of Sweden, Public Health England has estimated that the true prevalence of AF in England
is likely to be 2.5% and that 1.4 million people in England are living with AF.10 In the most recent
data from the NHS Quality and Outcomes Framework for 2016–17, the prevalence of AF in England is
estimated to be 1.8%, equating to 1,066,000 people.11 An assessment of electronic primary care records
identified an increase in the prevalence of AF in the UK from 2.14% in 2000 to 3.29% in 2016 in those
aged ≥ 35 years.12
The prevalence of AF increases with age and a higher proportion of men than women live with the
condition (2.9% and 2.0%, respectively).10 The median age at which people are diagnosed with AF is
75 years.10 The largest numbers of AF diagnoses in men and women occur between the ages of 75 and
79 years and 80 and 84 years, respectively.10 Although fewer women than men have AF, women
experience higher mortality rates owing to AF-related strokes.10
Paroxysmal AF is estimated to account for between 25% and 62% of patients with AF treated in hospitals
and general practitioner (GP) practices.13 Patients with paroxysmal AF tend to be younger and have fewer
comorbidities (e.g. hypertension or congestive heart failure) than patients with persistent or permanent
AF.13,14
Impact of atrial fibrillation
Untreated AF is a major risk factor for stroke. AF is associated with a fivefold increase in the risk of stroke
and a threefold increase in the risk of congestive heart failure.15 Strokes with AF as the underlying cause
may be more severe than strokes unrelated to AF.16 Furthermore, each year in the UK, 100,000 people
have a stroke and one in five of those strokes has AF as the underlying cause.17
There is evidence to suggest that there are differences in the risk of stroke between patients with paroxysmal,
persistent and permanent AF, with patients with paroxysmal AF having a lower risk of stroke than those
with persistent or permanent AF.18,19 The risk of stroke in patients with symptomatic AF is similar to that in
patients with asymptomatic AF.20
The ESC reports that, annually, between 10% and 40% of patients with AF are hospitalised and
that patients with AF have impaired health-related quality of life (HRQoL), regardless of co-existing
cardiovascular conditions.2 Cognitive decline and vascular dementia are conditions suggested to develop
from the onset of AF.2
Current diagnostic and treatment pathways
The National Institute for Health and Care Excellence (NICE) clinical guideline CG1803 provides
recommendations for the diagnosis and management of AF. An update of CG1803 is in progress.
Diagnosis of atrial fibrillation
In CG180,3 NICE recommends the use of manual pulse palpation (MPP) to detect the presence of an
irregular pulse that may indicate underlying AF in people who have symptoms such as breathlessness/
dyspnoea, palpitations, syncope/dizziness, chest discomfort, previous stroke or suspected transient
ischaemic attack (TIA).
BACKGROUND
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During the scoping stage of this assessment, clinical experts commented that people presenting with a
stroke or TIA would undergo electrocardiogram (ECG) testing for AF in secondary care and are, therefore,
outside the scope of an assessment that focuses on diagnosis in primary care.
If AF is suspected because of an irregular pulse, NICE3 recommends that the diagnosis should be confirmed
based on the results of an ECG. Patients who are suspected of having paroxysmal AF that is not detected
by the ECG should be monitored using either a 24-hour ambulatory monitor or an event recorder ECG.
Patients with confirmed AF may also undergo echocardiography to further inform the management of their
condition. The current diagnostic pathway for people presenting to primary care with signs or symptoms of
the condition and who have an irregular pulse is depicted in Figure 1.
Management of atrial fibrillation
An overview of the treatment pathway described in CG1803 is provided in Figure 2. As shown in Figure 2,
the management of AF is subdivided into four algorithms.
The aim of treatment is to reduce the symptoms of AF and prevent the potential consequences of
undiagnosed AF, such as stroke.3
Reducing stroke risk
In CG180,3 NICE recommends that patients with AF should be assessed for both their risk of stroke and
their risk of bleeding. The risk of stroke should be assessed using the CHA2DS2-VASc21 algorithm [history
of congestive heart failure, hypertension, age ≥ 75 years (doubled), diabetes mellitus, prior stroke or TIA
(doubled), vascular disease, age 65–74 years, female] and the risk of bleeding should be assessed using the
HAS-BLED22 algorithm (hypertension, abnormal liver/renal function, stroke history, bleeding predisposition,
labile international normalised ratio, age, drug/alcohol use).
Depending on the age of the patient, the results of the CHA2DS2-VASc21 assessment and the results of the
HAS-BLED22 assessment, patients with non-valvular AF may be offered stroke prevention treatment with
either a vitamin K antagonist (usually warfarin) or a non-vitamin K antagonist oral anticoagulant (NOAC)
[i.e. apixaban (Eliquis®; Bristol–Myers Squibb, NY), dabigatran etexilate (Pradaxa®, Prazaxa®, Pradax®;
Boehringer Ingelheim GmbH, Germany), rivaroxaban (Xarelto®; Bayer Health Care, Germany) or edoxaban
(Lixiana®; Daiichi Sankyo, Japan)].
Rate and rhythm control
In CG180,3 NICE recommends (with some exceptions) that people with AF who need drug treatment as
part of their rate-control strategy should be offered either a standard beta-blocker or a rate-limiting
calcium-channel blocker. Exceptions include people whose AF has a reversible cause, those who have heart
failure thought to be primarily caused by AF, those with new-onset AF, those with an atrial flutter whose
condition is considered suitable for an ablation strategy to restore sinus rhythm or for those whom a
rhythm control strategy would be more suitable based on clinical judgement. Digoxin may be offered to






FIGURE 1 Current diagnostic pathway.
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the symptoms are a result of poor ventricular rate control, dual therapy with any two of a beta-blocker,
diltiazem and digoxin is recommended.3 For rhythm control, NICE3 recommends pharmacological treatment
with or without electrical rhythm control (cardioversion).
In CG180,3 NICE also recommends strategies for left atrial ablation to control AF.
Description of technologies under assessment
The technologies assessed (i.e. index tests) were lead-I ECG devices. Lead-I ECG devices are handheld
instruments that can be used in primary care to detect AF at a single time point in people who present
with relevant signs or symptoms (i.e. palpitations, dizziness, shortness of breath and tiredness). Although
lead-I ECG devices may also be used for ongoing or repeated testing for AF, and for the diagnosis of
non-AF conditions, this use is outside the scope of this assessment.
Diagnosis of AF
Overview of the AF algorithms
Personalised package of care and information













FIGURE 2 Overview of AF algorithms. Source: NICE CG180.3 © NICE 2014 Atrial fibrillation: management. Available
from www.nice.org.uk/guidance/cg180. All rights reserved. Subject to notice of rights (www.nice.org.uk/terms-and-
conditions#notice-of-rights).
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Lead-I ECG devices feature touch electrodes and internal storage for ECG recordings, as well as software
with an algorithm to interpret the ECG trace and indicate the presence of AF. Data from the lead-I ECG
device can be uploaded to a computer to allow further analysis if necessary (e.g. in cases of paroxysmal AF).
The manufacturers of lead-I ECG devices all state that the diagnosis of AF should not be made using the
algorithm alone, and that the ECG traces measured by the devices should be reviewed by a qualified
health-care professional. The use of lead-I ECG devices following the detection of an irregular pulse by
MPP may allow people with AF to initiate and benefit from earlier treatment with anticoagulants instead of
waiting for the results of a confirmatory 12-lead ECG as per current practice.
Five different lead-I ECG devices are included in the final scope issued by NICE: imPulse (Plessey
Semiconductors, Ilford, UK),23 Kardia Mobile (AliveCor Inc., Mountain View, CA, USA),24 MyDiagnostick
(MyDiagnostick Medical B.V., Maastricht, the Netherlands),25 RhythmPad GP (Cardiocity, Lancaster, UK)26
and Zenicor ECG (Zenicor Medical Systems AB, Stockholm, Sweden).27 The features of each device are
described in imPulse, Kardia Mobile, MyDiagnostick, RhythmPad GP and Zenicor-ECG, respectively. All
devices are CE (Conformité Européenne) marked.
imPulse
The lead-I ECG device is provided with downloadable software for data analysis (imPulse Viewer) and a
cable for charging the device. The ECG readings are taken by holding the device in both hands and
placing each thumb on a separate sensor on the device for a pre-set length of time (from 30 seconds to
10 minutes). To be operated, the device requires the associated software to be installed on a nearby PC or
tablet. Data are transferred to hardware hosting the analytical software using Bluetooth (Bluetooth Special
Interest Group, WA, USA), with the recorded ECG trace being displayed in real time.
Once the recording has finished, the generated ECG trace can be saved in the imPulse viewer. Previously
recorded readings can also be loaded into this viewer and ECG traces can be saved as a PDF (Portable
Document Format). The software has an AF algorithm that analyses the reading and states whether AF is
unlikely, possible or probable. In the event of a ‘possible’ or ‘probable’ result, the company recommends
that the person should undergo further investigation, and that the algorithm should not be used for a
definitive clinical diagnosis of AF.
Kardia Mobile
The Kardia Mobile lead-I ECG device works with the Kardia Mobile app to record and interpret ECGs.
In addition to the Kardia Mobile device and app [www.alivecor.com/ (accessed January 2018)], a compatible
Android (Google Inc., Mountain View, CA, USA) or Apple (Apple Inc., Cupertino, CA, USA) smartphone or
tablet is required.
Two fingers from each hand are placed on the Kardia Mobile device to record an ECG that is sent
wirelessly to the device hosting the Kardia Mobile app. The default length of recording is 30 seconds;
however, this can be extended up to 5 minutes. The measured ECG trace is then automatically transmitted
as an anonymous file to a European server for storage as an encrypted file.
The app uses an algorithm to classify measured ECG traces as (1) normal, (2) possible AF detected or
(3) unclassified. The instructions for use state that the Kardia Mobile app assesses the patient for AF only,
and the device will not detect other cardiac arrhythmias. Any detected non-AF arrhythmias, including
sinus tachycardia, are labelled as unclassified. The company states that any ECG labelled as ‘possible
AF’ or ‘unclassified’ should be reviewed by a cardiologist or trained health-care professional. ECG traces
measured by the device can be sent from a smartphone or tablet by e-mail as a PDF attachment and
stored in the patient’s records. The first version of the Kardia app did not have automatic diagnostic
functionality. The AF algorithm was added to the app in January 2015. The Kardia Mobile has previously
been available as the AliveCor Heart Monitor.
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MyDiagnostick
The MyDiagnostick lead-I ECG recording is generated after a patient holds the metal handles at each end
of the device for 1 minute. A light on the device will turn green if no AF is detected or turn red if AF is
detected. If an error occurs during the reading, the device produces both an audible warning and a visible
warning from the light on the device. Up to 140 ECG recordings can be recorded on the device before it
starts to overwrite previous recordings. The MyDiagnostick device can be connected to a computer via a
USB (universal serial bus) connection to download the generated ECG trace for review and storage using
free software that can be downloaded from the MyDiagnostick website [www.mydiagnostick.com
(accessed January 2018)].
RhythmPad GP
The RhythmPad GP lead-I ECG readings are taken by placing the palms of both hands on the surface of the
device for 30 seconds. Alternative configurations can be used if a person is unable to place their hands flat
on the device, for example if they have arthritis. The software needs to be installed on a device running
Windows XP (Microsoft, WA, USA) or a later version, and that has a USB port. Data are transferred directly
to a computer using the USB connection to be stored on the device’s hard drive in PDF format.
The software includes an algorithm that can determine if a person has AF, and can additionally detect if a
person has bradycardia, tachycardia, sinus arrhythmia, premature ventricular contractions or right bundle
branch block. The recorded ECG trace is also available for further analysis by a health-care professional.
The company recommends that a 12-lead ECG device is used to confirm a case of AF detected by the
RhythmPad GP device.
Zenicor-ECG
The Zenicor-ECG is a system with two components: a lead-I ECG device (Zenicor-EKG 2) and an online
system for analysis and storage (Zenicor-EKG Backend System version 3.2). The online system is not locally
installed; the device transmits data to a remote server that can be accessed using a web browser, without
prior installation of software, and requires a user licence. ECG readings are taken by placing both thumbs
on the device for 30 seconds. The instructions for use state that the electrodes in the Zenicor EKG-2
should be replaced after every 500 measurements. The device is powered by three alkaline batteries that
the company states are expected to last for at least 200 measurements and transmissions.
Once a measurement is made using the Zenicor-EKG 2 device, the ECG measurement can be transferred
from the device (using a built-in mobile network modem) to a Zenicor server in Sweden. Here, the ECG
trace is analysed using the Zenicor-EKG Backend System, which includes an automated algorithm. The
algorithm categorises an ECG into one of 12 groups corresponding to potential arrhythmias, one of which
includes AF. The algorithm will also report if the recorded ECG trace cannot be analysed. The company
states that a clinician needs to manually interpret the ECG trace generated by the Zenicor-ECG to make a
final diagnosis of AF.
The measured ECG trace can be downloaded or printed as a PDF report. The company states that the ECG is
available via the web interface approximately 4–5 seconds after the ECG has been transmitted from the device.
The company states that the Zenicor EKG-2 does not store, contain or transmit any patient-identifying
information. ECGs are sent via the built-in mobile network modem to the Zenicor server labelled with the
device’s identity number. Communication between the Zenicor server and the web browser accessing it
is encrypted.
Comparator
To evaluate the diagnostic accuracy of lead-I ECG devices, the comparator of interest is other lead-I ECG
devices as described above or no comparator (Table 2). To evaluate the clinical impact of lead-I ECG
devices, the comparator of interest is MPP followed by a 12-lead ECG in primary or secondary care prior to
initiation of anticoagulation therapy.
BACKGROUND
NIHR Journals Library www.journalslibrary.nihr.ac.uk
6
Reference standard
The index test results are compared with the results of a reference standard for an assessment of DTA. The
reference standard is used to verify the presence or absence of the target condition (i.e. AF). The reference
standard for this assessment is 12-lead ECG performed and interpreted by a trained health-care professional.
TABLE 2 Eligibility criteria
Characteristic Description
Population (1) People with signs or symptoms that may indicate underlying AF and who have an irregular pulse; or
(2) asymptomatic populationa if no evidence for (1) is available
Setting Primary care (ideal), secondary or tertiary care







Comparator Manual pulse palpation followed by a 12-lead ECG in primary
or secondary care prior to initiation of anticoagulation therapy
or other lead-I ECG devices as specified in Description of
technologies under assessment
Other lead-I ECG devices as specified
above, or no comparator
Reference
standard
Not applicable 12-lead ECG performed and
interpreted by a trained health-care
professional
Outcomes Intermediate outcomes
l Time to diagnosis of AF
l Time to initiation of preventative treatment (such as
interventions to prevent stroke)
l Concordance between lead-I ECG devices
l Test failure rate
l Time to complete testing and store produced ECG trace
l Ease of use of devices (for patients and health-care
professionals), including training requirements
l Impact of test results on clinical decision-making
l Number of 12-lead ECGs carried out
l Diagnostic yield (number of AF diagnoses)
DTA
l Numbers of true-positive,
false-negative, false-positive
and true-negative test results
Clinical outcomes
l Mortality
l Morbidity (including stroke, other thromboembolisms
and heart failure, and any complications arising from
preventative treatments, such as adverse effects of anti-
arrhythmic, rate-control or anticoagulation treatment)
Patient-reported outcomes
l Health-related quality of life
l Acceptability of the devices
Study design RCTs, cross-sectional, case–control, cohort and uncontrolled
single-arm studies. Qualitative studies were considered to
evaluate the ease of use of the devices
Diagnostic cross-sectional and
case–control studies
RCT, randomised controlled trial.
a Asymptomatic population defined as people presenting with no symptoms of AF, with or without previously
diagnosed AF.
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Aim of the assessment
The aim of this assessment was to evaluate whether or not the use of lead-I ECG devices to detect AF in
people presenting to primary care with signs or symptoms of the condition and who have an irregular
pulse represents a cost-effective use of NHS resources compared with MPP followed by a 12-lead ECG
in primary or secondary care prior to initiation of anticoagulation therapy.
BACKGROUND
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Chapter 2 Methods for assessing diagnostic test
accuracy and clinical impact
Two systematic literature reviews were conducted to evaluate (1) the DTA of single-time point lead-IECG for the diagnosis of AF, using 12-lead ECG as the reference standard, in people with signs or
symptoms that may indicate underlying AF and who have an irregular pulse, and (2) the clinical impact of
single time point lead-I ECG devices compared with MPP followed by a 12-lead ECG in both primary care
and secondary care. The methods for the systematic review followed the general principles outlined in the
Centre for Reviews and Dissemination guidance for conducting reviews in health care,28 NICE’s Diagnostics
Assessment Programme manual29 and the Cochrane Handbook for Systematic Reviews of Diagnostic Test
Accuracy.30 The systematic review is reported in accordance with the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA) guidelines for DTA studies.31 The PRISMA-DTA checklist
and PRISMA-DTA for abstracts checklist are presented in Appendices 1 and 2, respectively.
Search strategy
The search strategies were designed to focus on the specified devices (i.e. imPulse, Kardia Mobile,
MyDiagnostick, RhythmPad GP and Zenicor ECG) and the target condition (i.e. AF). No study design filters
were applied and all electronic databases were searched from inception to 9 March 2018. The search
strategy used for the MEDLINE database is presented in Appendix 3. The MEDLINE search strategy was
adapted to enable similar searches of the other relevant electronic databases. The following databases
were searched for relevant studies:
l MEDLINE (via Ovid)
l MEDLINE Epub Ahead of Print and MEDLINE In-Process & Other Non-Indexed Citations (via Ovid)




l DARE (via The Cochrane Library)
l Health Technology Assessment (HTA) database (via The Cochrane Library).
The results of the searches were uploaded to, and managed, using EndNote X8 software [Clarivate
Analytics (formerly Thomson Reuters), Philadelphia, PA, USA]. The reference lists of relevant systematic
reviews and eligible studies were hand-searched to identify further potentially relevant studies. Data
submitted by the manufacturers of the five lead-I ECG devices that are the focus of this assessment were
considered for inclusion in the review.
Eligibility criteria
The eligibility criteria for the inclusion of studies assessing the clinical impact or DTA of lead-I ECG devices
are presented in Table 2.
Although the index test (i.e. the test being evaluated) should be performed in a primary care setting,
studies in which the index tests were performed and interpreted by a cardiologist in a secondary or tertiary
care setting were also considered eligible for inclusion. This is because it is plausible that in clinical practice
(primary care setting) the test results could be sent for remote interpretation by a cardiologist.
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Studies that assessed the DTA or the clinical impact of lead-I ECG devices used at a single time point to
detect AF in an asymptomatic population were considered for inclusion if no studies were identified in
a symptomatic population. An asymptomatic population was considered to be people not presenting
with symptoms of AF, with or without a previous diagnosis of AF. These patients could have other
cardiovascular comorbidities, or could be attending a clinic for cardiovascular-related reasons, but not be
presenting with signs or symptoms of AF. The use of lead-I ECG devices for ongoing or repeated testing
for AF is outside the scope of this assessment.
Studies that did not present original data (i.e. reviews, editorials and opinion papers), case reports and
non-English language studies were excluded from the review. Conference proceedings published from
2013 onwards were considered for inclusion.
Study selection
The citations identified were assessed for inclusion in the review using a two-stage process. First, two
reviewers independently screened all of the titles and abstracts identified by the electronic searches to
distinguish the potentially relevant studies to be retrieved. Second, full-text copies of these studies were
obtained and assessed independently by two reviewers for inclusion using the eligibility criteria outlined
in Table 2. Any disagreements were resolved through discussion at each stage, and, if necessary, in
consultation with a third reviewer.
Data extraction
A data extraction form was designed, piloted and finalised to enable data extraction relating to study
authors, year of publication, study design, characteristics of study participants, prevalence of comorbidities,
prevalence of AF by type, characteristics of the index, comparator and reference standard tests (including
length of monitoring, who performed and interpreted the test), the order in which the index and
comparator/reference standard tests were performed, whether or not the person who interpreted the
reference standard test was blind to the results of the index test, and the outcome measures as described
in Table 2.
Data extraction was performed by one reviewer and checked for accuracy by a second reviewer. Any
disagreements were resolved through discussion, and, if necessary, in consultation with a third reviewer.
The manufacturers of the index tests and the corresponding authors of the studies selected for assessment
of DTA were contacted for missing data or clarification of the data presented.
Quality assessment
The methodological quality of DTA studies was assessed using the QUality Assessment of Diagnostic
Accuracy Studies–2 (QUADAS-2) tool tailored to the review question.32 The QUADAS-2 tool considers four
domains: (1) patient selection, (2) index test(s), (3) reference standard and (4) flow of patients through the
study and the timing of the tests.
The methodological quality of cross-sectional and case–controlled studies that evaluated the clinical impact
of lead-I ECG devices was assessed using the Newcastle–Ottawa quality assessment scale.33,34 We had
planned to use the Cochrane Risk of Bias tool35 to assess the methodological quality of randomised
controlled trials (RCTs) of clinical impact, but no RCTs were identified.35 Qualitative studies were assessed
using the Critical Appraisal Skills Programme (CASP) tool.36
METHODS FOR ASSESSING DIAGNOSTIC TEST ACCURACY AND CLINICAL IMPACT
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Quality assessment of the included studies was undertaken by one reviewer and checked by a second
reviewer. Any disagreements were resolved by discussion, and, if necessary, in consultation with a third
reviewer.
Methods of analysis/synthesis of diagnostic test accuracy studies
Statistical analysis and data synthesis
Individual study results
The sensitivity and specificity of each index test from studies of diagnostic accuracy were summarised in
forest plots and plotted in receiver operating characteristic (ROC) space.
Meta-analysis
The bivariate model was used to obtain pooled estimates of sensitivity and specificity for lead-I ECG devices.37
The pooled estimates for sensitivity and specificity were plotted in ROC space with a 95% confidence region
around this summary estimate. The 95% confidence region depicts a range of sensitivity and specificity
values within which the analyst can be 95% confident that the true sensitivity and specificity values for the
index test lie.
The analyses were stratified by whether the diagnosis of AF was made by a trained health-care professional
interpreting the lead-I ECG trace, or by the lead-I ECG algorithm. Within these stratified analyses, it was not
possible to compare the diagnostic accuracy of different types of lead-I ECG device by adding a covariate for
device type owing to the sparsity of the data. We were also unable to perform subgroup analyses to assess
the impact of potential sources of heterogeneity on the diagnostic accuracy of lead-I ECG devices owing to
the sparsity of the data.
For one study38 that reported data for two types of lead-I ECG device (MyDiagnostick and Kardia Mobile)
and for two different interpreters of lead-I and 12-lead ECG traces for the same patient cohort, we
performed multiple analyses so that we could investigate the impact of varying both the type of lead-I ECG
device and the interpreter on the results of the overall pooled analysis. Therefore, no set of patients was
double-counted in any of the meta-analyses performed. The data for the lead-I ECG device (MyDiagnostick
defined as device 1 and Kardia Mobile defined as device 2) and the electrophysiologist (EP) (EP1 or EP2)
that were included in the main analysis were randomly selected by using the command r(uniform) in Stata
version 14 (StataCorp LP, College Station, TX, USA) to randomly generate the number 1 or 2 first for
device and then for EP. Additional analyses are presented as sensitivity analyses.
One study39 reported data for one lead-I ECG device (Kardia Mobile) and two different interpreters
(a cardiologist and a GP with an interest in cardiology) of lead-I and 12-lead ECG traces. The data interpreted
by the cardiologist were used in the main analysis because the interpreters in the other included studies were
either cardiologists or EPs. The analysis with data interpreted by the GP is presented as a sensitivity analysis.
The bivariate model was fitted using the metandi and xtmelogit commands in Stata version 14 where at
least four studies could be included in meta-analysis. Summary receiver operating characteristic (SROC)
plots were produced using RevMan 5.3 (RevMan; The Cochrane Collaboration, The Nordic Cochrane
Centre, Copenhagen, Denmark). When there were fewer than four studies, the bivariate model was
reduced to two univariate random-effect logistic regression models by assuming no correlation between
sensitivity and specificity across studies.40 When little or no heterogeneity was observed on forest plots and
SROC plots, the models were further simplified into fixed-effect models by eliminating the random-effects
parameters for sensitivity and/or specificity.40 Judgement of heterogeneity was based on the visual
appearance of forest plots and SROC plots in addition to clinical judgement regarding potential sources of
heterogeneity.
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Sensitivity analyses
We had planned to conduct sensitivity analyses by excluding studies judged as having a high risk of bias
or studies where the appropriateness of inclusion in the primary meta-analyses was uncertain. Sensitivity
analyses stratified by risk of bias were not performed owing to the small number of studies included in the
meta-analysis with similar risk-of-bias judgements.
Methods of analysis/synthesis of clinical impact studies
We had planned to perform a meta-analysis of the clinical and intermediate outcomes stated in Table 2.
After data extraction, we considered pooling data for the outcome of diagnostic yield; however, on
examination of the forest plots displaying diagnostic yield data for the included studies, we judged the
data to be too heterogeneous for pooling to give clinically meaningful results. Therefore, we produced
forest plots displaying individual study results from all included studies and additional forest plots
displaying individual study results stratified by device type and by setting. These forest plots were produced
in Stata 14 using the metaprop command.
Other considerations
‘Real-world’ data describing the clinical impact of lead-I ECG devices were received from the Kent Surrey
Sussex Academic Health Science Health Network (AHSN) and these are included in Chapter 3, Clinical
impact results.
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Chapter 3 Results of the assessment of diagnostic
test accuracy and clinical impact
Study selection
The searches of the electronic databases identified 1151 citations. After the removal of duplicate records,
915 potential citations remained. Following initial screening of titles and abstracts, 54 publications were
considered to be potentially relevant and were retrieved to allow assessment of the full-text publication.
No studies were identified for the population of interest (i.e. people with signs or symptoms that may
indicate underlying AF and who have an irregular pulse). Therefore, all of the included studies assessed the
DTA and clinical impact of lead-I ECG devices used at a single time point to detect AF in an asymptomatic
population (see Chapter 2, Eligibility criteria).
After review of the full-text publications, 13 publications38,39,41–51 reporting on nine studies were included in the
DTA review and 24 publications38,41–48,51–65 reporting on 19 studies were included in the clinical impact review.
Where there were overlaps in data and reporting as a result of studies being reported in several papers and
abstracts, we selected the publication with the most complete data and treated it as the main publication.
The PRISMA66 flow chart detailing the screening process for the review is shown in Figure 3. Studies
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(n = 27 publications reporting on 22 studies)
Studies included in diagnostic test accuracy review
(n = 13 publications reporting on 9 studies)
Studies included in clinical impact review
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• Ineligible test, n = 19
• Ineligible outcomes, n = 7
























FIGURE 3 The PRISMA flow chart. Reproduced from Duarte et al.67 © The Authors, 2019. This is an Open Access
article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which
permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work
is properly cited. See: http://creativecommons.org/licenses/by/4.0/.
DOI: 10.3310/hta24030 HEALTH TECHNOLOGY ASSESSMENT 2020 VOL. 24 NO. 3
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Duarte et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
13
We contacted the authors of three studies47,50,51 to obtain additional data on DTA or to clarify the data on
DTA reported in the publication. We did not receive a response from one set of authors.51 One set of
authors provided additional information that allowed their study47 to be included in the DTA meta-analysis.
One set of authors also provided additional information on their study,50 but stated that the algorithm had
been modified since the study was reported. For this reason, the sensitivity and specificity of the lead-I ECG
device used are presented but are not included in the meta-analysis.
Assessment of diagnostic test accuracy
Characteristics of the included studies
The characteristics of the nine included DTA studies are summarised in Table 3.
The studies included in the DTA review were either case–control studies38,39,43,45,47–49 or cross-sectional
studies.50,51 Two of the studies were based in the UK.39,50 Only one study was conducted in primary care,49
with the remaining studies being conducted in either secondary39,43,45,47,48,50 or tertiary care.38,51 All of the
studies included either patients with a known history of AF or patients recruited from cardiology clinics.
Only one study38 presented the reasons that patients were admitted to a cardiology department. Eleven
patients (3.4%) were admitted because of symptomatic AF, all of whom had a known history of AF. The
study by Haberman et al.45 included a community-based population comprising healthy young adults and
elite athletes. The results for the healthy young adults and elite athletes were excluded from the analysis
because these participants did not meet the population inclusion criteria for this review and do not represent
the typical population with AF (i.e. those aged > 75 years).10 The study by Lau et al.47 included a ‘learning set’
and data from this group were used to optimise the algorithm. The ‘learning set’ data were excluded from
the analysis because, according to the author of the study (Ben Freedman, University of Sydney, 15 June 2018,
personal communication), two separate cardiologists interpreted the rhythm strips, and the interpretation
by cardiologist A seemed to have a bias towards sensitivity, with a resultant lower specificity, while the
interpretation by cardiologist B had a slightly lower sensitivity, with a resulting higher specificity.
Only one study included results based on lead-I ECG interpretation by the device algorithm and a trained
health-care professional presenting the results separately.38 One study39 reported data for a lead-I ECG
trace that was interpreted both by a cardiologist and by a GP with an interest in cardiology; the results
were presented separately for each interpreter. In four studies,47–50 the lead-I ECG was interpreted by the
device algorithm alone.
The lead-I ECG devices used in the included studies were Kardia Mobile,39,45,47,51 MyDiagnostick,48,49
RhythmPad GP50 and Zenicor-ECG.43 The study by Desteghe et al.38 used both Kardia Mobile and
MyDiagnostick and presented the results separately for each device.
The trained health-care professional interpreting the 12-lead ECG in all of the studies included in the DTA
review was a cardiologist,39,43,47–49,51 an EP38,45,50 or a GP with an interest in cardiology.39
Quality assessment of diagnostic accuracy studies
All of the included studies were assessed for risk of bias and applicability using the QUADAS-2 tool.32
A summary of the results that assessed risk of bias and applicability concerns across all studies is presented
in Table 4. The full assessment for each included study is presented in Appendix 5.
All of the included studies were judged as being at an unclear risk of bias for the patient selection domain.
Only one study48 reported the method used for patient inclusion. There was an overall lack of information
regarding patient eligibility for participation in the studies, and whether or not any patients were excluded
at the stage of study selection. All of the included studies were judged as having a high applicability concern
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Mean age and SD (years);





Crockford, 201350 Cross-sectional; UK;
secondary care
Patients referred to an
electrophysiology
department; N = 176; NR
NR RhythmPad GP Algorithm 12-lead ECG followed by
lead-I ECG
Desteghe, 201738 Case–control; Belgium;
tertiary care
Inpatients at cardiology
ward; N = 265; NR
67.9± 14.6; female, n = 138
(43.1%);
Pacemaker: 4 out of 55
(7.3%) were intermittently
paced, and 18 out of 55
(32.7%) were not being
paced during the recordings
Known AF: 114 out of 320
(35.6%)
AF at time of study: 11.9%
on 12-lead ECG; 3.4% of all









12-lead ECG followed by
lead-I ECG (order for the
use of the different lead-I
ECG tests not specified)
Doliwa, 200943 Case–control; Sweden;
secondary care
People with AF, atrial flutter
or sinus rhythm; N = 100;
patients were recruited from
a cardiology outpatient
clinic
NR Zenicor-ECG Cardiologist 12-lead ECG followed by
lead-I ECG
Haberman, 201545 Case–control; USA;
community and secondary
care
Healthy young adults, elite
athletes and cardiology
clinic patients; N = 130; NRa
59± 15; male, n = 73 (56%);
NR
Kardia Mobile EP Lead-I ECG followed by
12-lead ECG
Koltowski, 201751 Cross-sectional; Poland;
tertiary care
Patients in a tertiary care
centre; N = 100; NR


















































































































































































Mean age and SD (years);





Lau, 201347 Case–control; Australia;
secondary care
Patients at cardiology
department; N = 204; NR
NR;
Known AF: n = 48 (24%)
Kardia Mobile Algorithm Lead-I ECG followed by
12-lead ECG
Tieleman, 201448 Case–control; Netherlands;
secondary care
Patients with known AF and
patients without a history of
AF attending an outpatient
cardiology clinic or a
specialised AF outpatient
clinic; N = 192; random
selection of patients
awaiting a 12-lead ECG
69.4± 12.6; male, 48.4%;
NR
MyDiagnostick Algorithm Lead-I ECG followed by
12-lead ECG
Vaes, 201449 Case–control; Belgium;
primary care
Patients with known AF and
patients without a history of
AF; N = 181; GP invitation
74.6± 9.7; female, n = 91
(48%);
Known AF: n = 151 (83.4%)
MyDiagnostick Algorithm Lead-I ECG followed by
12-lead ECG
Williams, 201539 Case–control; UK;
secondary care
Patients with known AF
attending an AF clinic and
patients with AF status
unknown who were
attending the clinic for
non-AF-related reasons;
N = 95; patients attending
clinic appointments who
were awaiting a 12-lead
ECG
NR Kardia Mobile Cardiologist and GP with
an interest in cardiology
12-lead and lead-I ECG
carried out simultaneously
NR, not reported; SD, standard deviation.
a Community population not included in the analysis as these comprised healthy young adults and elite athletes; only secondary care patients were included in the analysis.
Reproduced from Duarte et al.67 © The Authors, 2019. This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license,











































for patient selection as none of these studies was performed in the population of interest. One study38
included a proportion (3.4%) of patients admitted to a cardiology department because of symptomatic AF;
however, all of these patients had a known history of AF.
Three studies45,50,51 were judged as having an unclear risk of bias in the index test domain because there
was lack of information regarding whether or not the index tests were interpreted without knowledge of
the reference standard test result. The remaining six studies38,39,43,47–49 were judged as having a low risk of
bias on the index test domain. Studies in which the index test was interpreted by a trained health-care
professional were judged to be more applicable (low concern)38,39,43,45 than those interpreted by the lead-I
ECG device algorithm alone.47–49 Two studies50,51 were judged as having an unclear applicability concern
because of a lack of information in the publication.
Three studies45,50,51 were judged as having an unclear risk of bias for the reference standard domain because
they did not explicitly report whether or not the interpreters of the reference standard were blinded to the
results of the index test. The reference standard for all of the included studies was the results of a 12-lead
ECG, which were interpreted by a trained health-care professional; therefore, all of the studies were judged
to have a low concern regarding applicability of the reference standard.
Risk of bias was judged as being unclear for three studies39,49,50 for the flow and timing domain because
not all patients were included in the study analyses.
Diagnostic test accuracy results
Interpreter of lead-I electrocardiogram: trained health-care professional
All lead-I electrocardiogram devices: main analysis
We investigated the sensitivity and specificity of a lead-I ECG device when the trace was interpreted by a
trained health-care professional and the reference standard was a 12-lead ECG interpreted by a trained
health-care professional. Data from four studies38,39,43,45 were included in a meta-analysis. Two studies39,45
had data for Kardia Mobile alone, one study43 had data for Zenicor-ECG and one study38 had data for
MyDiagnostick and Kardia Mobile. One additional study51 had data for Kardia Mobile but was not included
TABLE 4 The QUADAS-2 assessment of DTA studies
Study (first
author, year)















aCrockford, 201350 Unclear Unclear Unclear Unclear High Unclear Low
Desteghe, 201738 Unclear Low Low Low High Low Low
Doliwa, 200943 Unclear Low Low Low High Low Low
Haberman, 201545 Unclear Unclear Unclear Low High Low Low
bKoltowski, 201751 Unclear Unclear Unclear Low High Unclear Low
Lau, 201347 Unclear Low Low Low High High Low
Tieleman, 201448 Unclear Low Low Low High High Low
Vaes, 201449 Unclear Low Low Unclear High High Low
Williams, 201539 Unclear Low Low Unclear High Low Low
a The poster based on the conference proceeding by Crockford et al.50 was provided and used for the purposes of data
extraction and quality assessment.
b The study by Koltowski et al.51 was available only as a conference proceeding.
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in the pooled analysis because the numbers of true-positive, false-negative, false-positive and true-negative
test results were not reported. The sensitivity and specificity values reported in this study51 were 92.8%
and 100%, respectively.
Four meta-analyses were conducted to investigate the impact of using data for each combination of type
of lead-I ECG device (MyDiagnostick or Kardia Mobile) and interpreter (EP1 or EP2) from the Desteghe
et al. study38 from the results of the meta-analysis. Both EPs interpreted the lead-I ECG trace and the
12-lead ECG trace. The data based on the use of Kardia Mobile lead-I ECG device and interpretation by
EP1 were randomly selected to be included in the main analysis. Additional meta-analyses are presented as
sensitivity analyses (see Appendix 6, Figure 13).
One study39 reported data for one lead-I device (Kardia Mobile) and two different interpreters (a cardiologist
and a GP with an interest in cardiology) of lead-I and 12-lead ECG traces. The data interpreted by the
cardiologist were used in the main analysis because the interpreters in the other included studies were
either cardiologists or EPs. The analysis with data interpreted by the GP is presented as a sensitivity analysis
(see Appendix 6, Figure 17).
A forest plot displaying the results of the individual studies included in the meta-analysis is presented in
Figure 4.
A SROC plot that displays the individual study results as well as the meta-analysis result is presented in
Figure 5. A visual inspection of Figure 4 and the individual study results presented in Figure 5 shows that
the results were relatively homogeneous across the included studies in this meta-analysis. However,
owing to some potential heterogeneity between studies, we adopted a conservative approach and used a
bivariate model with random effects in the meta-analysis.
This meta-analysis included 580 participants, of whom 118 had AF. The pooled sensitivity was 93.9%
(95% CI 86.2% to 97.4%) and the pooled specificity was 96.5% (95% CI 90.4% to 98.8%).
All lead-I electrocardiogram devices: sensitivity analyses
Forest plots displaying the results of the individual studies included in the meta-analyses are presented in
Appendix 6, Figure 13.
Summary receiver operating characteristic plots are presented in Appendix 6, Figure 14. A visual inspection
of the forest plots (see Appendix 6, Figure 13) and the individual study results (see Appendix 6, Figure 14)
shows that the results were relatively homogeneous across the included studies in these meta-analyses.
However, owing to some potential heterogeneity between studies, we adopted a conservative approach
and used a bivariate model with random effects in the meta-analysis.
Pooled sensitivity values from these additional meta-analyses ranged from 89.8% to 91.8%, while pooled
specificity values ranged from 95.6% to 97.1% (Table 5). Overall, the use of either Kardia Mobile or
MyDiagnostick lead-I ECG and an interpretation by different EPs does not seem to make a difference to the
pooled results. Considering only the study by Desteghe et al.,38 specificity is similar across all combinations,
whereas the sensitivity of Kardia Mobile seems higher than the sensitivity of MyDiagnostick and EP1 seems
to show slightly higher sensitivity than EP2.
One study39 also presented data for one lead-I device (Kardia Mobile) that were interpreted by a GP with
an interest in cardiology, and these data were included in a sensitivity analysis. The forest plot displaying
the results of the individual studies included in the meta-analysis is presented in Appendix 6, Figure 17.
The SROC plot that shows the individual study results as well as the meta-analysis result is presented in
Appendix 6, Figure 18. When the results presented in Appendix 6, Figure 17, and the individual study
results presented in Appendix 6, Figure 18, were studied, they were found to be relatively homogeneous;
RESULTS OF THE ASSESSMENT OF DIAGNOSTIC TEST ACCURACY AND CLINICAL IMPACT
NIHR Journals Library www.journalslibrary.nihr.ac.uk
18
0.0 0.2 0.4 0.6 0.8 1.0 0.0 0.2 0.4 0.6 0.8 1.0
Study (first author 

























1.00 (0.83 to 1.00)
0.92 (0.81 to 0.98)
0.94 (0.73 to 1.00)
0.90 (0.73 to 0.98)
0.98 (0.95 to 0.99)
0.96 (0.86 to 1.00)
0.99 (0.95 to 1.00)
0.86 (0.76 to 0.94)
Specificity (95% CI)
FIGURE 4 Forest plot of individual studies included in the meta-analysis of all lead-I ECG devices; trace interpreted by a trained health-care professional (Kardia Mobile and
EP1 data from the Desteghe study). FN, false negative; FP, false positive; TN, true negative; TP, true positive. Reproduced from Duarte et al.67 © The Authors, 2019. This is an
Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and








































































































































































however, in the study by Williams et al.,39 specificity was lower when the lead-I ECG trace was interpreted
by the GP (76%), than when it was interpreted by a cardiologist (86%) (see Figure 4). Owing to some
potential heterogeneity between studies, we adopted a conservative approach and used a bivariate model
with random effects in the meta-analysis.
For this meta-analysis (number of AF cases, 118; total number of patients, 580), the sensitivity was 94.3%
(95% CI 87.9% to 97.4%) and the specificity was 96.0% (95% CI 85.4% to 99.0%).
Kardia Mobile lead-I electrocardiogram device
Data for the Kardia Mobile device were derived from only three studies.38,39,45 We conducted two
meta-analyses to investigate the impact of using data for each interpreter (EP1 or EP2) from the study by
Desteghe et al.38 on the results of the meta-analysis. Forest plots displaying the results of the individual
























FIGURE 5 Summary receiver operating characteristic plot for lead-I ECG device as index test with trace interpreted
by a trained health-care professional and 12-lead ECG interpreted by a trained health-care professional as
reference standard (using Kardia Mobile lead-I ECG device and EP1 data from the study by Desteghe et al.38).
TABLE 5 Results from the meta-analyses of all lead-I ECG devices (trace interpreted by a trained health-care
professional)
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For both meta-analyses, we fitted a univariate random-effects logistic regression model for specificity and a
univariate fixed-effects logistic regression model for sensitivity because minimal variability in sensitivity was
observed across the studies.
For the meta-analysis that included EP1 data from the study by Desteghe et al.38 (number of AF cases, 67;
total number of patients, 480), sensitivity was 94.0% (95% CI 85.1% to 97.7%) and specificity was
96.8% (95% CI 88.0% to 99.2%). For the meta-analysis that included EP2 results from the study by
Desteghe et al.38 (number of AF cases, 69; total number of patients, 484), sensitivity was lower, at 91.3%
(95% CI 82.0% to 96.0%), and specificity was slightly higher, at 97.4% (95% CI 88.3% to 99.5%). As
only three studies38,39,45 were included in this analysis, it was not possible to produce confidence regions.
There were insufficient data to generate pooled estimates of sensitivity and specificity for other types of
lead-I ECG device based on the interpreter of the lead-I ECG being a trained health-care professional, or to
assess differences between types of devices. The sensitivity and specificity estimates for Zenicor-ECG and
MyDiagnostick lead-I ECG devices are presented in Appendix 6, Figure 13.
Interpreter of lead-I electrocardiogram: algorithm
All lead-I electrocardiogram devices
We investigated the sensitivity and specificity of the lead-I ECG device when the trace was interpreted by the
device algorithm alone. The reference standard used was interpretation of the 12-lead ECG trace by a trained
health-care professional. Data from four studies38,47–49 were included in a meta-analysis. Two studies48,49 had
data for MyDiagnostick alone,48,49 one study47 had data for Kardia Mobile alone and one study38 had data
for MyDiagnostick and Kardia Mobile. One study50 reported sensitivity (67%) and specificity (97%) for
RhythmPad GP. Although the authors of this study50 provided the numbers for true-positive, false-negative,
false-positive and true-negative test results, these were not included in the pooled analysis because the
authors reported that the algorithm had since been modified (Chris Crockford, CardioCity, 3 August 2018,
personal communication via NICE). We conducted two meta-analyses in order to investigate the impact of
using data for each type of lead-I ECG device (MyDiagnostick or Kardia Mobile) from the study by Desteghe
et al.38 on the results of the initial meta-analysis. In the study by Desteghe et al.,38 the same patient cohort
was tested using both lead-I ECG devices. We performed multiple analyses in order to investigate the impact
of varying the type of lead-I ECG device on the results of the overall pooled analysis with no set of patients
double-counted. Forest plots displaying the results of the individual studies included in each meta-analysis are
presented in Figure 6.
The SROC plots are presented in Appendix 6, Figures 20 and 21. The results were relatively homogeneous
across the included studies in both meta-analyses. However, owing to some potential heterogeneity
between studies, we adopted a conservative approach and used a bivariate model with random effects in
the meta-analysis.
For the meta-analysis that included MyDiagnostick data from the study by Desteghe et al.38 (number of AF
cases, 219; total number of patients, 842), sensitivity was 96.2% (95% CI 86.0% to 99.0%) and specificity
was 95.2% (95% CI 92.9% to 96.8%). For the meta-analysis that included Kardia Mobile data from the
study by Desteghe et al.38 (number of AF cases, 219; total number of patients, 842), the pooled estimates
for sensitivity were 95.3% (95% CI 70.4% to 99.4%) and for specificity were 96.2% (95% CI 94.2% to
97.6%), which were similar to those obtained from the meta-analysis including MyDiagnostick data from
the study by Desteghe et al.38
MyDiagnostick lead-I electrocardiogram device
A forest plot displaying the results of the individual studies included in this meta-analysis is presented in
Appendix 6, Figure 22.
As only three studies38,48,49 were included in this analysis, it was not possible to produce a SROC plot with a
confidence region.
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FIGURE 6 Forest plots of individual studies included in each meta-analysis of all lead-I ECG devices (trace interpreted by the device algorithm). (a) MyDiagnostick data from the











































For MyDiagnostick, data from three studies38,48,49 (number of AF cases, 171; total number of patients, 638)
were included in the meta-analysis; sensitivity was 95.2% (95% CI 79.0% to 99.1%) and specificity was
94.4% (95% CI 91.9% to 96.2%). For this meta-analysis, we fitted a univariate random-effects logistic
regression model for sensitivity and a univariate fixed-effect logistic regression model for specificity because
minimal variability in specificity was observed across the studies. The results were relatively homogeneous
across the three included studies.
Kardia Mobile lead-I electrocardiogram device
We estimated sensitivity and specificity for the Kardia Mobile device, and for the MyDiagnostick device
separately. A forest plot displaying the results of the individual studies included in this meta-analysis is
presented in Appendix 6, Figure 23. In the study by Desteghe et al.,38 sensitivity was 55% (95% CI 32%
to 76%), much lower than that in the study by Lau et al.,47 which was 98% (95% CI 89% to 100%).
As only two studies38,47 were included in this analysis, it was not possible to produce a SROC plot with a
confidence region.
For Kardia Mobile, data from two studies (number of AF cases, 70; total number of patients, 469) were
included in the meta-analysis; sensitivity was 88.0% (95% CI 32.3% to 99.1%), and specificity was 97.2%
(95% CI 95.1% to 98.5%). For this meta-analysis, we fitted a univariate random-effects logistic regression
model for sensitivity and a univariate fixed-effect logistic regression model for specificity, because minimal
variability in specificity was observed across the studies.
Data were not sufficient to pool estimates of sensitivity and specificity for other types of lead-I device
based on the interpreter of the lead-I ECG being a trained health-care professional, or to formally assess
the differences between types of devices.
Summary of findings: diagnostic test accuracy
No studies were identified that evaluated the DTA of lead-I ECG devices in people presenting to primary
care with signs or symptoms of AF and an irregular pulse.
Of the nine included studies, only one study49 was conducted in primary care. The remaining eight studies
were conducted in secondary care, tertiary care or community settings.
Of the nine included studies, only one study38 explicitly stated that some patients (n = 11, 3.4%) had signs
or symptoms of AF on admission to a cardiology ward. Another study49 included a large proportion of
people with known AF (83.4%); however, it is not clear whether or not the patients had signs or symptoms
of AF at the time of the assessment and/or if the patients had been previously diagnosed with AF.
As prespecified in the protocol,68 owing to a lack of evidence, we next focused the reviews on an
asymptomatic population in any health-care setting. We considered an asymptomatic population to be
people not presenting with signs or symptoms of AF, with or without a previous diagnosis of AF. These
patients could have had co-existing cardiovascular conditions or could have been attending a cardiovascular
clinic but did not present with signs or symptoms of AF. We identified 13 publications38,39,41–51 reporting on
nine studies assessing the DTA of lead-I ECG devices in an asymptomatic population. However, all of these
studies were judged as having a high applicability concern for patient selection, as none was performed in
the population and setting of interest.
We included studies in which the interpreter of the lead-I ECG trace was a trained health-care
professional38,39,43,45,51 and studies that included interpretations of the lead-I ECG trace by the lead-I ECG
device algorithm only.38,47–50 The lead-I ECG devices used in the studies were Kardia Mobile,39,45,47
MyDiagnostick48,49 and Zenicor-ECG.43 The study by Desteghe et al.38 used both Kardia Mobile and
MyDiagnostick.
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The results from the meta-analyses are summarised in Table 6. Across all meta-analyses where the
interpreter of the lead-I ECG trace was a trained health-care professional, the sensitivity ranged from
89.8% to 94.3% and the specificity ranged from 95.6% to 97.4%. Across all meta-analyses where the
interpreter of the lead-I ECG trace was the device algorithm, the sensitivity ranged from 88% to 96.2%
and the specificity ranged from 94.4% to 97.2%. Pooled sensitivity and specificity values were similar
across the different meta-analyses, irrespective of the interpreter of the lead-I ECG trace or the lead-I ECG
device used. However, it should be noted that studies in which the index test was interpreted by the lead-I
ECG device algorithm alone were judged as having a high applicability concern for the index test domain.
This judgement was based on the consideration made by all manufacturers of the lead-I ECG devices that
the diagnosis of AF should not be made using the algorithm alone, and that the ECG traces measured by
the devices should be reviewed by a qualified health-care professional.
TABLE 6 Results from meta-analyses of lead-I ECG devices
















Lead-I ECG trace interpreted by a trained health-care professional (main analysis)
Kardia Mobile device,


































Lead-I ECG trace interpreted by a trained health-care professional (sensitivity analyses, GP datab)
Kardia Mobile device,







Lead-I ECG trace interpreted by a trained health-care professional (sensitivity analyses, Kardia Mobile)
Kardia Mobile device
and EP1a data










Lead-I ECG trace interpreted by lead-I ECG device algorithm alone




















a From the study by Desteghe et al.38
b From the study by Williams et al.39
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Details of the excluded studies that report sensitivity and specificity values for the lead-I ECG devices
investigated in this assessment, and the reasons for exclusion, are presented in Appendix 7.
Assessment of clinical impact
Characteristics of the included studies
The characteristics of the 18 quantitative studies included in the clinical impact review are summarised in
Table 7. One qualitative study53 included in the clinical impact review reported the results of semistructured
interviews with patients, receptionists, practice nurses and GPs.
Eleven of the studies included in the clinical impact review were cross-sectional studies,51,52,54,56–59,61,63–65
seven were case–control studies38,43,45,47,48,60,62 and one study was qualitative.53 Seven studies were conducted
in primary care,53,54,57–60,62 five were conducted in secondary care,43,47,48,63,65 two were conducted in tertiary
care38,51 and the remaining four were conducted in a community setting.52,56,61,64 One study45 included
participants recruited from secondary care, but also included (as separate groups) elite athletes and healthy
young adults. As discussed in Characteristics of the included studies, the results for these populations45 were
excluded from the analysis as these participants did not meet our inclusion criterion for population and do
not represent the typical population with AF (i.e. those aged ≥ 75 years).
Four studies included only people without known AF.52,58,61,65 Three studies54,59,64 may have included only
people without known AF as either participants were attending a primary care clinic or the study was
conducted in a community setting. However, these studies were available only as conference abstracts and
did not provide sufficient information to enable us to determine whether or not the population had a history
of AF. The remaining 11 studies38,43,45,47,48,51,56,57,60,62,63 recruited people with known AF or cardiovascular
comorbidities or who were attending a clinic for cardiovascular-related reasons.
Quality assessment
The methodological quality of the four cross-sectional52,56,57,61 and the two case–control studies60,62 included
in the clinical impact review of lead-I ECG devices, was assessed using the Newcastle–Ottawa quality
assessment scale.33,34 The results of the quality assessment of cross-sectional and case–control studies are
presented in Appendix 8, Table 40.
The methodological quality of the diagnostic accuracy studies included in the clinical impact review was
assessed using the QUADAS-2 tool.32 A summary of the results for the risk of bias in the studies38,43,45,47,48,51
that were included in the clinical impact review but had already been assessed as part of the DTA review is
presented in Table 4 and a full assessment is reported in Appendix 5. A summary of the risk of bias for
one diagnostic accuracy study63 not eligible for inclusion in the DTA review is presented in Appendix 8,
Table 41; the full quality assessment for this study63 is presented in Appendix 5.
Five studies54,58,59,64,65 that were available only as conference abstracts and were assessed as meeting the
study eligibility criteria for inclusion in the clinical impact review were subjected to data extraction only and
not to quality assessment, because there was not enough information to allow a judgement to be made
on some of the quality assessment criteria.
Overall, the quality of the four cross-sectional52,56,57,61 and the two case–control studies60,62 was similar across
the different domains. None of the included studies was considered to be representative of the target
population. Only one study61 included a sample size calculation. In all studies, the test failure rate was low;
therefore, the response rate was considered satisfactory. All of the included studies described the intervention.
None of the studies accounted for confounding factors in the analyses presented. An assessment of the
outcome was described in all of the studies; however, those studies with independent blind assessment or record
linkage were judged as being of better quality than the studies without blind assessment or record linkage.
The statistical tests used to analyse the data were clearly described and appropriate in all included studies.
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known AF or implanted
pacemaker; N = 855;
campaign for rhythm
awareness in a shopping
centre
NR MyDiagnostick Cardiologist NA
Chan, 201756 Cross-sectional; China;
community
People aged ≥ 18 years;
N = 13,122; screening
programme publicised via
channels including media
promotion and placement of




n = 9384 (71.5%)
Hypertension: n = 5012
(38.2%)
Diabetes: n = 1944 (14.8%)
Hyperlipidaemia: n = 2613
(19.9%)
Heart failure: n = 97 (0.7%)
Stroke: n = 367 (2.8%)
Coronary artery disease:
n = 295 (2.2%)
Valvular heart disease:
n = 114 (0.9%)
Peripheral vascular disease:
n = 66 (0.5%)
Obstructive sleep apnoea:
n = 146 (1.1%)
Thyroid disease: n = 517
(3.9%)
COPD: n = 56 (0.4%)
Cardiothoracic surgery:
n = 354 (2.7%)


















































Mean age and SD (years);
sex; risk factors for AF Lead-I ECG device
Interpreter of lead-I
ECG Test sequence
Chan, 201657 Cross-sectional; China;
primary care
People with history of
hypertension and/or diabetes
mellitus or aged ≥ 65 years;
N = 1013; patients recruited
from a general outpatient
clinic
68.4± 12.2; Sex: 539
(53.2%) female
Hypertension: n = 916
(90.4%)
Diabetes: n = 371 (36.6%)
Coronary artery disease:
n = 164 (16.2%)
Previous stroke: n = 106
(10.5%)
Mean CHA2DS2-VASc± SD –
3.0± 1.5
Kardia Mobile Algorithm and
cardiologist
12-lead ECG performed
only when a diagnosis of AF
was made by the algorithm
(results not presented)
Chan, 201754 Cross-sectional; Hong
Kong; primary care
Patients aged ≥ 65 years
attending primary care
clinics; N = 1041; NR
Aged ≥ 65 years;
NR






ward; N = 265; NR
67.9± 14.6; female,
n = 138 (43.1%);
Pacemaker: 4 out of 55
(7.3%) were intermittently
paced, and 18 out of 55
(32.7%) were not being
paced during the recordings
Known AF: 114 out of 320
(35.6%)
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People with atrial fibrillation,
atrial flutter or sinus rhythm;
N = 100; patients were
recruited from a cardiology
outpatient clinic






Patients aged ≥ 65 years
without a diagnosis of AF,
attending a practice nurse or
health-care assistant clinic;
N = 445; NR






Healthy young adults, elite
athletes and cardiology clinic
patients; N = 130; NRa
59± 15; male, n = 73
(56%); NR






Patients attending a flu
clinic; N = 357; lead-I ECG
used while patients waited
for flu vaccination
Aged > 65 years: n = 257;
NR





Patients aged ≥ 60 years
with and without known AF
attending for flu vaccination;
N = 3269; asked by nurses










Patients in a tertiary care
centre; N = 100; NR
NR Kardia Mobile Cardiologist Lead-I ECG followed by
12-lead ECG
Lau, 201347 Case–control; Australia;
secondary care
Patients at cardiology
department; N = 204; NR
NR;
Known AF: n = 48 (24%)
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People aged ≥ 65 years
entering the pharmacy
without a severe coexisting
medical condition; N = 1000;





and staff also directly
approached potentially
eligible clients
76± 7; male, n = 436
(44%);
NR
Kardia Mobile Algorithm and
cardiologist
Pulse palpation followed by
lead-I ECG (12-lead ECG
used for participants with
suspected unknown AF





Patients with known AF and
patients without a history
of AF attending for flu
vaccination; N = 972
New AF: n = 7; 80 ± 3;
male; 3 out of 7 male;
Known AF: n = 29;
77.1± 1; male; n = 15
(52%)
All AF (N = 36);
78 years ± 1; male, n = 18
(50%); NR
Kardia Mobile Algorithm and
cardiologist
Lead-I ECG followed by
12-lead ECG in cases where
AF was detected by lead-I
(and was a new diagnosis)
Reeves, (NR)63 Cross-sectional; UK;
secondary care
Patients aged ≥ 18 years
recovering in the cardiac
intensive care unit or a cardiac
surgery ward, following
cardiac surgery, or who
had been admitted to the
coronary care unit or a
cardiology ward after a
cardiac related event; N = 53;
research nurses working in
one or other of the clinical
settings identified and
approached eligible patients


























































































































































































Mean age and SD (years);








Patients with known AF and
patients without a history of
AF visiting an outpatient
cardiology clinic or a
specialised AF outpatient
clinic; N = 192; random
selection of patients due to
have a 12-lead ECG
69.4± 12.6; male, 48.4%;
NR
MyDiagnostick Algorithm Lead-I ECG followed by
12-lead ECG
Primary care People with unknown AF
status; N = 676; people











People aged ≥ 65 years;
N = 1153; NR
NR Kardia Mobile Cardiologist NA
Yan, 201665 Cross-sectional; Hong
Kong; secondary care
People aged ≥ 65 years
without a history of AF;
N = 9046; consecutive
patients attending clinics
79± 12.1; male, 49.4%;
NR
Kardia Mobile Cardiologist NA
COPD, chronic obstructive pulmonary disease; NA, not applicable; NR, not reported; SD, standard deviation.











































The diagnostic accuracy study63 was judged as being at an unclear risk of bias and having a high applicability
concern for patient selection. This study63 was judged as being at low risk of bias on the index test domain
as the test results were interpreted without knowledge of the reference standard test result and, therefore,
there was also low applicability concern for this domain. All of the interpreters of the reference standard
test results were blind to the results of the index test; therefore, the study63 was judged as being at low risk
of bias for the reference standard domain. However, there were two reference standards: (1) a clinical ECG
diagnosis based on additional information not available to the assessors, and (2) consensus (three of the
four assessors) that matched this clinical ECG diagnosis. Therefore, this study63 was judged as having a high
concern regarding applicability of the reference standard test.
The methodological quality of the qualitative study53 included in the clinical impact review was assessed
using the CASP tool36 and the results are presented in Appendix 8, Table 42. In the qualitative study,53
semistructured interviews were conducted with two receptionists, one nurse, three GPs and eight patients
across three GP practices. The aim of the study was to investigate the feasibility of using practice nurses
and receptionists to systematically screen patients aged ≥ 65 years for AF using a lead-I ECG device
(Kardia Mobile) prior to the GP consultation. No details were available about the selection of the
interviewees; although the study aim was to investigate the feasibility for practice nurses and receptionists
to use the lead-I ECG device, these were the least represented groups in the interviews. The researchers do
not discuss their own potential biases, such as relationships with participants or choice of locations for the
study. Although the methods are not described in depth, the publication clearly states how the interviews
were analysed and how themes were derived from the data and that interviews ceased once information
saturation was reached. The duration of the interviews ranged from 5 to 40 minutes. Considering that
there were four different groups of participants (i.e. receptionists, nurses, GPs and patients), it is unclear
how information saturation was reached, especially for nurses’ views, as only one nurse was interviewed.
Clinical impact results
Intermediate outcomes
The results for the most commonly reported intermediate outcomes (test failure rate, time to complete test
and store the ECG trace, number of 12 lead ECGs carried out and diagnostic yield) are provided in Table 8.
Results for failure rate included both failure of the lead-I ECG algorithm to produce a result and poor
quality of the lead-I ECG trace (i.e. uninterpretable or illegible trace).
Time to diagnosis of AF was reported in only one study61 [16.6 ± 14.3 days (mean ± standard deviation)].
This was measured as the mean time between the initial diagnostic test with the lead-I ECG device at a
pharmacy and the confirmation of result with a 12-lead ECG.
One study48 reported that the participants were able to use the MyDiagnostick device with minimal
instructions and another study reported that the Kardia Mobile lead-I ECG device was easy to operate.54
A key barrier was identified relating to the ease of use of the lead-I ECG devices. Specifically, it was difficult
for elderly patients to hold the device very still, which was required to take a reading.62 One study38 reported
that 24 out of 344 (7%) patients were excluded because they were not able to hold the devices properly
(MyDiagnostick and Kardia Mobile lead-I ECG devices were used in the study and the type of lead-I ECG
device, on which this proportion is based, was not provided).
Only the study by Desteghe et al.38 reported the concordance between lead-I ECG devices (Kardia Mobile
and MyDiagnostick) and there were no differences in agreement (based on kappa values) between devices
when all patients were included (p = 0.677) and after patients with an implanted device (i.e. pacemaker or
implantable cardioverter defibrillator) were excluded (p = 0.411).
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Battipaglia, 201652 MyDiagnostick 60 out of 855 (7%) 15-second rhythm strips NA 7 out of 855 (0.8%)
Chan, 201656 Kardia Mobile 56 out of 13,122 (0.4%) 30-second rhythm strips NA 101 out of 13122 (0.8%)
Chan, 201657 Kardia Mobile 13 out of 1026 (1.3%) 30-second rhythm strips Unclear 5 out of 1013 (0.5%)
Chan, 201754 Kardia Mobile NR NR NA 15 out of 1041 (1.4%)
Desteghe, 201738 MyDiagnostick
and Kardia Mobile
MyDiagnostick 8 out of 265 (3%) for both EP1 and
EP2
Kardia Mobile 10 out of 265 (3.8%) for EP1 and 6 out
of 265 (2.3%) for EP2
MyDiagnostick – 1-minute recording
Kardia Mobile – 30-second recording
265 1 out of 265 (0.4%)
Doliwa, 200943 Zenicor-ECG NR 10-second rhythm trace.
Registration, transfer and evaluation
of the information take ≤ 5 minutes
100 NR
Gibson, 201758 MyDiagnostick NR NR NA 26 out of 445 (5.8%)
Haberman, 201545 Kardia Mobile 1 out of 381 (0.3%) based on overall study
population
NR 130 NR
Hussain, 201659 Kardia Mobile NR 30–45 seconds to apply NA 6 out of 357 (1.7%)
Kaasenbrood, 201660 MyDiagnostick 3 out of 3269 (0.1%) uninterpretable results 1-minute recording NA 37 out of 3269 (1.1%)
Koltowski, 201751 Kardia Mobile NR NR 100 NR
Lau, 201347 Kardia Mobile NR 1 minute 204 NR
Lowres, 201461 Kardia Mobile 4 out of 1000 (0.4%) excluded as a result of excessive
movement artefact
≤ 5 minutes 35 15 out of 1000 (1.5%)
Orchard, 201662 Kardia Mobile 82 out of 1044 (7.9%) recorded ECGs unclassified of
which 20 were as a result of unreadable trace
5 minutes (range 1.5 to 10 minutes) 30 8 out of 973 (0.8%)
Reeves, (NR)63 imPulse 5 out of 53 (9%) 2-minute recording 53 NR
Tieleman, 201448 MyDiagnostick NR 1-minute recording 192 (secondary
care population)
11 out of 676 (1.6%)
(primary care population)
Waring, 201664 Kardia Mobile NR NR NA 5 out of 1153 (0.4%)
Yan, 201665 Kardia Mobile NR NR NA 121 out of 9046 (1.3%)











































Two studies59,61 reported the impact of test results on clinical decision-making. In the study by Hussain and
Thakar,59 there was a change in treatment management as a result of using the Kardia Mobile lead-I ECG
device for five out of six new cases of AF in 357 people tested (one patient was clinically unwell and died
as an inpatient following referral to the hospital). In the study by Lowres et al.,61 oral anticoagulants
(OACs) were prescribed in 6 out of 10 new cases of AF as a consequence of using the lead-I ECG device
followed by a 12-lead ECG interpreted by a cardiologist. Of five participants with unknown recurrence of
AF ≥ 3 years after cardioversion, three were prescribed OACs following review by a cardiologist.61
Diagnostic yield was reported in 13 studies.38,48,52,54,56–62,64,65 The proportion of new patients diagnosed with
AF ranged from 0.4% to 5.8%. The proportions of new patients diagnosed with AF in all of the included
studies are presented in Appendix 9, Figure 24, in Appendix 9, Figure 25 (studies grouped by type of lead-I
ECG device) and in Appendix 9, Figure 26 (studies grouped by setting).
Time to initiation of preventative treatment was not reported in any of the identified studies.
Clinical outcomes
Only one study59 reported clinical outcomes. One patient had a normal 12-lead ECG trace and did not
receive anticoagulant therapy, but later had a stroke. The authors reported that the Kardia Mobile lead-I
ECG trace had been difficult to interpret for this patient, who probably had AF.
Acceptability and patient-reported outcomes
The acceptability of the lead-I ECG devices was reported in four studies.54,58,59,62 In one of the studies using
the Kardia Mobile lead-I ECG device, the staff indicated that the patients generally liked the device and
the screening process. It was also reported that the GPs liked the lead-I ECG device because it raised
awareness of AF and nurses could perform the screening.62 One study reported that all patients were
willing to undergo repeated screening with the Kardia Mobile lead-I ECG device in future GP visits, and
86% of the GPs considered that the lead-I ECG device was useful for AF screening and said that they
would use it in their daily practice.54 Although the views were generally positive, one study reported that
patients’ suggestions for improvements in the use of the MyDiagnostick lead-I ECG device included having
more time to make decisions about taking the test and being given a clearer explanation of the results
(it was unclear if this was in the context of patient self-use of the device or the clinician’s explanation of the
results).58 In the same study, interviews with seven staff members suggested that, although the opportunity
to detect and treat AF was valued, challenges (e.g. technical problems, documentation and referral, and
management of workload) needed to be overcome.58 In another study,59 the process was found to be
acceptable and it was reported that the Kardia Mobile lead-I ECG test was easily administered and that no
patients refused to be tested.
Barriers to and enablers of the use of lead-I ECG devices for AF screening in primary care were explored in
a qualitative study.53 This study investigated the feasibility of using practice nurses and receptionists to
systematically screen patients aged ≥ 65 years for AF using a lead-I ECG device (Kardia Mobile) prior to a
GP consultation. Barriers that were identified by three GPs were having to rely on others to carry out the
screening, not having the required software, information technology (IT) being blocked, having to remember
to charge the phone and the technology not working. GPs liked the lead-I ECG device and its portability, and
they considered that use of the lead-I ECG device could add value, provide reassurance and act as a prompt
to look for other health conditions. The eight patients who were interviewed did not understand the reasons
for screening and were not interested in whether or not the result was negative. However, they considered
that having access to the lead-I ECG device in the surgery was more convenient than having to attend
another health-care facility for a 12-lead ECG, and they stated that they were impressed with the technology.
One practice nurse mentioned two barriers: (1) the possible lack of availability of the lead-I ECG device when
required and (2) that the results needed to be reviewed by a GP. The practice nurse was able to confidently
screen patients and explain the process. The nurse considered that the use of the lead-I ECG device raised
awareness of AF in the practice and believed that the lead-I ECG device algorithm was an enabler of the
screening for AF. Although both receptionists expressed their ease with using the device, they explicitly
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identified only barriers: they were reluctant to ask patients to use the lead-I ECG device, were uncertain
about how to explain the purpose of the AF screening and were unsure how to respond to patients’
questions.
None of the studies identified reported on HRQoL.
‘Real-world’ data
Evidence was submitted on the use of Kardia Mobile lead-I ECG across Eastbourne, Hailsham and Seaford
Clinical Commissioning Group (CCG) and Hastings and Rother CCG (Kent Surrey Sussex AHSN and Richard
Blakey, AliveCor in East Sussex, unpublished evidence submitted via NICE, 28 March 2018). Over a 2-year
period, Kardia Mobile lead-I ECG was used in primary care or during home visits if people were found to
have an irregular pulse or symptoms indicative of AF. During this time, 183 lead-I ECG traces were reported,
identifying 128 new cases of AF. The percentage of new patients diagnosed with AF during the project was
69.9%, which is considerably higher than the diagnostic yield reported in our included studies (0.4–5.8%).
There was also a higher increase in the prevalence of AF in the participating CCGs (2.73–2.96% for Hastings
& Rother CCG and 3.01–3.22% for Eastbourne, Hailsham & Seaford CCG) than for other CCGs in the Kent
Surrey Sussex AHSN.11
Summary of findings: clinical impact
As per the DTA review, no studies were identified that evaluated the clinical impact of lead-I ECG devices
in people presenting to primary care with signs or symptoms of AF and an irregular pulse, which limits the
applicability of the results presented. Therefore, the 24 publications38,41–48,51–65 reporting on the 19 studies
that were included in the clinical impact review were focused on an asymptomatic population. Four studies
included only people without known AF.52,58,61,65 Three studies54,59,64 may have included only people without
known AF, as either participants were attending a primary care clinic or the study was conducted in a
community setting. However, the information describing these studies was limited and the data were
available only as conference abstracts.
Test failure rate was reported in nine studies38,45,52,56,57,60–63 and ranged from 0.1% to 9%. Results for test
failure rate included both failure of the lead-I ECG algorithm to produce a result and poor quality of the
lead-I ECG trace. Diagnostic yield was reported in 13 studies.38,48,52,54,56–62,64,65 The percentage of new
patients diagnosed with AF ranged from 0.38% to 5.84%. Two studies59,61 reported a change in treatment
management following the use of the Kardia Mobile lead-I ECG for new patients diagnosed with AF.
Acceptability of lead-I ECG devices was reported in four studies,54,58,59,62 with generally positive views.
Time to initiation of preventative treatment and HRQoL were not reported in any of the identified studies.
The ‘real-world’ data submitted by Kent Surrey Sussex AHSN reports on the use of Kardia Mobile lead-I
ECG device for people with signs or symptoms of AF and an irregular pulse during a 2-year project.
Although the information available was limited [Microsoft PowerPoint presentation (Microsoft Corporation,
Redmond, WA, USA) and a one-page summary], we considered it relevant to the population of interest.
Data from this 2-year project showed that the percentage of new patients diagnosed with AF during the
project was 69.9%, which is considerably higher than the diagnostic yield reported in our included studies
(0.4–5.8%).
RESULTS OF THE ASSESSMENT OF DIAGNOSTIC TEST ACCURACY AND CLINICAL IMPACT
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Chapter 4 Methods for assessing cost-effectiveness
The External Assessment Group’s (EAG’s) economic evaluation assesses the cost-effectiveness of singletime point lead-I ECG devices compared with MPP for people presenting to primary care with signs or
symptoms of AF who have an irregular pulse followed by a 12-lead ECG in primary or secondary care.
The economic evaluation includes a systematic review of existing economic evaluations of lead-I ECG
devices and the creation of a de novo economic model.
The economic evaluation is applicable to the use of lead-I ECG devices in primary care practices where
there is a wait of ≥ 48 hours between initial presentation and follow-up with a 12-lead ECG.
Systematic review of cost-effectiveness evidence
Search strategy
The EAG undertook a systematic review to identify published full economic evaluations of lead-I ECG
devices for detecting AF. A search filter to identify economic evaluations was applied to the search
strategies and the electronic databases were searched from inception until 24 April 2018. The search
strategy used in MEDLINE is presented in Appendix 10. The MEDLINE search was adapted to enable similar
searching of the other relevant electronic databases. The following databases were searched for relevant
studies:
l MEDLINE (via Ovid)
l MEDLINE Epub Ahead of Print and MEDLINE In-Process & Other Non-Indexed Citations (via Ovid)
l EMBASE (via Ovid)
l PubMed
l EconLit (via EBSCOhost)
l NHS Economic Evaluation Database.
The results of the searches were uploaded to, and managed using, EndNote X8 software. The reference
lists of relevant systematic reviews and eligible studies were hand-searched to identify further potentially
relevant studies.
Broader searches were carried out to identify existing economic models of ECG devices when used for
the detection of AF. Separate searches were carried out to identify supporting information on costs and
health-state utility data.
Eligibility criteria
In stage 1, all titles and abstracts identified via searches of the electronic databases were screened for
relevance according to prespecified eligibility criteria (Table 9). Any studies that did not meet the criteria
were excluded. The EAG planned to obtain full-text manuscripts for all economic evaluations identified at
stage 1 to assess relevance against the prespecified eligibility criteria (stage 2).
Data extraction and quality assessment strategy
The EAG planned to extract data relating to bibliographic information [author(s) and year of publication];
general information [country, condition, intervention and comparator(s)]; methodological characteristics
(type of economic evaluation, perspective, time horizon, discount rate, key cost categories, year of
valuation and key outcomes) and main findings. The EAG planned to assess the quality of all economic
evaluations identified for inclusion in the review using the Drummond 10-point checklist.69
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Results of the systematic review of existing cost-effectiveness evidence
The searches of electronic databases identified 40 unique citations after de-duplication. Following
screening of titles and abstracts, all 40 records were excluded as they did not include the relevant
interventions or comparator, did not consider an eligible study population or were not full economic
evaluations.
Conclusions of the systematic review of cost-effectiveness evidence
The EAG did not identify any published papers that met the inclusion criteria for the systematic review.
Development of a de novo economic model
Approach to modelling
The EAG did not identify any studies in a systematic review of the economic literature that evaluated the
cost-effectiveness of single time point lead-I ECG devices compared with MPP followed by a 12-lead ECG
in primary or secondary care (prior to initiation of anticoagulation therapy) in people presenting to primary
care with signs or symptoms of AF who have an irregular pulse. The EAG therefore undertook a de novo
economic analysis.
The economic analysis follows the diagnostic pathway for patients presenting to primary care with signs or
symptoms indicative of AF plus an irregular pulse. The results are presented over a time horizon of 30 years,
with patients entering the model at the age of 70 years.
The economic evaluation is relevant only to primary care practices where patients have to wait ≥ 48 hours
between an initial consultation with the GP and a 12-lead ECG; this allows the benefit of early anticoagulation
and rate-control treatment for those patients who receive a positive lead-I ECG to be considered.
A decision tree and two cohort Markov models were built in Microsoft Excel® (Microsoft Corporation,
Redmond, WA, USA). The decision tree describes the pathway that a patient presenting to primary care
with signs or symptoms of AF and an irregular pulse follows in the initial GP consultation. The first Markov
model captures the differences in the costs and benefits of treatment (standard diagnostic pathway
compared with lead-I ECG pathway) during the first 3 months after the initial appointment. During this
period, some patients will have a diagnosis of AF and start treatment for AF, whereas other patients will
have further tests to diagnose or to rule out AF (where ‘rule out’ means that no diagnosis of AF is
recorded in the patient’s notes and no treatment for AF is started). The second Markov model captures
the differences in lifetime costs and benefits after diagnosis of AF or the time when AF is ruled out.
TABLE 9 Eligibility criteria for economic literature search
Characteristic Inclusion criteria Exclusion criteria
Intervention or
comparator
Single time point lead-I or single lead ECG, MPP Ambulatory, inserted, multiple
assessments
Indication AF Not AF
Study designa Full economic evaluation Partial economic evaluation,
methodological paper
Perspective UK or European perspective Non-European perspective
Population Adults with signs or symptoms indicative of AF plus irregular pulse
assessed by MPPs presenting at primary care
Screening population, adults
with asymptomatic or silent AF
a Studies published as letters or abstracts/conference proceedings only were considered for inclusion if sufficient
information was available.
METHODS FOR ASSESSING COST-EFFECTIVENESS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
36
Population
The modelled patient population is adults presenting to primary care with signs or symptoms of AF who
have an irregular pulse. The DTA data included in the model are based on the results of a systematic review
(see Chapter 3, Study selection). However, no studies included in the systematic review were carried out in
the population of interest. All studies included asymptomatic patients who either had a known history of AF
or were recruited from cardiology clinics, except for one study49 that was carried out in primary care. It has
been recognised that diagnostic accuracy test specificity and sensitivity values may be affected by prevalence;
the use of a test in a more severely diseased population is associated with better performance of the test.70
It is therefore possible that the sensitivity and specificity data from the systematic review do not represent
the true DTA of lead-I ECG devices in the population of interest. It is not possible to know how the sensitivity
and specificity of lead-I ECG devices would be affected if different populations were tested. The economic
evaluation is therefore limited by the lack of DTA data in the population of interest.
The symptomatic population with an irregular pulse is assumed to consist of people with AF and people
with atrial or ventricular ectopy. Clinical advice to the EAG is that the only other condition that would
produce an irregular pulse similar to that found with AF is atrial or ventricular ectopy. It is assumed that
the symptoms of patients with AF, or atrial or ventricular ectopy, are not severe enough to require urgent
referral to cardiology. Advice from the NICE Clinical Knowledge Summary71 on managing atrial and
ventricular ectopy for patients without underlying heart disease is to reassure patients.
The mean age of patients in the base-case model is 70 years. The proportions of men and women are
based on the age-adjusted ratio in the general population.72
Comparators
Diagnostic test accuracy data were not available for the population of interest (symptomatic patients with
suspected AF and an irregular pulse presenting to primary care) for any of the devices listed in the final
scope issued by NICE9 (see Chapter 3, Characteristics of the included studies). The EAG therefore searched
for DTA data in an asymptomatic population as prespecified in the protocol to use as a proxy for the
population of interest. The economic model includes only the diagnostic strategies for which proxy DTA
data were available. The diagnostic strategies (following MPP and before 12-lead ECG) included in the
economic model are:
l standard diagnostic pathway (no further testing)
l any lead-I ECG device (interpreted by trained health-care professional)
l imPulse (interpreted by trained health-care professional)
l Kardia Mobile (interpreted by trained health-care professional)
l MyDiagnostick (interpreted by trained health-care professional)
l RhythmPad-GP (interpreted by algorithm)
l Zenicor-ECG (interpreted by trained health-care professional).
Model structure
The model comprises decision trees and two cohort Markov models that describe the patient pathway over
a lifetime horizon of 30 years. A decision tree covers the patient pathway in the initial consultation. Patients
then feed into a cohort Markov structure with daily cycles for 3 months. This first Markov model includes
all testing for AF after the initial GP consultation (12-lead ECG and Holter monitoring for paroxysmal AF).
By the end of the first 3-month Markov model, all patients either have an AF diagnosis or have AF ruled
out. Patients then move into the second Markov model. All patients in the second Markov model have AF
diagnosed or ruled out (either correctly or incorrectly). Patients remain in the second Markov model until
death. The cycle length is 3 months in the second Markov model. Costs and benefits are discounted at
3.5% per year.
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Diagnostic phase
The diagnostic phase of the model encompasses the initial consultation and the following 3 months.
At the end of the first 3-month period in the model, all patients who remain alive have had AF either
diagnosed or ruled out (whether correctly or incorrectly; here ‘ruled out’ means that no diagnosis of AF
is recorded in the patient’s notes and no treatment for AF has started).
A decision tree structure describes the pathway that a patient presenting to primary care with signs or
symptoms of AF and an irregular pulse follows in the initial GP consultation. Patients then enter a cohort
Markov model either in a testing state (while waiting for the results of a 12-lead ECG or paroxysmal test)
or in a diagnosed state (AF diagnosed or ruled out). Patients may stay in the testing period for a maximum
number of days, depending on the test. Clinical advice to the EAG is that patients who cannot have a
12-lead ECG in the GP practice immediately would have to wait between 2 and 14 days for the test.
Patients receiving testing for paroxysmal AF using a Holter monitor will stay in the paroxysmal testing state
for 7 days.
At the end of the testing period, patients who received a 12-lead ECG may move to another testing state
(paroxysmal test), to a diagnosed state (AF diagnosed or ruled out) or to the death state. At the end of
the testing period, patients receiving a paroxysmal test may move to a diagnosed state (AF diagnosed or
ruled out) or to the death state.
Patients may move out of a testing state before the end of the testing period by experiencing a cardiovascular
event (CVE) or death. Patients who experience a CVE and who have not had AF diagnosed or ruled out are
assumed to receive a diagnosis as part of treatment for the CVE. CVEs included in the model are TIA, ischaemic
stroke (IS) and haemorrhagic stroke (HS). Patients can experience up to two CVEs. Clinically relevant adverse
events (AEs) are included in the model (e.g. non-major bleeds). An AE can be experienced in any state and
does not affect the risk of transition to another state.
The schematics for the decision tree element of the diagnostic phase of the model are shown in Figures 7–9.
The schematic for the Markov element of the diagnostic phase of the model is shown in Figure 10.
Standard pathway
All patients in the standard pathway are sent for a 12-lead ECG. No patients receive treatment for AF
while waiting for the 12-lead ECG test.
All patients with a positive result from a 12-lead ECG are assumed to be correctly diagnosed with AF and
begin treatment. A proportion of patients with a negative result from the 12-lead ECG are sent for further
testing for paroxysmal AF and a proportion of patients have AF ruled out at this point in the pathway.
All patients with a positive result from further testing for paroxysmal AF with a Holter monitor are correctly
diagnosed with AF and begin treatment. All patients with a negative result from a paroxysmal test have AF
ruled out. A proportion of patients who have AF ruled out after either a 12-lead ECG or a paroxysmal test
will have false-negative results owing to patients with paroxysmal AF not being in AF at the time of the
12-lead ECG or paroxysmal test.
Lead-I electrocardiogram pathway: positive result
All patients in the lead-I ECG pathway with a positive result from a lead-I ECG (who are either true
positives or false positives for AF) are diagnosed with AF and sent for a 12-lead ECG following the initial
consultation. Clinical advice to NICE, as reported in the final scope,9 is that a 12-lead ECG is important so
that any additional abnormalities can be identified in people diagnosed with AF, such as left ventricular
hypertrophy. All patients in the lead-I ECG pathway with a positive result from a lead-I ECG begin
rate-control treatment for AF, but do not receive Holter monitoring to test for paroxysmal AF, before the
12-lead ECG. As per the final scope issued by NICE,9 patients with positive lead-I ECG test results begin
rate-control treatment and NOACs after the initial GP consultation unless contraindicated.
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Patients with a positive 12-lead ECG result retain the (correct) diagnosis of AF and continue treatment.
Patients with a negative 12-lead ECG result are assumed to have paroxysmal AF and continue treatment,
have AF ruled out and discontinue treatment for AF or are sent for further testing for paroxysmal AF.
The last group of patients remains on treatment during further testing.
All patients with a positive result from a paroxysmal test are correctly diagnosed with AF and stay
on treatment. Patients with a negative result from a paroxysmal test either have AF ruled out and
discontinue treatment or are assumed to have paroxysmal AF based on the original lead-I ECG diagnosis
and continue treatment despite the negative 12-lead ECG and paroxysmal test result. A proportion of
patients who have AF ruled out after either a 12-lead ECG or a paroxysmal test will have false-negative
results owing to patients with paroxysmal AF not being in AF at the time of the 12-lead ECG or
paroxysmal test.
Lead-I electrocardiogram pathway: negative result
No patients begin treatment following a negative result from a lead-I ECG test. Clinical advice to the
EAG about whether patients who receive a negative result from a lead-I ECG device would be sent for a
12-lead ECG or for further testing for paroxysmal AF (see Appendix 11) indicated substantial variation in
clinical practice. The EAG has assumed in the base case that 80% of patients who receive a negative result
from a lead-I ECG device would be sent for a 12-lead ECG, 10% would be sent for ambulatory Holter
monitoring and the remaining 10% of patients would have AF ruled out. The EAG acknowledges that
this base case may not represent clinical practice anywhere in the UK; however, it considers that these
assumptions may represent ‘average’ clinical practice, given the variation in clinical advice received. These
assumptions are tested in scenario analyses.
All patients with a positive result from a 12-lead ECG are correctly diagnosed with AF and begin rate-
control treatment and NOACs. A proportion of patients with a negative result from the 12-lead ECG are
sent for further testing for paroxysmal AF and a proportion of patients have AF ruled out at this point in
the pathway. All patients with a positive result from a paroxysmal test are correctly diagnosed with AF and
begin treatment. All patients with a negative result from a paroxysmal test have AF ruled out. A proportion
of patients who have AF ruled out after either a 12-lead ECG or a paroxysmal test will have false-negative
results owing to patients with paroxysmal AF not being in AF at the time of testing.
Post-diagnostic phase
Once AF has been either diagnosed or ruled out, patients move into a second cohort Markov model that
tracks the costs and benefits of these decisions over their lifetime (Figure 11). The second Markov model
follows the same structure as the first Markov model after AF has been diagnosed or ruled out. Patients enter
the second Markov model in a diagnosed state (AF diagnosed or ruled out) having experienced zero, one or
two CVEs. In each cycle, patients with zero or one previous CVE can remain in their current state, move to a
worse state following a CVE or move to the death state. Patients with two previous CVEs remain in that state
until death. Patients who have incorrectly had AF ruled out and experience a CVE are assumed to have their
AF diagnosed as part of the treatment for the CVE. These patients then move on to treatment for AF.
Model parameters
Patient population
Signs or symptoms of atrial fibrillation
The modelled patient population is people with signs or symptoms of AF plus an irregular pulse. This
population comprises patients with AF and patients without AF who are similarly symptomatic. Clinical
advice to the EAG is that the symptomatic population with an irregular pulse but without AF will consist
of people with atrial or ventricular ectopy. Estimates of the proportion of patients with signs or symptoms
of AF plus an irregular pulse who have AF compared with those who have atrial or ventricular ectopy were
not available in the literature. Clinical advice to the EAG is that around 20% of patients with signs or
symptoms of AF plus an irregular pulse will have AF.
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Prevalence of atrial fibrillation
Estimates of the prevalence of AF by age and sex were taken from a paper by Adderley et al.12 The age-
and sex-specific prevalence estimates reported by Adderley et al.12 are based on the results of a study
carried out using primary care records from UK general practice in 2016. The prevalence estimates in this
paper12 were identified by the EAG as being the most up-to-date estimates available for the UK primary
care population. The age- and sex-standardised prevalence rates used in the model are shown in Table 10.
Proportion of atrial fibrillation population who are symptomatic
The proportion of patients with AF who are symptomatic is taken from an observational cohort study of
data from the US Outcomes Registry for Better Informed Treatment of Atrial Fibrillation by Piccini et al.73
The study reported that women with AF were more likely to be symptomatic than men with AF (67.9% vs.
57.5%). The proportions of women and men with AF who are symptomatic used in the model are 0.679















FIGURE 11 Post-diagnostic phase: Markov model. Note: death is possible from all states.
TABLE 10 Prevalence of AF by age and sex
Age group (years)
Prevalence per 1000 population
Men (95% CI)a Women (95% CI)a
45–54 7.60 (5.90 to 9.30) 2.55 (2.26 to 2.88)
55–64 24.01 (23.18 to 24.86) 9.28 (8.79 to 9.86)
65–74 66.78 (65.85 to 67.70) 34.25 (33.33 to 35.19)
75–84 147.38 (145.20 to 149.60) 97.56 (95.70 to 99.40)
≥ 85 220.94 (218.40 to 223.50) 165.33 (163.00 to 167.60)
Source: Adderley et al.12
a Confidence interval estimated by EAG.
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Proportion of patients with undiagnosed symptomatic atrial fibrillation who have
paroxysmal atrial fibrillation
The proportion of patients with symptomatic undiagnosed AF who have paroxysmal AF could not be
found in the literature. A fixed-effects meta-analysis by Welton et al.74 reported that the proportion of
patients with paroxysmal AF (not explicitly symptomatic) varied substantially between the studies75–77
included in the meta-analysis (from 0.059 to 0.835). Given the wide range reported by Welton et al.74 and
the lack of evidence specifically on incidence rates for symptomatic paroxysmal AF, in the base case it was
assumed that 50% of patients in the model with AF would have paroxysmal AF; a sensitivity analysis was
carried out to explore the impact of changes in the proportions between all patients with AF having
paroxysmal AF and no patients having paroxysmal AF.
Proportion of symptoms reported by symptomatic patients
The prevalence of AF symptoms in men and women was taken from a study of sex differences in clinical
presentation in AF by Schnabel et al.78 The prevalence of symptoms was used in the EAG’s model to
estimate the disutility associated with having symptoms indicative of AF. The paper by Schnabel et al.78
does not give associated EQ-5D (EuroQol-5 Dimensions) measures for the symptoms noted in the study,
so symptoms were mapped to a set of symptoms given in a HRQoL study by Berg et al.79 The paper by
Berg et al.79 gives utility decrement estimates for various AF symptoms but does not list the baseline
frequency of those symptoms. The prevalence of symptoms from the Schnabel et al.78 paper is shown
in Table 11. The prevalence of symptoms used in the model after mapping to symptoms reported by
Berg et al.79 is shown in Table 12.
TABLE 11 Prevalence of reported AF symptoms reported in Schnabel
Symptom
Occasional, intermediate or frequent symptoms at baseline by sex
in patients with new-onset AF (< 90 days), n (%) (N= 847)
Men Women
Palpitations 291 (61) 267 (73)
Fatigue 321 (67) 270 (75)
Dizziness 156 (33) 159 (44)
Dyspnoea 282 (58) 240 (66)
Chest pain 142 (30) 99 (27)
Anxiety 208 (44) 218 (61)
Source: Schnabel et al.78
TABLE 12 Prevalence of reported AF symptoms used in the model
Symptoms reported Modelled prevalence (%)
Shortness of breath 62
Fatigue 70
Other AF symptoms 52
Congestive heart failure symptoms 29
Angina pectoris symptoms 29
Source: Berg. et al.79
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Eligible population
The modelled cohort (eligible population) is the estimated mean number of people with signs or symptoms
of AF plus an irregular pulse that would present to a single GP over the course of a year. The eligible
population is calculated using the equation:




where nAF is the number of symptomatic patients with AF estimated to visit a GP in 1 year, nnoAF is the number
of symptomatic patients without AF estimated to visit a GP in 1 year and pAF is the estimated proportion of
patients with signs or symptoms of AF who have AF and are estimated to visit a GP in 1 year.
The cost of a lead-I ECG device is estimated on a per-patient basis depending on whether a GP practice
has one lead-I ECG device per GP or a single lead-I ECG device is shared among all GPs in the same
practice. Real-world evidence from a report (Kent Surrey Sussex AHSN and Richard Blakey, AliveCor in East
Sussex, unpublished evidence submitted via NICE) indicates that each GP in a practice will use their own
device. It is assumed in the EAG base case that each GP in a practice will have access to their own device.
Number of general practitioners per practice
The mean number of GPs per practice in England was taken from the Practice List Size and GP Count
report (January 2018) published by NHS Business Services.80 The mean number of GPs per practice used in
the model is 5.90 (95% CI 5.81 to 5.99).
Practice list size
The mean practice list size in England was taken from the Practice List Size and GP Count report (January
2018) published by NHS Business Services.80 The mean practice list size used in the model is 8187 (95% CI
8068 to 8306). The corresponding average list size per GP is 1388 patients (8187/5.90).
Proportion of patients for whom use of the lead-I electrocardiogram device
will be unsuitable
For a proportion of patients, use of the lead-I ECG device will be unsuitable, and this proportion is likely
to vary depending on the device owing to the different methods of operation. The manufacturer of the
RhythmPad GP device estimates that around 6% of patients would not be able to get a usable reading from
the lead-I ECG test owing to low voltage emitted from the patient’s hands or if the patient is deemed to be
isoelectric. Therefore, a value of 6% is applied in the model to all index tests to estimate the proportion of
people unable to use the lead-I ECG device.
Proportion of lead-l electrocardiogram tests interpreted by algorithm, general
practitioner or cardiologist
It is assumed in the EAG base-case analysis that the algorithm will not be used in isolation for making a
judgement about whether or not patients have AF. Diagnostic accuracy data according to interpretation by
a trained health-care professional were applied for each index test, with the exception of the RhythmPad
GP device. Sensitivity and specificity estimates were not available for trained health-care professional
interpretation for the RhythmPad GP device. Therefore, sensitivity and specificity estimates for algorithm
interpretation for the RhythmPad GP device were used in the model as a proxy for interpretation by a
trained health-care professional. The proportion of lead-I ECG test results that require interpretation by a
cardiologist is assumed to be 10%, following assumptions in a previous economic evaluation of screening
tests for AF.74
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The DTA estimates for each lead-I ECG index test have been taken from the available published evidence
(see Chapter 3, Study selection). Sensitivity and specificity values included in the model base case for each
index test are presented in Table 13. It is assumed that all patients presenting to a GP who are experiencing
symptoms of AF will be in AF at the time of the lead-I ECG test and so the sensitivity and specificity of the
lead-I ECG devices are equal for paroxysmal and permanent or persistent AF.
Sensitivity and specificity estimates for the MyDiagnostick device varied depending on the interpreter (EP1
and EP2) of the results. Interpreter EP1 produced results with higher sensitivity and lower specificity than
interpreter EP2. The EAG has used the diagnostic accuracy estimates for the MyDiagnostick device from
EP1 in the base case, as these had the highest sensitivity and might be expected to produce the most
benefits in patients receiving early NOAC treatment. Diagnostic accuracy results based on interpretation of
MyDiagnostick lead-I ECG trace by EP2 are presented as a scenario analysis. The sensitivity and specificity
values used in the scenario analysis are presented in Table 14.
12-lead electrocardiogram
The EAG has assumed that 12-lead ECG tests have 100% specificity and sensitivity when patients are in AF
at the time of the test, as a 12-lead ECG is the gold-standard reference test for lead-I ECG devices.
A proportion of patients with paroxysmal AF will not be in AF at the time of the 12-lead ECG. The
estimate of the proportion of patients with paroxysmal AF who are not in AF at the time of the 12-lead
ECG is taken from a study by Israel et al.81 to investigate the long-term risk of recurrence of AF. This trial
was conducted in patients with an existing diagnosis of paroxysmal or persistent AF who were receiving
anti-arrhythmic therapy. Patients were given an implantable device to record episodes of AF and were also
followed up with standard resting ECGs. The EAG acknowledges that the trial population is different from
the population in the model and notes that this is a limitation. In the study by Israel et al.,81 47.5% (46 out
of 97) of patients had an episode of AF picked up by the implanted device that was not picked up by
resting ECG. The EAG has used this estimate in the model to represent the proportion of patients with
paroxysmal AF who are not in AF at the time of a 12-lead ECG.
TABLE 13 Sensitivity and specificity values used in the economic model
Index test Interpreter Source Sensitivity (%) Specificity (%)
imPulse Health-care professional Reeves (NR)63 83.5a 91.5a
Kardia Mobile Health-care professional Pooled analysis 94.0 96.8
MyDiagnostick Health-care professional Desteghe, 2017 (EP1)38 85.0 95.0
RhythmPad GP Algorithm Crockford, 201350 67.0 97.0
Zenicor-ECG Health-care professional Doliwa, 200943 92.0 96.0
Generic lead-I device Health-care professional Pooled analysis from EAG SR 93.9 96.5
NR, not reported; SR, systematic review.
a Estimated as mid-point of range.
TABLE 14 Sensitivity and specificity values used in an economic model scenario analysis
Index test Interpreter Source (first author and year) Sensitivity (%) Specificity (%)
MyDiagnostick Health-care professional Desteghe 201738 (EP2) 80.0 98.0
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Holter monitoring
The EAG has assumed that Holter monitor tests have 100% specificity and sensitivity when patients are in
AF at the time of the test.
An estimate of the proportion of patients with paroxysmal AF who are not in AF at the time of a 7-day
Holter monitor test was taken from a paper reporting the consensus of members of the German Atrial
Fibrillation Competence NETwork and the European Heart Rhythm Association on outcome parameters
for atrial fibrillation trials.82 This report suggests that 7-day Holter monitoring will detect around 70% of
AF recurrences.
Treatment after diagnosis
According to NICE CG180,3 patients with a positive diagnosis of AF and a CHA2DS2-VASc score of ≥ 2
should be offered anticoagulation treatment (once bleeding risk has been taken into account). It is
assumed in the model that a proportion of patients who are AF-positive and have a CHA2DS2-VASc score
of ≥ 2 will receive both anticoagulation (NOACs) and rate-control treatment (beta blockers). No patients
are modelled to receive anticoagulation without rate-control treatment. The remaining patients will not
receive anticoagulation, as a result of either contraindications or patient choice, but a proportion will
still receive rate-control treatment. The proportion of patients who have a positive lead-I ECG test who do
not receive anticoagulation but do receive rate-control treatment is assumed to be 100% in the base case.
Proportion of atrial fibrillation-positive patients with CHA2DS2-VASc score of ≥ 2
The proportion of AF-positive patients with a CHA2DS2-VASc score of ≥ 2 used in the base-case analysis
is 82.4%. This value is calculated as the ratio of the number of patients with AF in England with a
CHA2DS2-VASc score of ≥ 2 and the registered number of patients diagnosed with AF in England reported
in the NHS Quality and Outcomes Framework 2016/17 indicator AF007.11
Proportion of atrial fibrillation-positive patients with CHA2DS2-VASc score ≥ 2 treated
with anticoagulants
The proportion of AF-positive patients with a CHA2DS2-VASc score of ≥ 2 who are treated with
anticoagulants used in the base-case analysis is 81.2%. This value is taken from the NHS Quality and
Outcomes Framework 2016/17 indicator AF007.11
Proportion of patients who receive anticoagulants who receive NOACs
The proportion of patients who receive anticoagulants who receive NOACs used in the base-case model is
calculated using data from May 2018, from the openprescribing.net database published by the University of
Oxford.83 The openprescribing.net database brings together raw, GP-level prescribing data published by
NHS Digital.84 Analysis of the data from the openprescribing.net database indicates that NOAC prescriptions
(apixaban, rivaroxaban, dabigatran and edoxaban) have increased steadily in England, overtaking warfarin
prescriptions in March 2018. The EAG notes that these figures are for anticoagulants prescribed for any
condition and are not restricted to prescriptions for AF; however, the EAG considers that the rapid increase
in use of NOACs over warfarin suggests that NOACs are becoming the treatment of choice for patients and
physicians. To produce a tractable model without unnecessary complexity, the EAG assumed all patients
would be prescribed a NOAC rather than warfarin. This assumption also allows the maximum potential
benefit from earlier diagnosis with lead-I ECG to be achieved; clinical advice to the EAG is that NOAC
could be prescribed immediately but prescribing warfarin would always require an appointment with the
anticoagulation clinic first.
The overall proportion of patients diagnosed with AF (false or true positives following testing) who receive
NOACs is estimated to be 66.9%. This proportion is based on estimates of the proportion of patients with
a CHA2DS2-VASc score of ≥ 2 and the proportion of those patients treated with anticoagulants (assumed
to be 100% NOACs) (Table 15).
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The EAG used a single NOAC (apixaban) as the basis for modelling costs and outcomes for patients
receiving NOAC therapy. Apixaban has been shown to be the most cost-effective NOAC for patients with
AF in England and Wales; however, other NOACs have been found to have similar costs and benefits.85
Apixaban is also the most commonly prescribed NOAC in England and accounted for almost 50% of all
NOAC prescriptions in May 2018.83 This approach has been taken in previous economic evaluations for AF.74
Time to initiation of anticoagulation treatment after lead-I electrocardiogram test
Clinical advice to the EAG on how long it would take for a patient to be prescribed NOACs (if indicated)
after a positive lead-I ECG test varied substantially depending on local Clinical Commissioning Group
guidelines. In some cases, patients would be prescribed NOACs immediately after taking the lead-I ECG test
during the initial consultation. In others, patients would need to wait ≥ 2 weeks for an appointment at an
anticoagulation clinic. It is assumed in the base-case analysis that treatment with NOACs will be offered
immediately to those patients who do not have contraindications. This approach was used to capture the full
potential benefit of beginning NOAC treatment earlier than would be the case in the standard diagnostic
pathway (when anticoagulation treatment is assumed to begin immediately after the 12-lead ECG test).
Time to 12-lead ECG
An estimate of the time taken to diagnose AF following a lead-I ECG test is reported by Lowres et al.61
However, the study by Lowres et al.61 was carried out in pharmacies in Australia. This setting was not
considered to be sufficiently similar to the setting of interest in this assessment for the data to be included in
the model. The EAG therefore sought clinical advice from primary care physicians in the NHS. Clinical advice
given to the EAG on how long it would take for a patient to receive a 12-lead ECG varied substantially.
In some cases, the patient would be expected to have a 12-lead ECG within 48 hours. In others, the wait
might be up to 2 weeks. The EAG has produced base-case cost-effectiveness estimates for two scenarios
(2 days and 14 days) to account for the variation in time to 12-lead ECG in clinical practice.
Mortality rates (no previous cardiovascular events)
Age- and sex-adjusted general mortality rates for England86 were used to estimate deaths in the AF-negative
population. Annual mortality rates are interpolated linearly between published annual mortality rates and
then converted to daily probabilities using the equation:
p = 1− e−(1+λ)
1
365.25−1. (2)
Age- and sex-adjusted mortality rates in the AF-positive population were estimated based on published risk (or
hazard) ratios or incidence rates. Single incidence rates were adjusted for age according to the proportionate
mortality risk for the given age in the general population. Risk ratios were applied to mortality rates in the
appropriate comparative population. It was assumed that proportionate risk remains stable over time.
Mortality rates and mortality risk ratios for patients with no history of CVEs are given in Table 16.
TABLE 15 Calculation of the proportion of AF patients treated with NOACs





Proportion of AF-positive patients with a CHA2DS2-VASc score of ≥ 2 82.4 82.4
Proportion of AF-positive patients with a CHA2DS2-VASc score of ≥ 2
treated with anticoagulants (assumed to be NOACs)
81.2 66.9
DOI: 10.3310/hta24030 HEALTH TECHNOLOGY ASSESSMENT 2020 VOL. 24 NO. 3
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Duarte et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
49
Mortality rates (previous cardiovascular events)
The risk of death for people who have had a previous IS, HS or TIA increased compared with that of
people who have not had a previous CVE by applying a hazard ratio (HR) to mortality rates for people with
no previous CVEs. The HR was taken from a study of stroke survivors in Norway by Mathisen et al.,87 which
reported mortality HRs for stroke survivors (IS, HS or TIA) with a mean age of 67 years compared with
those for people without these events aged > 16 years. This study did not report results according to AF
status, which is a limitation of the data. The HR after repeated stroke or TIA versus mortality in the general
population reported in this study87 was 2.6. The EAG considered it appropriate to apply the HR to all ages
in the model because analysis of the Kaplan–Meier data from the study by Mathisen et al.87 suggested
that HR was proportional over time. As the HR reported in the study by Mathisen et al.87 was pooled for
patients with IS, HS and TIA, the EAG assumed that the risk of death after any CVE was 2.6 times greater
than the risk of death with no history of CVEs. This increased mortality risk is applied for life once a patient
experiences a CVE.
Cardiovascular and adverse event rates (no previous cardiovascular events)
The CVEs included in the model are IS, TIA and HS. Clinically relevant bleeds are considered to be AEs.
Rates for AEs are assumed to be independent and do not take account of the history of previous events.
Age- and sex-adjusted CVE rates in the AF-positive population for patients with no history of previous
CVEs are estimated based on published risk (or hazard) ratios, incidence rates or probabilities. Incidence
rates are adjusted for age according to the proportionate mortality risk for the given age in the general
population. Probabilities are adjusted for age by translating the probability into a rate before adjusting by
the proportionate mortality risk for the given age in the general population. Risk ratios are applied to CVE
in the appropriate comparative population. It is assumed that proportionate risk remains stable over time.
CVE rates in the untreated AF-negative population with no history of previous CVEs are estimated based
on published incidence rates. CVE rates in the NOAC- and warfarin-treated AF-negative population (i.e. the
false-positive population) are estimated based on the following rule: if the risk ratio for a particular event
between the treated and untreated AF-positive populations is > 1, increase the risk for that event in the
treated AF-negative population. If the risk ratio for a particular event between the treated and untreated
AF-positive populations is ≤ 1, the model uses general population rates86 for that event.
Base-case CVE and AE rates used in the economic model are given in Tables 17–20. Rates for warfarin
treatment are given, whereas rates for NOAC and no treatment are calculated using a HR applied to the
rate associated with treatment with warfarin.
Cardiovascular and adverse event rates (previous cardiovascular events)
A meta-analysis of stroke recurrence was conducted in 2010 that reported recurrence rates of 6.5% at
1 year and 14.3% at 5 years.91 These subsequent stroke rates were applied to people in the model after
their first TIA, IS or HS. The proportion of subsequent strokes that were TIA, IS or HS was calculated using
TABLE 16 Mortality rates and risk ratios (no previous CVEs) used in the economic model
State Source Value type Value Use
AF: treated – NOAC Sterne 201785 HR vs. warfarin (< 80 years) 0.890
AF: untreated Sterne 201785 HR vs. warfarin 1.178
AF: treated – warfarin Sterne 201785 Annual rate (70 years) 0.038 Reference value
No AF: treated – NOAC ONS86 Annual rate Various
No AF: untreated
HR, hazard ratio; ONS, Office for National Statistics.
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proportionate incidence rates reported in a study by Rothwell et al.90 The annual recurrent stroke rate
between year 2 and year 5 was calculated by assuming the rate was constant between years 2 and 5.
The subsequent stroke rate from year 5 onwards was assumed to be the same as in years 2–5. Having a
subsequent stroke after first IS or HS post-discharge did not alter any transition probabilities in the model
as the increase in mortality risk was assumed to have been captured after the initial IS or HS. The probability
of subsequent stroke and the proportion of subsequent strokes that are TIA, IS or HS are shown in Table 21.
TABLE 17 Cardiovascular and adverse event rates: IS
State Source (first author and year) Value type Value
AF: treated – NOAC Sterne 201785 HR vs. warfarin 0.9000
AF: treated – warfarin Sterne 201785 Annual rate (70 years) 0.0120
AF: untreated Sterne 201785 HR vs. warfarin 1.1780
No AF: treated – NOAC Equal to ‘No AF:
untreated’
No AF: untreated PHE 201888 Annual rate (female, 50 years) 0.0007
Annual rate (female, 60 years) 0.0013
Annual rate (female, 70 years) 0.0030
Annual rate (female, 80 years) 0.0060
Annual rate (female, 90 years) 0.0108
Annual rate (male, 50 years) 0.0012
Annual rate (male, 60 years) 0.0023
Annual rate (male, 70 years) 0.0044
Annual rate (male, 80 years) 0.0064
Annual rate (male, 90 years) 0.0099
PHE, Public Health England.
TABLE 18 Cardiovascular and adverse event rates: bleeds
State Source (first author and year) Value type Value
AF: treated – NOAC Sterne 201785 HR vs. warfarin 0.820
AF: treated – warfarin Sterne 201785 Annual rate (70 years) 0.066
AF: untreated Sterne 201785 HR vs. warfarin 0.543
No AF: treated – NOAC Calculated HR vs. untreated 1.511





non-malignant GI tract disorders
(FD10 A: FD10M)
Annual rate (assume 70 years) 0.011a
a Estimated as incidence of activity reported in 2016/17 Reference Costs and Guidance89 per population in England (≥ 19)
reported by the Office for National Statistics86
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TABLE 19 Cardiovascular and adverse event rates: TIA
State Source (first author and year) Value type Value
AF: treated – NOAC Sterne 201785 HR vs. warfarin 0.7400
AF: treated – Warfarin Sterne 201785 Annual rate (70 years) 0.0250
AF: untreated Sterne 201785 HR vs. warfarin 1.6170
No AF: treated – NOAC Equal to ‘No AF:
untreated’
No AF: untreated aRothwell 200590 Annual rate (female, 50 years) 0.0003
Annual rate (female, 60 years) 0.0011
Annual rate (female, 70 years) 0.0022
Annual rate (female, 80 years) 0.0057
Annual rate (female, 90 years) 0.0093
Annual rate (male, 50 years) 0.0002
Annual rate (male, 60 years) 0.0005
Annual rate (male, 70 years) 0.0014
Annual rate (male, 80 years) 0.0034
Annual rate (male, 90 years) 0.0080
a Incidence rates estimated from published figures.
TABLE 20 Cardiovascular and adverse event rates: HS
State Source Value type Value
AF: treated – NOAC Sterne 201785 HR vs. warfarin 0.46000
AF: treated – warfarin Sterne 201785 Annual rate (70 years) 0.00900
AF: untreated Sterne 201785 HR vs. warfarin 0.54300
No AF: treated – NOAC Equal to ‘No AF:
untreated’
No AF: untreated aRothwell 200590 Annual rate (female, 50 years) 0.00002
Annual rate (female, 60 years) 0.00019
Annual rate (female, 70 years) 0.00034
Annual rate (female, 80 years) 0.00100
Annual rate (female, 90 years) 0.00104
Annual rate (male, 50 years) 0.00002
Annual rate (male, 60 years) 0.00019
Annual rate (male, 70 years) 0.00026
Annual rate (male, 80 years) 0.00171
Annual rate (male, 90 years) 0.00078
a Incidence rates estimated from published figures.
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Utility values have been estimated for symptomatic and asymptomatic populations with and without AF.
Utility values are assumed to be the same for all populations except those people with symptomatic
(i.e. untreated) AF (Table 22).
Utility values for the symptomatic and asymptomatic AF-positive population are based on a study by Berg
et al.79 Berg et al. provide the coefficients of two regression models fitted to the results of the EQ-5D-3L
(EuroQol-5 Dimensions, three-level version)92 questionnaire, completed at baseline and follow-up as part of
a large European survey of patients with AF. Mean age-specific utility values for symptomatic patients with
AF were calculated using the baseline coefficients from the study by Berg et al.79 and adjusted for model
age, sex ratio and symptom proportions. Mean age-specific utility values for asymptomatic patients with AF
were calculated similarly using the coefficients at follow-up.
The HRQoL of people without AF presenting at primary care with symptoms indicative of AF was assumed
to be lower than that of the general population, as the former are still ill with symptoms assumed to be
caused by atrial or ventricular ectopy. However, HRQoL was assumed not to be as low as that of patients
with symptomatic AF, as the recommended action for patients with atrial or ventricular ectopy (who are not
showing immediate signs of a serious underlying cardiac cause or complication) is to reassure.71 Treatment
for AF was assumed not to have an impact on the HRQoL of patients without AF, as in the model treatment
is associated with a reduction in AF symptoms. Utility values for the AF-negative population (both treated
and untreated) were assumed to be equal to the utility values for the treated AF population whose AF is
under control.
Cardiovascular and adverse event utility decrements
Lifetime utility decrements were assumed to apply to all ischaemic and HS events (Table 23). Utility
decrements for stroke were taken from the study by Berg et al.79 Utility decrements were applied at the
time of the first IS or HS and no further decrements were applied for any subsequent IS or HS. Bleed and
TIA events were assumed in the base case to be acute events that fully resolve and have no long-term
impact on HRQoL.
TABLE 21 Probability of subsequent stroke and the proportion of subsequent strokes that are TIA, IS or HS
Event Base case Source (first author and year)
Probability of subsequent CVE (annual)
Year 1 0.065 Mohan 201191
Year 2 onwards 0.038
Probability of subsequent CVE type
TIA 0.640 Rothwell 200590
IS 0.057
HS 0.303
TABLE 22 Age- and sex-adjusted utility values (aged 70 years) used in the base-case model
AF (95% CI) No AF (95% CI)
Untreated (symptomatic) 0.665 (0.537 to 0.881) 0.744 (0.480 to 0.942)
Treated (asymptomatic) 0.744 (0.480 to 0.942) 0.744 (0.480 to 0.942)
Source: Adapted from Berg et al.79
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Test costs
Annual lead-I electrocardiogram device unit costs
The annual cost of each lead-I ECG device was calculated as the unit cost per device [excluding VAT
(value-added tax)] divided across the expected life of the device in years, plus annual licence fee. No companies
reported any maintenance costs associated with their devices, so these have not been included in the model.
The cost of an accompanying smartphone or tablet for the Kardia Mobile device has not been included in the
base case, as it was assumed that GPs would already have access to a smartphone or tablet. An average cost
for a generic lead-I ECG device was calculated using the simple mean of the annual cost of individual devices.
The annual cost of each index test included in the model is given in Table 24. Lead-I ECG devices are also likely
to be used in populations other than the population with signs or symptoms of AF, which would decrease
the unit cost per use of each device. The impact on cost-effectiveness of not including the cost of the lead-I
ECG device has been investigated in a sensitivity analysis.
Cost per lead-I electrocardiogram test
The cost per lead-I ECG test in the standard diagnostic pathway was zero, as it was assumed the only
resource use in this context was the cost of the GP consultation. The cost of the initial GP consultation
is assumed to be equal in both diagnostic pathways and is not included in the model. No extra time is
included in the base-case model for administering the lead-I ECG or interpreting the results during the
initial consultation. It is assumed that review of the results of a lead-I ECG test by a cardiologist would take
1 minute, in accordance with results from the study by Hobbs et al.94 Assumptions about the time taken to
administer and review a lead-I ECG test are varied in the sensitivity analysis.
TABLE 23 Utility decrements for acute adverse events
AE
Base case Sensitivity analysis
Decrement
Source (first author
and year) Decrement or value
Source (first author
and year)
IS –0.272 (95% CI –0.345
to –0.198)
Berg 201079 –0.590 Robinson 200193
HS Assumed equal to IS Value for ICH: –0.108 (95% CI
–0.135 to –0.082)
Berg 201079
ICH, intracerebral haemorrhage; SE, standard error.
TABLE 24 Annual costs of lead-I ECG devices and user licences
Device Item
Lifetime cost (£)
(excluding VAT) Life of device (years) Annual cost (£)
imPulse Device 175.00 2 87.50
Kardia Mobile Device 82.50 5 16.50
MyDiagnostick Device 450.00 5 90.00
RhythmPad GP Device 1100.00 1 1100.00
Zenicor ECG Device and 36-month licence 1980.00 10 613.27
Extra 36-month licence 1780.00
Generic lead-I device 381.45
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The cost per lead-I ECG test was calculated as the annual cost per device divided by the number of
patients in the eligible population per year, plus any extra costs associated with each use of the device;
the Zenicor-ECG device was the only index test included in the model to incur extra costs with each use,
as the manufacturer recommends that the electrodes are replaced after 500 uses.
The costs per index test and cost of interpreting the lead-I ECG test included in the model are given in
Table 25 and 26.
Cost per 12-lead electrocardiogram test
The cost per 12-lead ECG test varies depending on whether the test is carried out in primary or secondary care.
For 12-lead ECG tests carried out in primary care, the unit cost of a 12-lead ECG device is estimated to
be £2251, in line with the estimate used in NICE Guideline 45 (NG45),96 inflated to 2017 prices using the
Office for National Statistics Consumer Price Index for Medical Services [DKC3].97 It is assumed in the model
that a 12-lead ECG device may be used 1000 times before being replaced, in line with the assumption in
NICE NG45,96 which equates to £2.25 per use. The cost of disposables such as electrodes and gels is estimated
to be £1.13 per use, uplifted to 2017 prices from the estimate used in NICE NG45.96
The cost of administering a 12-lead ECG test in secondary care is estimated using the NHS Reference Costs
2016/1798 for Electrocardiogram Monitoring or Stress Testing [directly accessed diagnostic services HRG
(healthcare resource group): EY51Z DADS].
The costs of administering the 12-lead ECG test in primary and secondary care are summarised in Table 27.
TABLE 25 Cost per lead-I ECG test
Device








imPulse 87.50 54 0.00 1.62
Kardia Mobile 16.50 54 0.00 0.31
MyDiagnostick 90.00 54 0.00 1.67
RhythmPad GP 1100.00 54 0.00 20.42
Zenicor ECG 613.27 54 0.02 11.40
Generic lead-I device 381.45 54 0.02 7.10
a Some costs may not calculate precisely as a result of rounding.
TABLE 26 Cost per administration and interpretation of lead-I ECG test (base case)





Algorithm 0 0 0
GP 0 0 0
Cardiologist 107 per hour PSSRU95 1a 1.78
a Based on data from Hobbs et al.94
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Cost per paroxysmal test
Further testing for paroxysmal AF is represented by the use of a Holter monitor. The cost of a Holter
monitor test is taken from an estimate in a NICE Medtech innovation briefing [MIB101]99 published in
March 2017. The list price of a Holter monitor device in the NHS Supply Chain catalogue is given as
£1632.14 in NICE MIB101.99 It assumed that the device will be used 1000 times before it needs to be
replaced, giving a marginal cost per use of £1.63. The cost of administering and interpreting a Holter
monitor test is estimated in NICE MIB10199 to be £118.60 including overheads. The total cost per each
Holter monitor test in the model is £120.23.
Treatment costs
The NOAC drug costs
The cost of treatment with NOACs was assumed to equal the cost of treatment with apixaban. The cost of
1 month’s (28 days) treatment with apixaban was calculated using dosing information from the British
National Formulary (BNF)100 and prices from the NHS Drug Tariff (July 2018)101 and adjusted to reflect the
number of days of treatment before receiving a 12-lead ECG. It was assumed that the dosage of NOACs
would be prescribed in equal proportions. The number of packs used per month for each dosage was
calculated based on the least costly combination of pack sizes. The base-case drug cost of apixaban used
in the model was £55.10 per 28 days (Table 28).
TABLE 27 Health-care practitioner costs per 12-lead ECG test (primary and secondary care)






Device 2.25 per use Estimate 2.25
Disposables 1.13 per use Hobbs et al. (2005)94 1.13
Nurse 42 per hour PSSRU95 Administration 7a 4.90
GP 137 per hour PSSRU95 Interpretation 1a 2.28
Cardiologist 107 per hour PSSRU95 Interpretation 1a 1.78








a Based on data from Hobbs et al.94















5 2 5 56 1 53.20 53.20
2.5 2 2.5 60 1 57.00 57.00
Average cost per 28 days 55.10
Source: BNF;100 NHS Drug Tariff.101
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Rate control drug costs
The cost of treatment with beta blockers was used as a proxy for the cost of all rate-control treatments.
The cost of 1 month’s (28 days) treatment with each of three beta blockers (atenolol, metoprolol and
propranolol) was calculated using dosing information from the BNF100 and prices from the NHS Drug Tariff
(July 2018)101 and adjusted to reflect the number of days of treatment before receiving a 12-lead ECG. It
was assumed that the dosage of rate-control drugs would be prescribed in equal proportions. The number
of packs used per month for each dosage was calculated based on the least costly combination of pack
sizes. The base-case drug cost of rate-control drugs used in the model was £2.59 per 28 days (Table 29).
Prescription costs
The EAG model base case includes a prescription cost for each treated patient. The same prescription cost
was applied regardless of the number of treatments a patient receives (anticoagulation plus rate control or
rate-control treatment alone). The prescription fee included in the model was £1.29 per prescription and
was taken from the NHS Drug Tariff (July 2018).101
The NOAC monitoring costs
No costs were included in the model for monitoring patients taking NOAC or rate-control treatment.
















50 1 50 28 1 0.47 0.47
100 1 100 28 1 0.51 0.51
Average cost per 28 days 0.49
Metoprolol
50 2 50 28 2 0.78 1.56
50 3 50 28 3 0.78 2.34
Average cost per 28 days 1.95
Propranolol
10 2.61 2.61 2.61 2.61 2.61 2.61
10 3.48 3.48 3.48 3.48 3.48 3.48
20 5.22 5.22 5.22 5.22 5.22 5.22
20 6.96 6.96 6.96 6.96 6.96 6.96
30 7.83 7.83 7.83 7.83 7.83 7.83
30 10.44 10.44 10.44 10.44 10.44 10.44
40 2.64 2.64 2.64 2.64 2.64 2.64
40 3.52 3.52 3.52 3.52 3.52 3.52
Average cost per 28 days 5.34
All drugs
Average cost per 28 days 2.59
Source: BNF;100 NHS Drug Tariff.101
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Cardiovascular and adverse event costs
Acute event costs
The cost of each acute bleed and TIA event was calculated as the weighted average of the appropriate
HRG codes included in the NHS Reference Costs 2016/17.98 The full cost of each event was applied.
Costs used in the model base case for each event are shown in Table 30.
Long-term cardiovascular event costs
Age- and sex-adjusted 1- and 5-year costs for ischaemic and HS were taken from the Sentinel Stroke
National Audit Programme (SSNAP) Cost and Cost-effectiveness report 2016 (Tables 31 and 32).102 One-year
costs were applied in the first year after the stroke event. The annual costs between year 2 and year 5 were
calculated by assuming that the difference in cost between year 1 and year 5 accrued linearly between
years 2 and 5. The cost from year 5 onwards was assumed to be the same as in years 2–5. Costs restart at
year 1 for patients who experience a subsequent CVE.
Summary of base-case assumptions
Parameter assumptions and sources used in the base-case model are summarised in Table 33.
TABLE 30 Acute costs per adverse event
AE HRG codes Mean cost per event (£) (IQR)
Bleed Gastrointestinal Bleed without Interventions (FD03F:FD03H)
Unspecified Haematuria with Interventions (LB38C:LB38E)
704.05 (592.24–782.48)
TIA Transient Ischaemic Attack (AA29C:AA29F) 729.62 (570.08–837.65)
IQR, interquartile range.
Source: NHS Reference Costs 2016/17.89
TABLE 31 Mean cost of IS, by age and sex
Sex Age (years)
1-year costs (£) 5-year costs (£)
NHS Social care NHS Social care
Male 40–64 9779 2241 16,017 8835
Male 65–74 11,495 3684 16,843 14,110
Male 75–84 13,217 7620 17,816 25,148
Male 85–100 14,906 13,070 18,613 38,623
Female 40–64 9627 2312 15,954 9308
Female 65–74 11,705 3878 16,987 14,668
Female 75–84 13,441 7923 17,995 26,370
Female 85–100 15,803 13,500 18,947 38,585
Source: SSNAP.102
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TABLE 32 Mean cost of HS, by age and sex
Sex Age (years)
1-year costs (£) 5-year costs (£)
NHS Social care NHS Social care
Male 40–64 11,465 3661 17,857 15,063
Male 65–74 12,773 4862 18,188 18,960
Male 75–84 14,605 10,545 19,389 36,994
Male 85–100 16,291 15,551 19,896 49,256
Female 40–64 11,260 3256 17,538 13,508
Female 65–74 12,734 5285 18,143 20,476
Female 75–84 14,747 11,379 19,103 37,630
Female 85–100 16,481 15,425 19,750 46,730
Source: SSNAP.102
TABLE 33 Base-case model assumptions
Parameter Assumption or source Justification
AF status at initial consultation All patients with AF are in AF
at the time of the initial
consultation
Population is patients presenting to
primary care with signs or symptoms
of AF and an irregular pulse. These
symptoms are assumed to be caused
by AF if the patient has AF
Mean age (years) 70 Mean age observed in RCTs used by
Sterne et al.85 and to estimate CVE
rate parameters
Per cent female 51.6 Age-adjusted proportion in the
general population, assumed to match
proportion in GP lists
AF prevalence Adderley et al., 201812 Recent data from UK primary care
Proportion of AF undiagnosed Turakhia et al., 2018103 Recent data
Proportion of AF with signs or
symptoms
Mapped from Schnabel et al.78
to Berg et al.79
Real-world data (Kent Surrey Sussex
AHSN)
Proportion of patients with
undiagnosed symptomatic AF
who have paroxysmal AF (%)
50 Assumption owing to wide range
reported by Welton et al.,74 and the
lack of evidence specifically on
incidence rates for symptomatic
paroxysmal AF
Number of lead-I ECG devices
per practice
One per GP Previous economic evaluation74
Proportion of lead-I ECG tests
interpreted by GP and
cardiologist (%)
10 Data from Hobbs et al.94 estimate
7 minutes for a nurse to administer a
12-lead ECG. Assume < 7 minutes for
a lead-I ECG, but some extra time still
required to explain and carry out
procedure
Extra time taken to administer
lead-I ECG test (minutes)
0 Test is assumed to be administered
during standard GP appointment
continued
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Uncertainty
Uncertainty in parameter values and the impact this could have on results has been explored both through
the scenario and through the sensitivity analyses. Parameters have been varied through probability sensitivity
analysis parameters, where probability distributions could be derived from, or were provided in, the literature.
Probabilistic sensitivity analysis results have been presented as cost-effectiveness acceptability curves (CEACs)
where different willingness to pay (WTP) thresholds for a quality-adjusted life-year (QALY) are used to show
which strategy is likely to have the largest net benefit for that threshold.
Interpreting results
Incremental cost-effectiveness ratios
The results of the cost-effectiveness analysis are presented as incremental cost-effectiveness ratios (ICERs)
per QALY gained. These are calculated by dividing the difference in costs associated with two alternative
strategies by the difference in QALYs:
ICER =
Cost of B−Cost of A
QALY of B−QALY of A
. (3)
TABLE 33 Base-case model assumptions (continued )
Parameter Assumption or source Justification
Proportion of patients receiving
anticoagulation




Proportion of patients receiving
anticoagulation who receive
NOACs (%)
100 Simplifying assumption based on
evidence that prescriptions for NOACs
overtook prescriptions for warfarin in
2018
Time from diagnosis to
anticoagulation
Immediate Simplifying assumption allowing the
maximum potential benefit from
earlier diagnosis with lead-I ECG
Proportion of patients receiving
12-lead ECG
100% for standard pathway
and lead-I positive
80% for lead-I negative
Standard pathway: NICE CG1803
Lead-I positive (AF diagnosed): NICE
CG1803
Lead-I negative: assumption based on
clinical advice (see Appendix 11) and
varied in sensitivity analyses
Diagnostic accuracy of 12-lead
ECG
100% sensitivity and specificity
for those patients in AF at time
of test
12-lead ECG is reference test for
lead-I devices, hence must be
assumed to be 100% accurate
Proportion of patients with
paroxysmal AF not in AF at time
of 12-lead ECG (%)
47.5 Data from Israel et al., 200481
Diagnostic accuracy of Holter
monitor
100% sensitivity and specificity
for those patients in AF at time
of test
Simplifying assumption
Proportion of patients with
paroxysmal AF not in AF at time
of Holter monitor (%)
30 Data from Kirchoff et al., 200682
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Where more than two strategies are compared, the ICER is calculated according to the following process:
1. The strategies are ranked in terms of cost, from least to most expensive.
2. If a strategy is more expensive and less effective than the preceding strategy, it is said to be ‘dominated’
and is excluded from further analysis.
3. ICERs are then calculated for each strategy compared with the next most expensive non-dominated
option. If the ICER for a strategy is higher than that of the next most effective strategy, then it is ruled
out by ‘extended dominance’.
4. ICERs are recalculated excluding any strategy subject to dominance or extended dominance.
5. The non-dominated strategies form an ‘efficiency frontier’ of strategies that are cost-effective and
can then be judged against the value of an ICER that is generally considered cost-effective by NICE
(i.e. £20,000–30,000 per QALY gained).
Base-case results
The model included a hypothetical cohort of 53.88 patients. This figure equates to the estimated number
of patients with signs or symptoms indicative of AF and with an irregular pulse who would visit a single GP
annually and be eligible for testing with a lead-I ECG device. Of the total eligible population in the model,
10.78 had AF and 43.11 did not have AF.
Four base-case scenarios were investigated to estimate cost-effectiveness depending on the waiting times
for a 12-lead ECG test and the location of the 12-lead ECG test. The base-case scenarios are:
l base case 1: 12-lead ECG in primary care, 2 days to 12-lead ECG
l base case 2: 12-lead ECG in primary care, 14 days to 12-lead ECG
l base case 3: 12-lead ECG in secondary care, 2 days to 12-lead ECG
l base case 4: 12-lead ECG in secondary care, 14 days to 12-lead ECG.
Results for base cases 2–4 are presented in Appendix 12.
Base case 1: 12-lead ECG in primary care, 2 days to 12-lead electrocardiogram
Costs and QALYs generated in base case 1 are shown in Tables 34 and 35, respectively.
Pairwise cost-effectiveness results from the base case 1 analysis for each index test versus the standard
diagnostic pathway are presented in Table 36 and incremental analysis results are shown in Table 37.















Standard pathway 0 90,630 420,279 536 2743 514,187
Kardia Mobile 26 102,952 409,881 452 2240 515,551
imPulse 97 116,317 411,612 454 2265 530,745
MyDiagnostick 100 107,077 411,358 451 2247 521,233
Generic lead-I device 392 103,746 409,898 452 2242 516,730
Zenicor-ECG 624 104,938 410,210 452 2244 518,468
RhythmPad GPa 1110 100,358 414,292 446 2231 518,436
a Algorithm interpretation.
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TABLE 35 Base case 1: QALYs and patient outcomes




positives Bleeds Total QALYs
Standard pathway 11.621 2.124 8.406 1.606 0.000 23.581 447.963
Kardia Mobile 11.452 1.996 8.359 0.144 1.379 23.751 449.249
imPulse 11.482 2.019 8.366 0.397 3.663 23.730 448.987
MyDiagnostick 11.478 2.015 8.365 0.361 2.155 23.720 449.024
Generic lead-I device 11.452 1.996 8.359 0.147 1.508 23.752 449.246
Zenicor-ECG 11.457 2.000 8.360 0.193 1.724 23.746 449.199
RhythmPad GPa 11.530 2.054 8.377 0.794 1.293 23.630 448.573
a Algorithm interpretation.
TABLE 36 Base case 1: pairwise cost-effectiveness analysis







Standard pathway 514,187 447.963
Kardia Mobile 515,551 449.249 1364 1.286 1060
imPulse 530,745 448.987 16,557 1.024 16,165
MyDiagnostick 521,233 449.024 7046 1.061 6638
Generic lead-I device 516,730 449.246 2543 1.284 1981
Zenicor-ECG 518,468 449.199 4281 1.236 3462
RhythmPad GPa 518,436 448.573 4249 0.610 6962
a Algorithm interpretation.
Reproduced from Duarte et al.67 © The Authors, 2019. This is an Open Access article distributed in accordance with the terms
of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this
work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/.
TABLE 37 Base case 1: incremental cost-effectiveness analysis







Standard pathway 514,187 447.963
Kardia Mobile 515,551 449.249 1364 1.286 1060
Generic lead-I device 516,730 449.246 1179 –0.002 Dominated
RhythmPad GPa 518,436 448.573 2885 –0.676 Dominated
Zenicor-ECG 518,468 449.199 2917 –0.050 Dominated
MyDiagnostick 521,233 449.024 5682 –0.225 Dominated
imPulse 530,745 448.987 15,194 –0.262 Dominated
a Algorithm interpretation.
Reproduced from Duarte et al.67 © The Authors, 2019. This is an Open Access article distributed in accordance with the terms
of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this
work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/.
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Summary of base-case cost-effectiveness results
The results of the pairwise analysis show that all lead-I ECG tests lie on the efficiency frontier in each of
the four base-case analyses, with ICERs below the £20,000–30,000 threshold usually considered to be
cost-effective by NICE. Kardia Mobile is the most cost-effective option in a full incremental analysis, with
an ICER no higher than £1060 per QALY gained, compared with the standard pathway and dominates the
other lead-I ECG devices (costing less and generating more QALYs).
Lead-I ECG devices are more cost-effective when there is a longer wait to 12-lead ECG (as treatment for
AF with a lead-I ECG device is assumed in the model to start earlier than in the standard pathway) and
if the 12-lead ECG is performed in hospital. The majority of the patient benefit, however, comes after
diagnosis, when a greater proportion of patients are correctly diagnosed with AF and treated for AF than
in the standard diagnostic pathway, even if this benefit is slightly offset by an increase in patients
incorrectly diagnosed with AF with a lead-I ECG device.
Scenario analyses
Scenario analyses were undertaken to investigate the impact on the ICER per QALY gained of varying some
of the base-case assumptions. Results for scenario analyses using the least cost-effective base case [base
case 1 (12-lead ECG in primary care, 2 days to 12-lead ECG)] are presented; if the conclusions drawn from
results remain unchanged from the least cost-effective scenario for lead-I ECG testing, they should also
remain unchanged for the more cost-effective scenarios. Scenario analyses are presented in Appendix 13.
The scenario analyses were as follows.
l Scenario A: the unit cost associated with the lead-I ECG device changed from full cost of the device to
no cost. This assumption was varied to take into account other populations that might use a lead-I ECG
device in primary care that would share the cost of the device.
l Scenario B: sensitivity and specificity estimates from interpretation of the MyDiagnostick lead-I ECG
trace by EP2.
l Scenario C: diagnosis and decisions made to refer for paroxysmal testing based only on the lead-I ECG
results (i.e. no referral for 12-lead ECG or Holter monitor).
l Scenario D: the time horizon is limited to 5 years to reflect clinical feedback to the EAG that it is
plausible that all patients with paroxysmal AF not correctly diagnosed with AF after lead-I, 12-lead ECG
or Holter monitoring will be picked up within 5 years if they do not have a CVE.
l Scenarios E1 to E40: the proportions of patients sent for further testing for paroxysmal AF depending
on the outcomes of the combined lead-I ECG and 12-lead ECG tests are varied. Clinical advice provided
to the EAG highlighted the significant difference in clinical practice around how patients with positive
or negative lead-I ECG and 12-lead ECG results would continue on the diagnostic pathway so each
scenario may represent the true ‘base-case’ scenario for a specific GP or practice depending on the
diagnostic pathway they follow.
l Scenario F: cost of a supplementary smartphone or tablet added to the cost of the Kardia Mobile
device. A threshold analysis was performed to determine the minimum unit cost of a smartphone or
tablet that would result in Kardia Mobile no longer dominating the other lead-I ECG devices.
l Scenario G: extending the lifespan of the RhythmPad GP device from 1 year to 3 years.
l Scenario H: including a QALY decrement for bleeds.
l Scenario I: using alternative sensitivity and specificity estimates for Kardia Mobile from the pooled
analysis with interpretation of the trace from EP2.
l Scenario J: assuming that rates of HS are the same for people treated with NOACs who do not have AF
as the rates of HS for people treated with NOACs who have AF.
DOI: 10.3310/hta24030 HEALTH TECHNOLOGY ASSESSMENT 2020 VOL. 24 NO. 3
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Duarte et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
63
Deterministic sensitivity analysis
One-way sensitivity analyses were run to identify the individual parameters with the biggest impact on the
model results. Tornado diagrams are presented in Appendix 14, Figures 28–33, for each index test using
base case 1 (12-lead ECG in primary care, 2 days to 12-lead ECG).
Probabilistic sensitivity analysis
Probabilistic sensitivity analyses were undertaken for the lead-I ECG pathway with each index test
compared with the standard diagnostic pathway. The CEACs in base case 1 for each device are presented
in Appendix 15, Figures 34–39. The CEAC for all devices is shown in Figure 12. The parameters for the
probability sensitivity analysis are presented in Appendix 16.
Summary of scenario and sensitivity analyses cost-effectiveness results
The one-way sensitivity analysis showed that the results were sensitive to the assumed prevalence of
paroxysmal AF versus persistent and permanent AF. Decreased prevalence of paroxysmal AF increased
incremental costs and decreased incremental QALYs for lead-I ECG devices versus the standard pathway.
At the extreme, where the prevalence of paroxysmal AF was assumed to be zero, incremental QALYs
decreased sufficiently to become negative and resulted in some lead-I ECG devices (imPulse, MyDiagnostick
and RhythmPad) being dominated by the standard pathway. The ICERs per QALY gained yielded for other
lead-I ECG devices when the prevalence of paroxysmal AF was zero were very large as a result of very small
incremental QALYs. When the prevalence of paroxysmal AF was assumed to be 1, incremental costs
decreased and incremental QALYs decreased. Increasing the prevalence of paroxysmal AF to 1 resulted in all
lead-I ECG devices except imPulse and MyDiagnostick dominating the standard pathway.
The results of the probabilistic sensitivity analysis indicate that, in pairwise comparisons, all lead-I ECG
devices included in this assessment were cost-effective in at least 50% of iterations with a WTP threshold of
around £15,000 per QALY. When all of the devices were considered together, at a threshold of £20,000
per QALY, just over 80% of iterations showed that Kardia Mobile would be the most cost-effective option,
with Zenicor-ECG being the most cost-effective in around 15% of iterations. The standard pathway was







































FIGURE 12 CEAC base case 1: all lead-I ECG devices.
METHODS FOR ASSESSING COST-EFFECTIVENESS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
64
The scenario analysis showed that the results were sensitive to using alternative sensitivity and specificity
values for MyDiagnostick. MyDiagnostick yielded the lowest overall costs of all the strategies when
sensitivity and specificity estimates from interpretation of the MyDiagnostick lead-I ECG trace by EP2 were
used. Kardia Mobile remained the index test with the highest overall QALYs in this scenario, which yielded
an ICER per QALY gained of £5503 versus MyDiagnostick (using EP2).
The scenario analysis showed that results were invariant to the following assumptions:
l removing the cost of the lead-I ECG device from the analysis
l patients with AF incorrectly ruled out are not diagnosed with AF prior to a CVE
l removal of 12-lead ECG and Holter monitoring from the lead-I ECG pathway
l shortening the time horizon to 5 years.
The finding that removal of the 12-lead ECG and Holter monitoring from the lead-I ECG pathway did not
affect cost-effectiveness results is unsurprising; if a patient had paroxysmal AF, they were assumed to be in
AF at the time of lead-I ECG monitoring and therefore the majority of paroxysmal AF would be detected
with a lead-I ECG device without the need for 12-lead ECG or Holter monitoring. However, this result
should be interpreted with caution as the potential further benefits of a specific diagnosis of paroxysmal
AF or of the more detailed diagnosis from 12-lead ECG testing was not considered in the model. Similarly,
the extensive scenario analyses on the use of Holter monitoring following 12-lead ECG tests, with or
without lead-I ECG testing, showed that, if Holter monitoring is not routinely used for the majority of
patients with a negative 12-lead ECG, Kardia Mobile will always have an ICER below £10,000 per QALY
gained compared with the standard pathway and, in some circumstances, will be a dominant strategy.
Effect of sensitivity and specificity
High specificity (i.e. high true-negative rate that results in a low false-positive rate) has a greater impact on
the model results than high sensitivity (i.e. high true-positive rate), although the impact of high specificity
is eroded the lower the sensitivity estimate becomes. For instance, the estimate of specificity for the
RhythmPad GP device in the base-case analysis is higher than that for any other device (97.0%, 95% CI
95.5% to 100.0%). However, the benefit of higher specificity for the RhythmPad GP device is eroded by
an estimate of sensitivity (67.0%, 95% CI 50.5% to 100.0%) that is substantially lower than the estimate
of sensitivity for any of the other devices. In contrast, the Kardia Mobile device has an estimate of
specificity (96.8%, 95% CI 88.0% to 99.2%) similar to that of the RhythmPad GP device but a much
higher estimate of sensitivity (94.0%, 95% CI 81.5% to 97.7%).
High specificity is important because it reduces the additional treatment costs associated with an incorrect
diagnosis of AF. It is assumed in the model that people incorrectly diagnosed with AF will remain
misdiagnosed for the rest of their lives, so those who begin treatment with NOACs and rate-control
treatment will remain on treatment for their lifetime. No benefit is assumed from treating people without
AF with NOACs and rate-control treatment, and a higher risk of bleeding is assumed as a result of
treatment with NOACs. Therefore, the higher the false positive rate (i.e. the lower the specificity), the
greater the costs that are accrued from the treatment itself and from treating bleeds associated with
NOACs without any associated benefit from treatment.
Sensitivity is important because the earlier people with AF are diagnosed, the sooner they can begin
treatment and reduce their risk of having a CVE. Low sensitivity (low true positive rate) means that many
people with AF may only be identified later and so do not benefit from early NOACs and rate-control
treatment. However, the impact of the sensitivity estimate is mitigated in the model by the assumption
that people with undiagnosed AF will later have their AF diagnosed (and begin treatment) if they
experience a CVE. This means that people with AF that is initially undiagnosed do not accrue the costs of
NOACs and rate-control treatment for some months or years, which offsets some of the costs associated
with their higher risk of experiencing a CVE.
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Assessment of diagnostic test accuracy
No studies were identified that evaluated the diagnostic accuracy of lead-I ECG devices in people presenting
to primary care with signs or symptoms of AF and an irregular pulse. As no studies were identified for the
population and setting of interest, the review focused on an asymptomatic population as prespecified in the
protocol.68 We considered an asymptomatic population to comprise people not presenting with symptoms
of AF, with or without a previous diagnosis of AF. These patients could have had co-existing cardiovascular
conditions or could have been attending a cardiovascular clinic but did not present with signs or symptoms
of AF.
We identified 13 publications38,39,41–51 reporting on nine studies assessing the DTA of lead-I ECG devices.
In three studies,43,45,51 the lead-I ECG trace was interpreted by one trained health-care professional (i.e.
cardiologist or EP). In one study,39 the lead-I ECG trace was interpreted independently by a cardiologist and by
a GP with an interest in cardiology. In one study,38 the trace was interpreted independently by two EPs and by
the device algorithm. In four studies,47–50 the lead-I ECG trace was interpreted by the device algorithm alone.
The reference standard in all of the included studies was a 12-lead ECG interpreted by a trained health-care
professional. The trained health-care professional was a cardiologist, an EP or a GP with an interest in
cardiology. The analyses were stratified by the interpreter of the lead-I ECG trace.
In the included studies, the sensitivity of lead-I ECG devices ranged from 80% to 100% and specificity
ranged from 76% to 99% when the lead-I ECG trace was interpreted by a trained health-care professional.
The lowest specificity value (76%) was observed when interpretation of the lead-I ECG trace was performed
by a GP with an interest in cardiology; sensitivity was similar to that observed in the other included studies.39
In the main meta-analysis, when the lead-I ECG trace was interpreted by a trained health-care professional,
the pooled sensitivity and specificity values were 93.9% and 96.5%, respectively. In the sensitivity analyses,
pooled sensitivity values ranged from 88.0% to 96.2% and pooled specificity values ranged from 94.4%
to 97.4%.
Across the meta-analyses, where the lead-I ECG trace was interpreted by the device algorithm, the
sensitivity ranged from 88% to 96.2% and the specificity ranged from 94.4% to 97.2%. Pooled sensitivity
and specificity values were similar across the different meta-analyses irrespective of the interpreter of the
lead-I ECG trace or the lead-I ECG device used.
In one study,38 inter-rater variability between the two EP interpreters was observed. When the lead-I ECG
trace was interpreted by EP1, sensitivity values were consistently higher than when the trace was interpreted
by EP2, irrespective of the lead-I ECG device being used (i.e. MyDiagnostick or Kardia Mobile). Specificity
values were similar irrespective of the interpreter of the lead-I ECG trace (i.e. EP1 or EP2) and lead-I ECG
device being used (i.e. MyDiagnostick or Kardia Mobile). The authors suggested that the reason for
discordance between the interpretation of the lead-I ECG trace and the 12-lead ECG was the presence of
repetitive atrial or ventricular premature beats, which may have misguided the EPs to classify those lead-I
ECG traces incorrectly as AF.38 The same reasons were suggested for the low sensitivity value reported when
the lead-I ECG trace was interpreted by the lead-I ECG device algorithm. The sensitivity values reported
were lower than those observed in other studies, irrespective of lead-I ECG device algorithm interpretation
(i.e. MyDiagnostick or Kardia Mobile).
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The sensitivity from the meta-analyses of lead-I ECG traces interpreted by a trained health-care professional
or the lead-I ECG device algorithm was 92% (95% CI 85% to 96%),104 which was similar to the sensitivity
reported for MPP in systematic reviews (91.6%, 95% CI 75% to 98.6%).74 The specificity values for lead-I
ECG traces interpreted by a trained health-care professional or the lead-I ECG device algorithm were
relatively higher, at 82% (95% CI 76% to 88%),104 than those reported for MPP (78.8%, 95% CI 51% to
94.5%).74
The included studies did not evaluate the presence of paroxysmal AF using prolonged monitoring following a
negative 12-lead ECG. It is likely that, in clinical practice, prolonged monitoring will be considered for people
presenting with signs or symptoms of AF who have an irregular pulse and a positive lead-I ECG test followed
by a negative 12-lead ECG. In the included studies, both the index test and the reference standard were
performed within a 6-hour time interval, with the exception of two studies49,50 in which the time interval for
use of the index test and reference standard was not specified. A patient correctly identified as having AF
could have this diagnosis ruled out if the AF episode had stopped by the time they underwent assessment
with a 12-lead ECG. It is not clear if there was an appropriate time interval between assessments in the study
by Crockford et al.;50 therefore, it is possible that paroxysmal AF contributed to a lower sensitivity than that
reported in the other studies. The specificity reported in the study by Crockford et al.50 was, however, similar
to the values reported in other studies. In the study by Vaes et al.,49 the sensitivity and specificity values
observed were similar to the values reported in other studies.
In the systematic review of DTA, none of the studies of lead-I ECG devices included people presenting to
primary care with signs or symptoms of AF and an irregular pulse. This means that all of the results presented
in this systematic review are derived from an asymptomatic population and were mostly conducted in a
setting other than primary care. It is plausible that, if the population in the review had been people with
signs or symptoms of AF and an irregular pulse, the sensitivity of lead-I ECG devices where the trace was
interpreted by a trained health-care professional would have been higher. However, it is also plausible that,
in such a population, the specificity of lead-I ECG devices where the trace was interpreted by a trained
health-care professional would have been lower.
Assessment of clinical impact
No studies were identified that evaluated the clinical impact of lead-I ECG devices in people presenting to
primary care with symptoms of AF and an irregular pulse. As no studies were identified for the population
and setting of interest, the review focused on an asymptomatic population as prespecified in the protocol.68
We identified 24 publications reporting on 19 studies: 18 studies with a total of 33,993 participants and
one study that conducted semistructured interviews with two receptionists, one nurse, three GPs and eight
patients across three GP practices. The index tests evaluated included imPulse (one study63), Kardia Mobile
alone (11 studies45,47,51,54,56,57,59,61,62,64,65), MyDiagnostick alone (four studies48,52,58,60), Zenicor ECG (one study43)
and MyDiagnostick and Kardia Mobile (one study38). In nine studies,43,45,51,52,54,56,59,64,65 the lead-I ECG trace
was interpreted by one trained health-care professional (i.e. a cardiologist, an EP or a GP with an interest in
cardiology). In four studies,57,60–62 the lead-I ECG trace was interpreted independently by one trained health-
care professional and by the device algorithm. In three studies,47,48,58 the lead-I ECG trace was interpreted by
the device algorithm alone. In one study,38 the trace was interpreted independently by two EPs and by the
device algorithm. In one study,63 the lead-I ECG trace was interpreted independently by two cardiology
registrars, two cardiac physiologists and two specialist cardiac nurses.
Diagnostic yield was the most commonly reported outcome in 13 studies.38,48,52,54,56–62,64,65 The diagnostic
yield reported in these studies ranged from 0.4% to 5.8% and was similar across the studies, taking into
account the type of lead-I ECG device used and the setting in which the study was conducted. One study58
conducted in UK primary care reported the greatest diagnostic yield. However, this study58 was available
only as a conference abstract and the reason for the high diagnostic yield is unclear because of the limited
DISCUSSION
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information available. Data submitted by Kent Surrey Sussex AHSN (Kent Surrey Sussex AHSN and Richard
Blakey, AliveCor in East Sussex, unpublished evidence submitted via NICE) on the use of the Kardia Mobile
lead-I ECG device for people with symptoms of AF and an irregular pulse during a 2-year project reported
a diagnostic yield of 69.9%. It is plausible that the diagnostic yield in people presenting to primary care
with signs or symptoms of AF and an irregular pulse would be more comparable with the values reported
by Kent Surrey Sussex AHSN than those reported in the published evidence available and included in the
systematic review of the clinical impact of lead-I ECG devices.
Test failure rate was reported in nine studies38,45,52,56,57,60–63 and ranged from 0.1% to 9%. Test failure rate
considered both failure of the lead-I ECG algorithm to produce a result and poor quality of the lead-I
ECG trace. Possible reasons suggested for uninterpretable lead-I ECG results were sinus tachycardia or
bradycardia (Kardia Mobile),62 that patients suffered from tremor, or that hospitalised patients were too
weak to hold the devices firmly enough (not specified if Kardia Mobile or MyDiagnostick).38
Two studies59,61 reported a change in treatment management following the use of the Kardia Mobile lead-I
ECG device, with OACs being prescribed for most new patients diagnosed with AF. Acceptability of the
lead-I ECG devices was reported in four studies54,58,59,62 with generally positive views. A key barrier that was
identified related to the ease of use of the lead-I ECG device; it was difficult for elderly patients to hold the
device still for long enough to take a reading.62 Furthermore, one study38 reported that 7% of patients
were excluded because they were not able to hold the devices properly. A qualitative study53 suggested
that nurses in GP practices could confidently use a lead-I ECG device (Kardia Mobile) and were well placed
to explain the screening process to and conduct AF screening in people aged ≥ 65 years before their GP
appointment. However, only one nurse was interviewed as part of this study, so there are concerns about
the generalisability of this finding. Moreover, the study was conducted to evaluate the feasibility of
screening in an asymptomatic population and so it is unclear if the results would be applicable to the
population of interest in this appraisal. Time to initiation of preventative treatment and HRQoL were not
reported in any of the identified studies.
Only one study59 reported on clinical outcomes. One patient who did not receive anticoagulant therapy
after a lead-I ECG trace that was difficult to interpret, followed by a normal 12-lead ECG result, later had
a stroke. The importance of prolonged monitoring in cases of suspected AF that may be paroxysmal is
evident. It has been reported that a period of 2-week monitoring using a hand-held device identified 7.4%
(30/403) of cases of paroxysmal AF who had screened negative on a 12-lead ECG but who had two or
more risk factors based on the CHADS2 risk classification.75
Assessment of cost-effectiveness
No published studies were identified that evaluated the cost-effectiveness of lead-I ECG devices compared
with MPP for people presenting to primary care with signs or symptoms of AF and an irregular pulse. As
no published data evaluating the DTA and the clinical impact of lead-I ECG devices were identified for
people presenting to primary care with signs or symptoms of AF and an irregular pulse, DTA data in an
asymptomatic population were used as a proxy for the population of interest.
The de novo economic model yielded ICERs per QALY gained. The results of the pairwise analysis show
that all lead-I ECG tests lie on the efficiency frontier in each of the four base-case analyses, with ICERs per
QALY gained below the £20,000–30,000 threshold usually considered to be cost-effective by NICE. Kardia
Mobile is the most cost-effective option in a full incremental analysis and dominates the standard pathway
and other lead-I ECG devices (costing less and generating more QALYs), with the exception of the generic
lead-I ECG device, which generates a very small QALY gain but at a cost that produces an ICER well above
£30,000 per QALY gained.
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Lead-I ECG devices are more cost-effective when there is a longer wait to a 12-lead ECG (because
treatment for AF with a lead-I ECG device is assumed in the lead-I ECG diagnostic pathway to start earlier
than in the standard diagnostic pathway) and when the 12-lead ECG is performed in a hospital. The
majority of the patient benefit, however, comes after diagnosis owing to a greater proportion of patients
being correctly diagnosed with AF and treated for AF when than using the standard diagnostic pathway,
even if this benefit is slightly offset by an increase in the number of patients incorrectly diagnosed with AF
by a lead-I ECG device.
The one-way sensitivity analysis showed that the results were particularly sensitive to the assumed prevalence
of paroxysmal AF versus persistent and permanent AF. Decreasing the prevalence of paroxysmal AF increased
incremental costs and decreased incremental QALYs for the lead-I ECG devices versus the standard pathway.
In the extreme, decreasing the prevalence of paroxysmal AF to zero either yielded very large, positive ICERs
per QALY gained or resulted in lead-I ECG devices being dominated by the standard pathway. The model
results were also shown to be sensitive to the rate of ISs in patients with AF. The results should, therefore,
be interpreted with caution if it is considered clinically plausible that the prevalence of paroxysmal AF in the
symptomatic population may be substantially lower than 50%.
In line with the conclusions of the EAG concerning the use of lead-I ECG devices for people presenting to
primary care with signs or symptoms of AF and an irregular pulse, the results of recently published economic
evaluations74,105 have suggested that lead-I ECG devices may represent a cost-effective use of resources for
systematic, opportunistic screening of people aged ≥ 65 years during a routine GP appointment. Lead-I ECG
devices may be cost-effective for an asymptomatic population because only people who have a positive
lead-I ECG test will have a subsequent 12-lead ECG test carried out. If a lead-I ECG test or an alternative
screening test were not used, people with asymptomatic AF would remain undiagnosed until the time of
an event (e.g. stroke). People with asymptomatic AF who are diagnosed early and receive appropriate
treatment gain health benefits in comparison with people whose AF remains undiagnosed and who do not
receive treatment for AF.
In the current NICE CG1803 it is recommended that an ECG is performed in all people, whether or not
symptomatic, in whom AF is suspected owing to detection of an irregular pulse. There is an emergence of
novel technologies to assist in the diagnosis of AF, such as lead-I ECG devices. These technologies need to
be clearly distinguished from 12-lead ECG devices when NICE CG1803 is updated.
Strengths and limitations
No published data evaluating the diagnostic accuracy, the clinical impact or the cost-effectiveness of lead-I
ECG devices were identified for people presenting to primary care with signs or symptoms of AF and an
irregular pulse. Therefore, all of the results presented in this assessment need to be interpreted with
caution as the results are based on data from an asymptomatic population used as a proxy for the
population of interest. Therefore, using data from asymptomatic patients as a proxy, we present the first
economic evaluation, to our knowledge, of lead-I ECG devices for people presenting to primary care with
signs or symptoms of AF and an irregular pulse.
Diagnostic test accuracy results are reported for all lead-I ECG devices (i.e. imPulse, Kardia Mobile,
MyDiagnostick, RhythmPad GP and Zenicor ECG) within the scope of this assessment. However, for
RhythmPad GP, results were based on interpretation by the lead-I ECG algorithm only and, according to the
manufacturer (Chris Crockford, CardioCity, 3 August 2018, personal communication via NICE), the device
algorithm has been modified since the identified study was published,50 and therefore the sensitivity and
specificity estimates observed may have been affected. One study63 reporting on the DTA of the imPulse
lead-I ECG device was excluded from the DTA review because the reference standard was ineligible.
However, the sensitivity and specificity values from this study63 were considered in the economic evaluation.
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Since January 2018, Kardia Mobile lead-I ECG devices have been rolled out to primary care practices as
part of the NHS England-funded NHS Innovation Accelerator, delivered in partnership with England’s
15 AHSNs.106 The aim of the initiative is to improve the detection of AF in order to reduce the number of
strokes.106,107 It has been suggested that, with this initiative, the lead-I ECG device can be used at any time,
regardless of whether patients have signs or symptoms of AF.108
No published data were identified that provided estimates of the effect of treatment for AF on cognitive
decline and vascular dementia associated with AF. Therefore, any potential benefit of treatment for AF on
the incidence or severity of cognitive decline and vascular dementia could not be included in the model.
There is an absence of data, both qualitative and quantitative, describing the effects of nurse assessment
rather than medical assessment. If assessments are undertaken in nurse-led-only clinics, there may be
significant delays in presentation of the data to the GP, with potential clinical implications.
Conclusions
The results of the systematic reviews of DTA and clinical impact of lead-I ECG devices suggest that these
devices are an important addition to the armamentarium of a GP when diagnosing AF. However, only
evidence supporting their use in an asymptomatic population was identified from the published literature.
In people with signs or symptoms of AF and an irregular pulse, it is recommended that a 12-lead-ECG is
performed. If a 12-lead ECG is carried out on the day of the initial appointment, there is unlikely to be any
diagnostic benefit to using a lead-I ECG device over a 12-lead ECG in the symptomatic population, as
patients with AF are in AF at the time of the initial appointment (and, therefore, at the time of the lead-I
ECG test and of any 12-lead ECG that takes place soon after the initial appointment). Only if there is a
time interval between the use of a lead-I ECG device and a 12-lead ECG would any health benefits from
early treatment initiation be obtained by patients. To allow for these benefits to be considered, the
economic evaluation considered primary care practices where patients have to wait at least 48 hours
between their initial consultation with the GP and a confirmatory 12-lead ECG.
Future research investigating the DTA of lead-I ECG devices in people presenting to primary care with
signs or symptoms of AF and an irregular pulse should take into consideration the added value that such
research would provide. Kardia Mobile lead-I ECG devices are currently being introduced for use in NHS
primary care settings for routine screening in people aged ≥ 65 years.
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author for consideration.
Patient data
This work uses data provided by patients and collected by the NHS as part of their care and support. Using
patient data is vital to improve health and care for everyone. There is huge potential to make better use of
information from people’s patient records, to understand more about disease, develop new treatments,
monitor safety, and plan NHS services. Patient data should be kept safe and secure, to protect everyone’s
privacy, and it’s important that there are safeguards to make sure that it is stored and used responsibly.
Everyone should be able to find out about how patient data are used. #datasaveslives You can find out
more about the background to this citation here: https://understandingpatientdata.org.uk/data-citation.
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Appendix 1 The PRISMA-DTA checklist




Title 1 Identify the report as a systematic review (+/− meta-analysis) of DTA studies NA
Abstract 2 Abstract: see PRISMA-DTA for abstracts Appendix 2
INTRODUCTION
Rationale 3 Describe the rationale for the review in the context of what is already known pp. 1–4
Clinical role of
index test
D1 State the scientific and clinical background, including the intended use and
clinical role of the index test, and if applicable, the rationale for minimally
acceptable test accuracy (or minimum difference in accuracy for comparative
design)
pp. 4–8
Objectives 4 Provide an explicit statement of question(s) being addressed in terms of





5 Indicate if a review protocol exists, if and where it can be accessed
(e.g. URL address), and, if available, provide registration information including
registration number
p. xxviii
Eligibility criteria 6 Specify study characteristics (participants, setting, index test(s), reference
standard(s), target condition(s), and study design) and report characteristics






7 Describe all information sources (e.g. databases with dates of coverage,
contact with study authors to identify additional studies) in the search and
date last searched
p. 9
Search 8 Present full search strategies for all electronic databases and other sources
searched, including any limits used, such that they could be repeated
Appendix 3
Study selection 9 State the process for selecting studies (i.e. screening, eligibility, included in




10 Describe method of data extraction from reports (e.g. piloted forms,





11 Provide definitions used in data extraction and classifications of target
condition(s), index test(s), reference standard(s) and other characteristics
(e.g. study design, clinical setting)
p. 10 and
Table 2
Risk of bias and
applicability
12 Describe methods used for assessing risk of bias in individual studies and




13 State the principal diagnostic accuracy measure(s) reported (e.g. sensitivity,




14 Describe methods of handling data, combining results of studies and
describing variability between studies. This could include, but is not limited
to a) handling of multiple definitions of the target condition, b) handling of
multiple thresholds of test positivity, c) handling multiple index test readers, d)
handling of indeterminate test results, e) grouping and comparing tests, and f)
handling of different reference standards
pp. 11–12
Meta-analysis D2 Report the statistical methods used for meta-analyses, if performed pp. 11–12
Additional
analyses
16 Describe methods of additional analyses (e.g. sensitivity or subgroup analyses,
meta-regression), if done, indicating which were prespecified
p. 12
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Study selection 17 Provide numbers of studies screened, assessed for eligibility, included in the
review (and included in meta-analysis, if applicable) with reasons for exclusions




18 For each included study provide citations and present key characteristics
including a) participant characteristics (presentation, prior testing), b) clinical
setting, c) study design, d) target condition definition, e) index test, f)
reference standard, g) sample size, and h) funding sources
Table 3
Risk of bias and
applicability





20 For each analysis in each study (e.g. unique combination of index test,
reference standard, and positivity threshold) report 2x2 data (TP, FP, FN, TN)
with estimates of diagnostic accuracy and confidence intervals, ideally with a




21 Describe test accuracy, including variability; if meta-analysis was done, include
results and confidence intervals
pp. 19–25
Additional analysis 23 Give results of additional analyses, if done (e.g. sensitivity or subgroup
analyses, meta-regression; analysis of index test: failure rates, proportion of





24 Summarise the main findings including the strength of evidence pp. 23–5
and 67–8
Limitations 25 Discuss limitations from included studies (e.g. risk of bias and concerns
regarding applicability) and from the review process (e.g. incomplete retrieval
of identified research
p. 70–1
Conclusions 26 Provide a general interpretation of the results in the context of other evidence.
Discuss implications for future research and clinical practice (e.g. the intended
use and clinical role of the index test)
p. 67–8, 71
FUNDING
Funding 27 For the systematic review, describe the sources of funding and other support
and the role of the funders
p. iii
FN, false negative; FP, false positive; NA, not applicable; TN, true negative; TP, true positive.
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Appendix 2 The PRISMA-DTA for abstracts
checklist




Title 1 Identify the report as a systematic review (+/− meta-analysis) of DTA studies NA
Objectives 2 Indicate the research question, including components such as participants, index
test, and target conditions
pp. xxv
METHODS
Eligibility criteria 3 Include study characteristics used as criteria for eligibility pp. xxv–xxvi
Information
sources
4 List the key databases searched and the search dates pp. xxv
Risk of bias &
applicability
5 Indicate the methods of assessing risk of bias and applicability pp. xxvi
Synthesis of
results
A1 Indicate the methods for the data synthesis pp. xxvi
RESULTS
Included studies 6 Indicate the number and type of included studies and the participants and




7 Include the results for the analysis of diagnostic accuracy, preferably indicating
the number of studies and participants. Describe test accuracy including






9 Provide a brief summary of the strengths and limitations of the evidence pp. xxviii
Interpretation 10 Provide a general interpretation of the results and the important implications pp. xxviii
OTHER
Funding 11 Indicate the primary source of funding for the review pp. xxviii
Registration 12 Provide the registration number and the registry name pp. xxviii
NA, not applicable.
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Appendix 3 Search strategy (MEDLINE)
MEDLINE (via OvidSP)
Date range searched: inception to 9 March 2018.
Date searched: 9 March 2018.
Search strategy
1. Lead-I ECG.tw.
2. single lead ECG.tw.
3. (lead I or single lead or automated algorithm).tw.
4. Electrocardiography/
5. (electrocardiog* or ECG).tw.
6. 4 or 5
7. 3 and 6
8. lead I electrocardiog*.tw.
9. single lead electrocardiog*.tw.
10. 1 or 2 or 7 or 8 or 9
11. Atrial Fibrillation/
12. AF.tw.
13. (Atr* adj3 Fibrill*).tw.
14. 11 or 12 or 13






21. 10 and 20
22. 15 or 16 or 17 or 18 or 19 or 21
23. Animals/not Humans/
24. 22 not 23
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Appendix 4 Excluded studies
Ineligible intervention (19 studies)
Boyle KO, Morra D, Dorian P, McCrorie A, Haddad P, Taylor L, et al. Atrial fibrillation screening using a
handheld ECG device: results from the heart and stroke foundation (HSF) ‘be pulse aware’ campaign.
Stroke 2013;44:e184.
Chellappan K, Ab Malek SNH, Jaafar R, Aminuddin A. Self-monitoring technique for stroke prevention
among atrial fibrillation patients. Int J Stroke 2016;11:248.
Chen YH, Hung CS, Huang CC, Hung YC, Hwang JJ, Ho YL. Atrial fibrillation screening in nonmetropolitan
areas using a telehealth surveillance system with an embedded cloud-computing algorithm: prospective
pilot study. JMIR Mhealth Uhealth 2017;5:e135.
Claes N, Van Laethem C, Goethals M, Goethals P, Mairesse G, Schwagten B, et al. Prevalence of atrial
fibrillation in adults participating in a large-scale voluntary screening programme in Belgium. Acta Cardiol
2012;67:273–8.
Gilani M, Eklund JM, Makrehchi M. Automated Detection of Atrial Fibrillation Episode Using Novel Heart
Rate Variability Features. Proceedings of the 2016 38th Annual International Conference of the IEEE
Engineering in Medicine and Biology Society, 16–20 Aug 2016, Orlando, FL, pp. 3461–64.
Hobbs FD, Fitzmaurice DA, Mant J, Murray E, Jowett S, Bryan S, et al. A randomised controlled trial and cost-
effectiveness study of systematic screening (targeted and total population screening) versus routine practice
for the detection of atrial fibrillation in people aged 65 and over. The SAFE study. Health Technol Assess
2005;9(40). URL: http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/854/CN-00530854/frame.html
Kaleschke G, Hoffmann B, Drewitz I, Steinbeck G, Naebauer M, Goette A, et al. Prospective, multicentre
validation of a simple, patient-operated electrocardiographic system for the detection of arrhythmias and
electrocardiographic changes. Europace 2009;11:1362–8.
Kearley K, Selwood M, Van den Bruel A, Thompson M, Mant D, Hobbs FDR, et al. Triage tests for
identifying atrial fibrillation in primary care: a diagnostic accuracy study comparing single-lead ECG and
modified BP monitors. BMJ Open 2014;4:e004565.
Mant J, Fitzmaurice DA, Hobbs FDR, Jowett S, Murray ET, Holder R, et al. Accuracy of diagnosing atrial
fibrillation on electrocardiogram by primary care practitioners and interpretative diagnostic software:
analysis of data from screening for atrial fibrillation in the elderly (SAFE) trial. BMJ 2007;335:380.
McManus DD, Lee J, Maitas O, Esa N, Pidikiti R, Carlucci A, et al. A novel application for the detection of
an irregular pulse using an iPhone 4s in patients with atrial fibrillation. Heart Rhythm 2013;10:315–9.
McManus DD, Chong JW, Soni A, Saczynski JS, Esa N, Napolitano C, et al. PULSE-SMART: pulse-based
arrhythmia discrimination using a novel smartphone application. J Cardiovasc Electrophysiol 2016;27:51–7.
Mortelmans C, Van Haelst R, Van Der Auwera J, Grieten L, Vandervoort P, Vaes B. Validation of a new
smartphone application for the diagnosis of atrial fibrillation in primary care. Europace 2017;19:iii16.
Newham WG, Tayebjee MH. Excellent symptom rhythm correlation in patients with palpitations using a
novel smartphone based event recorder. J Atr Fibrillation 2017;10:1514.
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Proietti M, Mairesse GH, Goethals P, Scavee C, Vijgen J, Blankoff I, et al. A population screening programme
for atrial fibrillation: a report from the Belgian Heart Rhythm Week screening programme. Europace
2016;18:1779–86.
Rajendram R, Patel S, Kale S, Nangalia V. Ability of clinicians trained in intensive care to interpret rhythm
strips. J Intensive Care Soc 2014;15:S70–S71.
Sandhu RK, Deif B, Barake W, Agarwal G, Connolly SJ, Dolovich L, et al. Identification of actionable atrial
fibrillation using an integrated cardiovascular screening approach in community pharmacies. Heart Rhythm
2016;13:S415–6.
Somerville S, Somerville J, Croft P, Lewis M. Atrial fibrillation: a comparison of methods to identify cases in
general practice. Br J Gen Pract 2000;50:727–9.
Vyas V, Duran J, Ansaripour A, Niedzielko M, Steel A, Bakhai A. Does a 12-lead ECG more reliably detect
atrial fibrillation than a rhythm strip only ECG? Value Health 2014;17:A485–A486.
Winkler S, Axmann C, Schannor B, Kim S, Leuthold T, Scherf M, et al. Diagnostic accuracy of a new
detection algorithm for atrial fibrillation in cardiac telemonitoring with portable electrocardiogram devices.
J Electrocardiol 2011;44:460–4.
Ineligible outcomes (seven studies)
Ara F, Crockford C, John I, Kaba RA. Novel galvanised titanium-based ECG technology can reliably detect
arrhythmias. Europace 2015;17:iii53.
Chan PH, Wong CK, Pun L, Wong YF, Wong MM, Chu DW, Siu CW. Diagnostic performance of an
automatic blood pressure measurement device, Microlife WatchBP Home A, for atrial fibrillation screening
in a real-world primary care setting. BMJ Open 2017;7:e013685.
Chung EH, Guise KD. QTC intervals can be assessed with the AliveCor heart monitor in patients on
dofetilide for atrial fibrillation. J Electrocardiol 2015;48:8–9.
Grieten L, Van Der Auwera J, Vandervoort P, Rivero-Ayerza M, Van Herendael H, De Vusser P, et al.
Evaluating smartphone based photoplesythmography as a screening solution for atrial fibrillation: a digital
tool to detect afib? J Am Coll Cardiol 2017;69:2499.
Jacobs MS, Kaasenbrood F, Postma MJ, Van Hulst M, Tieleman RG. Cost-effectiveness of screening for
atrial fibrillation in primary care with a handheld, single-lead electrocardiogram device in the Netherlands.
Europace 2018;20:12–18.
Khanbhai ZM, Manning SE, Hussain W. Community pharmacist led atrial fibrillation screening program has the
potential to improve atrial fibrillation detection rates and reduce stroke risk. Circulation 2016;134:A19641.
Mehta DD, Nazir NT, Trohman RG, Volgman AS. Single-lead portable ECG devices: perceptions and clinical
accuracy compared to conventional cardiac monitoring. J Electrocardiol 2015;48:710–6.
Ineligible language (one study)
Reimert M, Verhoeven A. Screening for atrial fibrillation with single-lead hand-held ECG. Huisarts
Wetenschap 2017;60:474.
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Appendix 5 The QUADAS-2 quality assessment
Ideal study
Characteristic Description
Population People with signs or symptoms that may indicate underlying AF and who have an irregular pulse
Presentation Presenting to primary care on account of signs or symptoms associated with AF (e.g. palpitations,
dizziness, shortness of breath and tiredness)
Prior tests No prior testing for AF






Purpose To detect AF at a single time point in people who present with relevant signs or symptoms to primary




12-lead ECG performed and interpreted by a trained health-care professional
QUADAS-2 assessment of studies included in the diagnostic test
accuracy review
Crockford 201350
Domain 1: patient selection
Risk of bias
Method used in the study for patient selection not described
Was a consecutive or random sample of patients enrolled? Unclear
Was a case–control design avoided? Unclear
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Risk: unclear
Concerns regarding applicability
Patients who had been referred to an electrophysiology department. Reason for referral not provided
Are there concerns that the included patients do not match the review question? Concerns: high
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Domain 2: index test(s)
Risk of bias
RhythmPad GP. No details provided regarding who performed the tests. Sequence of tests and blinding of interpreters
not clear
Were the index test results interpreted without knowledge of the results of the reference
standard?
Unclear
If a threshold was used, was it prespecified? Unclear
Could the conduct or interpretation of the index test have introduced bias? Risk: unclear
Concerns regarding applicability
Are there concerns that the index test, its conduct, or interpretation differ from the
review question?
Concerns: unclear
Domain 3: reference standard
Risk of bias
12-lead ECG interpreted by a cardiologist. No details provided regarding who performed the tests
Is the reference standard likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the
index test?
Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? Risk: unclear
Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard
does not match the review question?
Concerns: low
Domain 4: flow and timing
Risk of bias
All patients received the index test and reference standard. Data from 24 patients were excluded owing to data integrity,
or to copies of traces of lead-I ECG or 12-lead ECG not being available at the end of the study. The reference standard was
performed before the index test but the interval between assessments is not clear
Was there an appropriate interval between the index test and reference standard? Unclear
Did all patients receive a reference standard? Yes
Did patients receive the same reference standard? Yes
For comparative accuracy studies, did all patients receive all index tests? NA
Were all patients included in the analysis? No
Could the patient flow have introduced bias? Risk: unclear
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Desteghe 201738
Domain 1: patient selection
Risk of bias
The method used in the study for patient selection was not described
Was a consecutive or random sample of patients enrolled? Unclear
Was a case–control design avoided? Unclear
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Risk: unclear
Concerns regarding applicability
Hospitalised patients screened for AF at a cardiology ward. A proportion of the screened population (35.6%) had known
AF based on chart review. Reasons for admission were coronary angiography/elective revascularisation (n = 100, 31.2%),
electrophysiological examination/ablation (n = 64, 20%), heart failure (n = 37, 11.6%), acute coronary syndrome (n = 36,
11.3%), device implantation or replacement (n = 32, 10%), symptomatic AF (n = 11, 3.4%) or other (n = 40, 12.5%)
Are there concerns that the included patients do not match the review question? Concerns: high
Domain 2: index tests
Risk of bias: MyDiagnostick
MyDiagnostick lead-I ECG device. No details were provided regarding who performed the tests. The lead-I ECG was
performed immediately after the use of the reference standard and interpreted by the device algorithm and two EPs blind
to the diagnosis based on both the algorithm and the reference standard
Were the index test results interpreted without knowledge of the results of the reference
standard?
Yes
If a threshold was used, was it prespecified? Unclear
Could the conduct or interpretation of the index test have introduced bias? Risk: low
Concerns regarding applicability: MyDiagnostick
Are there concerns that the index test, its conduct, or interpretation differ from the
review question?
Concerns: low
Risk of bias: Kardia Mobile
Kardia Mobile lead-I ECG. No details were provided regarding who performed the tests. Lead-I ECG performed immediately
after the use of the reference standard and interpreted by device algorithm and two EPs blind to the diagnosis based on
both the algorithm and the reference standard
Were the index test results interpreted without knowledge of the results of the reference
standard?
Yes
If a threshold was used, was it prespecified? Unclear
Could the conduct or interpretation of the index test have introduced bias? Risk: low
Concerns regarding applicability: Kardia Mobile
Are there concerns that the index test, its conduct, or interpretation differ from the
review question?
Concerns: low
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Domain 3: reference standard
Risk of bias
A full 10-second 12-lead ECG performed by a trained nurse immediately before the use of lead-I ECG devices. 12-lead ECG
interpreted by two EPs blind to the results of the lead-I ECG algorithm
Is the reference standard likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the
index test?
Yes
Could the reference standard, its conduct, or its interpretation have introduced bias? Risk: low
Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard
does not match the review question?
Concerns: low
Domain 4: flow and timing
Risk of bias
Twenty-four patients were excluded from the 2x2 table because they were not able to hold the devices properly. The
reference standard was performed immediately before the index tests
Was there an appropriate interval between the index test and the reference standard? Yes
Did all patients receive a reference standard? Yes
Did patients receive the same reference standard? Yes
For comparative accuracy studies, did all patients receive all index tests? Yes
Were all patients included in the analysis? No
Could the patient flow have introduced bias? Risk: low
Doliwa 200943
Domain 1: patient selection
Risk of bias
The method used in the study for patient selection was not described
Was a consecutive or random sample of patients enrolled? Unclear
Was a case–control design avoided? Unclear
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Risk: unclear
Concerns regarding applicability
Patients with AF, atrial flutter or sinus rhythm were recruited from a cardiology outpatient clinic to evaluate the sensitivity
and specificity with a lead-I ECG device for sinus rhythm and atrial fibrillation detection. The reason for cardiology
outpatient appointment was not provided
Are there concerns that the included patients do not match the review question? Concerns: high
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Domain 2: index test
Risk of bias
Zenicor-ECG. No details were provided regarding who performed the tests. Lead-I ECG was performed immediately after
the use of the reference standard and was interpreted by a cardiologist blind to the 12-lead ECG registration
Were the index test results interpreted without knowledge of the results of the reference
standard?
Yes
If a threshold was used, was it prespecified? Unclear
Could the conduct or interpretation of the index test have introduced bias? Risk: low
Concerns regarding applicability
Are there concerns that the index test, its conduct, or interpretation differ from the
review question?
Concerns: low
Domain 3: reference standard
Risk of bias
A 12-lead ECG performed immediately before the use of a lead-I ECG device and interpreted by a cardiologist. No details
were provided regarding who performed the tests
Is the reference standard likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the
index test?
Yes
Could the reference standard, its conduct, or its interpretation have introduced bias? Risk: low
Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard
does not match the review question?
Concerns: low
Domain 4: flow and timing
Risk of bias
All patients received the index test and reference standard. All patients were included in the 2x2 table. The reference
standard was performed immediately before the index test
Was there an appropriate interval between the index test and the reference standard? Yes
Did all patients receive a reference standard? Yes
Did patients receive the same reference standard? Yes
For comparative accuracy studies, did all patients receive all index tests? NA
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? Risk: low
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Haberman 201545
Domain 1: patient selection
Risk of bias
The method used in the study for patient selection was not described
Was a consecutive or random sample of patients enrolled? Unclear
Was a case–control design avoided? Unclear
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Risk: unclear
Concerns regarding applicability
Patients were recruited from a cardiology outpatient clinic to evaluate the sensitivity and specificity with a lead-I ECG device
for sinus rhythm and AF detection. It was unclear if any patients had been previously diagnosed with AF. Reason for
cardiology outpatient appointment not provided
Are there concerns that the included patients do not match the review question? Concern: high
Domain 2: index test
Risk of bias
Kardia Mobile lead-I ECG. The test acquisitions were performed and supervised by study investigators. The lead-I ECG was
performed immediately before the use of the reference standard and was interpreted by two EPs. It was unclear if
interpreters of the test were blind to the results of the reference standard
Were the index test results interpreted without knowledge of the results of the reference
standard?
Unclear
If a threshold was used, was it prespecified? Unclear
Could the conduct or interpretation of the index test have introduced bias? Risk: unclear
Concerns regarding applicability
Are there concerns that the index test, its conduct, or interpretation differ from the
review question?
Concerns: low
Domain 3: reference standard
Risk of bias
A 12-lead ECG performed immediately after the use of a lead-I ECG device and interpreted by two EPs. Test acquisitions
were performed and supervised by study investigators
Is the reference standard likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the
index test?
Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? Risk: unclear
Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard
does not match the review question?
Concerns: low
APPENDIX 5
NIHR Journals Library www.journalslibrary.nihr.ac.uk
96
Domain 4: flow and timing
Risk of bias
All patients received the index test and the reference standard. All patients were included in the 2x2 table. The reference
standard was performed immediately after the index test
Was there an appropriate interval between the index test and the reference standard? Yes
Did all patients receive a reference standard? Yes
Did patients receive the same reference standard? Yes
For comparative accuracy studies, did all patients receive all index tests? NA
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? Risk: low
Koltowski 201751
Domain 1: patient selection
Risk of bias
The method used in the study for patient selection was not described
Was a consecutive or random sample of patients enrolled? Unclear
Was a case–control design avoided? Unclear
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Risk: unclear
Concerns regarding applicability
Patients in a tertiary care centre were recruited to evaluate the diagnostic accuracy of the Kardia Mobile lead-I ECG device.
Reasons for patients attending the tertiary care centre not provided
Are there concerns that the included patients do not match the review question? Concerns: high
Domain 2: index test
Risk of bias
Kardia Mobile lead-I ECG. The test acquisitions were performed by one physician. The lead-I ECG was performed before
the use of the reference standard and interpreted by three teams comprised of two cardiologists and one internal medicine
specialist
Were the index test results interpreted without knowledge of the results of the reference
standard?
Unclear
If a threshold was used, was it prespecified? Unclear
Could the conduct or interpretation of the index test have introduced bias? Risk: unclear
Concerns regarding applicability
Are there concerns that the index test, its conduct, or interpretation differ from the
review question?
Concerns: unclear
DOI: 10.3310/hta24030 HEALTH TECHNOLOGY ASSESSMENT 2020 VOL. 24 NO. 3
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Duarte et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
97
Domain 3: reference standard
Risk of bias
The 12-lead ECG was performed after the use of a lead-I ECG device and interpreted by three teams comprised of two
cardiologists and one internal medicine specialist. Test acquisitions were performed by one physician
Is the reference standard likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the
index test?
Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? Risk: unclear
Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard
does not match the review question?
Concerns: low
Domain 4: flow and timing
Risk of bias
All patients received the reference standard. One patient did not receive the index test. The reference standard was
performed after the index test
Was there an appropriate interval between the index test and the reference standard? Yes
Did all patients receive a reference standard? Yes
Did patients receive the same reference standard? Yes
For comparative accuracy studies, did all patients receive all index tests? NA
Were all patients included in the analysis? No
Could the patient flow have introduced bias? Risk: low
Lau 201347
Domain 1: patient selection
Risk of bias
The method used in the study for patient selection was not described
Was a consecutive or random sample of patients enrolled? Unclear
Was a case–control design avoided? Unclear
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Risk: unclear
Concerns regarding applicability
Patients were screened for AF at a cardiology department. A proportion of the screened population (24%) had known AF.
The reason for patient attendance at the cardiology department was not provided
Are there concerns that the included patients do not match the review question? Concerns: high
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Domain 2: index test
Risk of bias
Kardia Mobile lead-I ECG. No details were provided regarding who performed the tests. The lead-I ECG was performed
within six hours after the use of the reference standard and interpreted by device algorithm alone
Were the index test results interpreted without knowledge of the results of the reference
standard?
Yes
If a threshold was used, was it prespecified? Unclear
Could the conduct or interpretation of the index test have introduced bias? Risk: low
Concerns regarding applicability
Are there concerns that the index test, its conduct, or interpretation differ from the
review question?
Concerns: high
Domain 3: reference standard
Risk of bias
A 12-lead ECG was performed within six hours before the use of a lead-I ECG device and was interpreted by a cardiologist.
No details provided regarding who performed the tests
Is the reference standard likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the
index test?
Yes
Could the reference standard, its conduct, or its interpretation have introduced bias? Risk: low
Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard
does not match the review question?
Concerns: low
Domain 4: flow and timing
Risk of bias
All patients received the index test and the reference standard. All patients were included in the 2 × 2 table. The index test
was performed within six hours after the reference standard
Was there an appropriate interval between index test and reference standard? Yes
Did all patients receive a reference standard? Yes
Did patients receive the same reference standard? Yes
For comparative accuracy studies, did all patients receive all index tests? NA
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? Concern: low
DOI: 10.3310/hta24030 HEALTH TECHNOLOGY ASSESSMENT 2020 VOL. 24 NO. 3
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Duarte et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
99
Reeves (NR)63
Domain 1: patient selection
Risk of bias
Research nurses identified and approached eligible patients
Was a consecutive or random sample of patients enrolled? Unclear
Was a case–control design avoided? Unclear
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Risk: unclear
Concerns regarding applicability
Patients hospitalised after cardiac surgery or a cardiac-related event were recruited from cardiac intensive care unit,
coronary care unit and cardiac surgery and cardiology wards in a regional specialist cardiac centre. The aim of the study
was to obtain proof-of-principle data that the imPulse lead-I ECG device can capture and display an ECG trace with
sufficient detail and viewing quality to allow experienced practitioners to detect AF
Are there concerns that the included patients do not match the review question? Concerns: high
Domain 2: index test
Risk of bias
imPulse lead-I ECG. It is not clear who performed the tests. The lead-I ECG performed at the same time as the 12-lead
ECG. The index test was interpreted by two cardiology doctors, two specialist cardiac nurses and two cardiac physiologists,
all with expertise in assessing ECGs blind to the 12-lead ECG registration
Were the index test results interpreted without knowledge of the results of the reference
standard?
Yes
If a threshold was used, was it prespecified? Unclear
Could the conduct or interpretation of the index test have introduced bias? Risk: low
Concerns regarding applicability
Are there concerns that the index test, its conduct, or interpretation differ from the
review question?
Concerns: low
Domain 3: reference standard
Risk of bias
12-lead ECG performed at the same time as the lead-I ECG device and interpreted by two cardiology doctors, two specialist
cardiac nurses and two cardiac physiologists. There were two reference standards; the first was the clinical ECG diagnosis
and the second was the ECG diagnosis for a subgroup of patients for whom there was consensus among the assessors’
12-lead diagnoses (at least 3 of 4 in agreement) that the diagnosis was sinus rhythm or AF and this consensus diagnosis
matched the clinical ECG diagnosis. No details provided regarding who performed the tests
Is the reference standard likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the
index test?
Yes
Could the reference standard, its conduct, or its interpretation have introduced bias? Risk: low
Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard
does not match the review question?
Concerns: high
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Domain 4: flow and timing
Risk of bias
All patients received the index test and the 12-lead ECG. All patients were included in the 2 × 2 table, however,
interpretations by all of the six assessors were not presented. The 12-lead ECG was performed at the same time as the
index test
Was there an appropriate interval between index test and reference standard? Yes
Did all patients receive a reference standard? Yes
Did patients receive the same reference standard? Unclear
For comparative accuracy studies, did all patients receive all index tests? NA
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? Risk: low
Tieleman 201448
Domain 1: patient selection
Risk of bias
Random selection of patients visiting an outpatient cardiology clinic or a specialised AF outpatient clinic
Was a consecutive or random sample of patients enrolled? Yes
Was a case–control design avoided? Unclear
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Risk: unclear
Concerns regarding applicability
Patients with known AF and patients without a history of AF visiting an outpatient cardiology clinic or a specialised AF
outpatient clinic. Reasons for patients attending the clinics not presented
Are there concerns that the included patients do not match the review question? Concerns: high
Domain 2: index test
Risk of bias
MyDiagnostick lead-I ECG. No details were provided regarding who performed the tests. The lead-I ECG was performed
immediately before the use of the reference standard and trace interpreted by device algorithm alone
Were the index test results interpreted without knowledge of the results of the reference
standard?
Yes
If a threshold was used, was it prespecified? Unclear
Could the conduct or interpretation of the index test have introduced bias? Risk: low
Concerns regarding applicability
Are there concerns that the index test, its conduct, or interpretation differ from the
review question?
Concerns: high
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Domain 3: reference standard
Risk of bias
A 12-lead ECG performed immediately after the use of a lead-I ECG device and interpreted by a cardiologist blind to the
results of the index test. No details provided regarding who performed the tests
Is the reference standard likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the
index test?
Yes
Could the reference standard, its conduct, or its interpretation have introduced bias? Risk: low
Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard
does not match the review question?
Concerns: low
Domain 4: flow and timing
Risk of bias
All patients received the index test and the reference standard. All patients were included in the 2 × 2 table. The reference
standard was performed immediately after the index test
Was there an appropriate interval between the index test and the reference standard? Yes
Did all patients receive a reference standard? Yes
Did patients receive the same reference standard? Yes
For comparative accuracy studies, did all patients receive all index tests? NA
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? Risk: low
Vaes 201449
Domain 1: patient selection
Risk of bias
General practitioners invited patients with known, paroxysmal or chronic AF to participate in the study to achieve a
prevalence of AF of at least 50%. Subjects without a history of AF were also invited to participate in the study
Was a consecutive or random sample of patients enrolled? Unclear
Was a case–control design avoided? No
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Risk: unclear
Concerns regarding applicability
Patients with known AF (n = 161) and patients without a history of AF (n = 30) presenting to primary care. Reasons for
patients attending a primary care appointment not presented
Are there concerns that the included patients do not match the review question? Concerns: high
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Domain 2: index test
Risk of bias
MyDiagnostick lead-I ECG device. A researcher who was not blinded to the medical history of the patient performed the
tests. A lead-I ECG was performed before the use of the reference standard and trace interpreted by device algorithm alone
Were the index test results interpreted without knowledge of the results of the reference
standard?
Yes
If a threshold was used, was it prespecified? Unclear
Could the conduct or interpretation of the index test have introduced bias? Risk: low
Concerns regarding applicability
Are there concerns that the index test, its conduct, or interpretation differ from the
review question?
Concerns: high
Domain 3: reference standard
Risk of bias
A 12-lead ECG was performed after the use of the lead-I ECG device and interpreted by a cardiologist blind to the results
of the index test. A researcher who was not blinded to the medical history of the patient performed the tests
Is the reference standard likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the
index test?
Yes
Could the reference standard, its conduct, or its interpretation have introduced bias? Risk: low
Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard
does not match the review question?
Concerns: low
Domain 4: flow and timing
Risk of bias
Ten patients were excluded from the 2x2 table as the pacemaker was active at the moment of the ECG recording. The
reference standard was performed after the index test, but timing not specified
Was there an appropriate interval between the index test and the reference standard? Unclear
Did all patients receive a reference standard? No
Did patients receive the same reference standard? Yes
For comparative accuracy studies, did all patients receive all index tests? NA
Were all patients included in the analysis? No
Could the patient flow have introduced bias? Risk: unclear
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Williams 201539
Domain 1: patient selection
Risk of bias
The method used in the study for patient selection was not described
Was a consecutive or random sample of patients enrolled? Unclear
Was a case–control design avoided? Unclear
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Risk: unclear
Concerns regarding applicability
Patients with known AF attending an AF clinic and patients with AF status unknown who were attending the clinic for
non-AF related reasons
Are there concerns that the included patients do not match the review question? Concerns: high
Domain 2: index test
Risk of bias
Kardia Mobile lead-I ECG. No details were provided regarding who performed the tests. A lead-I ECG was performed at the
same time as the reference standard and interpreted by a cardiologist and a GP with an interest in cardiology. Interpreters
of the test were blind to the results of the reference standard
Were the index test results interpreted without knowledge of the results of the reference
standard?
Yes
If a threshold was used, was it prespecified? Unclear
Could the conduct or interpretation of the index test have introduced bias? Risk: low
Concerns regarding applicability
Are there concerns that the index test, its conduct, or interpretation differ from the
review question?
Concerns: low
Domain 3: reference standard
Risk of bias
A 12-lead ECG was performed at the same time as the index test and was interpreted by a cardiologist and a GP with an
interest in cardiology blind to the results of the index test. No details were provided regarding who performed the tests
Is the reference standard likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the
index test?
Yes
Could the reference standard, its conduct, or its interpretation have introduced bias? Risk: low
Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard
does not match the review question?
Concerns: low
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Domain 4: flow and timing
Risk of bias
Four patients were excluded as a result of artefacts in the ECG recordings (not clear whether these artefacts were in the
lead-I or 12-lead ECG traces). The reference standard was performed at the same time as the index test
Was there an appropriate interval between the index test and the reference standard? No
Did all patients receive a reference standard? No
Did patients receive the same reference standard? Yes
For comparative accuracy studies, did all patients receive all index tests? NA
Were all patients included in the analysis? No
Could the patient flow have introduced bias? Risk: unclear
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Appendix 6 Forest plots and summary receiver
operating characteristic plots
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FIGURE 13 Forest plots of individual studies included in each meta-analysis of all lead-I ECG devices (trace interpreted by a trained health-care professional). (a) MyDiagnostick
and EP1 data from the Desteghe study; (b) MyDiagnostick and EP2 data from the Desteghe study; and (c) Kardia Mobile and EP2 data from the Desteghe study. FN, false negative;







































FIGURE 14 Summary receiver operating characteristic plot for lead-I ECG device as index test with trace interpreted
by a trained health-care professional and 12-lead ECG interpreted by a trained health-care professional as a
























FIGURE 15 Summary receiver operating characteristic plot for lead-I ECG device as index test with trace interpreted
by a trained health-care professional and 12-lead ECG interpreted by a trained health-care professional as a
reference standard (using MyDiagnostick lead-I ECG device and EP2 data from the study by Desteghe et al.38).
DOI: 10.3310/hta24030 HEALTH TECHNOLOGY ASSESSMENT 2020 VOL. 24 NO. 3
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Duarte et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science

























FIGURE 16 Summary receiver operating characteristic plot for lead-I ECG device as index test with trace interpreted
by a trained health-care professional and 12-lead ECG interpreted by a trained health-care professional as a
reference standard (using Kardia Mobile lead-I ECG device and EP2 data from the study by Desteghe et al.38).
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FIGURE 17 Forest plots of individual studies included in the meta-analysis with trace interpreted by a trained health-care professional (using Kardia Mobile lead-I ECG device,
































































































































































































FIGURE 18 Summary receiver operating characteristic plot for lead-I ECG device as index test with trace interpreted
by a trained health-care professional (using Kardia Mobile lead-I ECG device, EP 1 data from the study by Desteghe
et al.38 and trace interpreted by a GP in the study by Williams et al.39).
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FIGURE 19 Forest plots of individual studies included in each meta-analysis of the Kardia Mobile lead-I ECG device (trace interpreted by a trained health-care professional).































































































































































































FIGURE 20 Summary receiver operating characteristic plot for lead-I ECG device as index test with trace interpreted
by the device algorithm and 12-lead ECG interpreted by a trained health-care professional as a reference standard
























FIGURE 21 Summary receiver operating characteristic plot for lead-I ECG device as index test with trace interpreted
by the device algorithm and 12-lead ECG interpreted by a trained health-care professional as a reference standard
(using Kardia Mobile lead-I ECG device data from the study by Desteghe et al.38).
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FIGURE 22 Forest plot displaying the results of individual studies included in the meta-analysis for the MyDiagnostick lead-I ECG device with trace interpreted by the device
algorithm.
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Appendix 7 Studies reporting on lead-I
electrocardiogram diagnostic test accuracy that were
excluded from the diagnostic test accuracy review
For the purposes of presenting all available diagnostic accuracy data for lead-I ECG devices, this sectionreports on studies that were excluded from the DTA review but that provided sensitivity and specificity
for the lead-I ECG devices investigated in this assessment. The characteristics of the studies that did not
meet all of the eligibility criteria but that presented sensitivity and specificity data of lead-I ECG devices are
presented in Table 38.
Some studies were excluded from the DTA review because, despite reporting sensitivity and specificity,
they did not present data for the true-positive, false-negative, false-positive and true-negative test
results50,51 or because the reference standard in the study was not a 12-lead ECG interpreted by a trained
health-care professional.57,61–63 The reference standard used in these studies is presented in Table 39. None
of the excluded studies was conducted in people with signs or symptoms of AF. One of the studies was
included in the DTA review, but one of its populations was excluded as the reference standard used was
not a 12-lead ECG interpreted by a trained health-care professional.48
Two studies were available only as conference abstracts50,51 and one study was available only as a report
submitted by the manufacturer of the lead-I device.63 Five of the studies50,51,57,61,62 were cross-sectional in
design and two were cohort studies.48,63 Three studies were performed in primary care,48,57,62 two studies in
secondary care,50,63 one study in tertiary care51 and one study was performed in a community setting.61
Only two studies48,61 did not recruit at least a proportion of people with known AF, with known
cardiovascular comorbidities57 or attending a clinic for a cardiovascular related condition.50,51,62,63
The reference standard used in the studies to assess the DTA of lead-I ECG devices was interpretation of
the lead-I ECG trace by a trained health-care professional.48,57,61,62 One study63 used a clinical ECG diagnosis
where additional information was available to the assessors and also a consensus among the assessors of
12-lead ECG (at least 3 of 4 in agreement) that matched the clinical ECG diagnosis.
Information on index test used, reference standard and diagnostic accuracy results for the studies that did
not meet all of the eligibility criteria but that presented sensitivity and specificity data of lead-I ECG devices
is presented in Table 39.
One study,63 although ineligible for inclusion in the DTA review, presented sensitivity and specificity results
for the imPulse lead-I ECG device. The sensitivity reported for imPulse lead-I ECG ranged from 67% to
100% and the specificity from 58% to 100%.63
We did not assess the methodological quality of these studies as they did not meet the eligibility criteria for
inclusion in the diagnostic accuracy review.
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Population; number of patients
in the analysis; recruitment
details
Mean age and SD (years);
sex; risk factors for AF
Reason for exclusion
from the DTA review
Chan, 201657 Cross-sectional; China;
primary care
People with a history of
hypertension and/or diabetes
mellitus or aged ≥ 65 years;
N = 1013; patients recruited from
a general outpatient clinic
68.4 ± 12.2; female,
n = 539 (53.2%)
Hypertension: n = 916
(90.4%)
Diabetes: n = 371 (36.6%)
Coronary artery disease:
n = 164 (16.2%)
Previous stroke: n = 106
(10.5%)




Lowres, 201461 Cross-sectional; Australia;
community
People aged ≥ 65 years entering
the pharmacy without a severe
coexisting medical condition;
N = 1000; availability of screening
in participating pharmacies was
advertised through flyers displayed
within each pharmacy, and
pharmacists and staff also directly
approached potentially eligible
clients
























Population; number of patients
in the analysis; recruitment
details
Mean age and SD (years);
sex; risk factors for AF
Reason for exclusion
from the DTA review
Orchard, 201662 Cross-sectional; Australia;
primary care
Patients with known AF and
patients without a history of AF
attending for flu vaccination;
N = 972
New AF (N = 7): 80 ± 3;
male, 3/7;
Known AF (N = 29):
77.1 ± 1; male, n = 15
(52%)
All AF (N = 36): 78± 1;
male, n = 18 (50%); NR
Ineligible reference
standard
Reeves63 Cohort; UK; secondary care Patients aged ≥ 18 years
recovering in the Cardiac Intensive
Care Unit or a cardiac surgery
ward, following cardiac surgery,
or who had been admitted to
the Coronary Care Unit or a
cardiology ward after a cardiac
related event; N = 53; research
nurses working in one or other of
the clinical settings identified and
approached eligible patients
23–90 years (range); male,
n = 37 (70%); NR
Ineligible reference
standard
Tieleman, 201448 Cohort; the Netherlands;
primary care
People with unknown AF status;
N = 676; people attending GP for
flu vaccination
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Appendix 8 Quality assessment clinical impact
studies
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Battipaglia, 201652 – – + + – ++ +
Chan, 201656 – – + + – ++ +
Chan, 201657 – – + + – ++ +
Kaasenbrood,
201660
– – + + – + +
Lowres, 201461 – + + + – ++ +
Orchard, 201662 – – + + – ++ +
















TABLE 41 The QUADAS-2 assessment of DTA studies
Study (first author
and year)















Reeves (NR)63 Unclear Low Low Low High Low High
NR, not reported.
TABLE 42 The CASP assessment of qualitative studies
Question Possible responses Response
Section A: Are the results valid?
1. Was there a clear statement of the aims of the research? Yes ✗
Cannot tell
No
2. Is a qualitative methodology appropriate? Yes ✗
Cannot tell
No
3. Was the research design appropriate to address the aims of the research? Yes ✗
Cannot tell
No
4. Was the recruitment strategy appropriate to the aims of the research? Yes
Cannot tell ✗
No
5. Was the data collected in a way that addressed the research issue? Yes ✗
Cannot tell
No





Section B: What are the results?
7. Have ethical issues been taken into consideration? Yes ✗
Cannot tell
No
8. Were the data analysis sufficiently rigorous? Yes ✗
Cannot tell
No
9. Is there a clear statement of findings? Yes ✗
Cannot tell
No
Section C: Will the results help locally?
10. How valuable is the research?
The authors discuss the implications of the study for a GP setting. However, the points raised do not necessarily follow from
the results of their study
✗ indicates the response to each question in the table.
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FIGURE 26 Forest plot displaying the diagnostic yield (percentage of new AF diagnoses) in each study
(studies grouped by setting).
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Appendix 10 Search strategy economic
evaluations (MEDLINE)
MEDLINE (via OvidSP)
Date range searched: inception to 24 April 2018.
Date searched: 24 April 2018.
Search Strategy
1. Lead-I ECG.tw.
2. single lead ECG.tw.
3. (lead I or single lead or automated algorithm).tw.
4. Electrocardiography/
5. (electrocardiog* or ECG).tw.
6. 4 or 5
7. 3 and 6
8. lead I electrocardiog*.tw.
9. single lead electrocardiog*.tw.






16. 10 or 11 or 12 or 13 or 14
17. 10 and 15
18. 16 or 17
19. Economics/





25. Cost of illness/
26. Cost sharing/
27. ‘deductibles and coinsurance’/
28. Medical savings accounts/
29. Health care costs/
30. Direct service costs/
31. Drug costs/




36. Value of life/
37. exp economics, hospital/
38. exp economics, medical/
39. Economics, nursing/
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40. Economics, pharmaceutical/
41. exp ‘fees and charges’/
42. exp budgets/
43. (low adj cost).mp.
44. (high adj cost).mp.
45. (health?care adj cost$).mp.
46. (fiscal or funding or financial or finance).tw.
47. (cost adj estimate$).mp.
48. (cost adj variable).mp.
49. (unit adj cost$).mp.
50. (economic$ or pharmacoeconomic$ or price$ or pricing).tw.
51. or/19-50
52. 18 and 51
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Appendix 11 Questions for clinicians
1. For patients who present at a GP practice with signs or symptoms of AF and in whom MPP suggests AF
and who do not have a lead-I ECG before being sent for a 12-lead ECG in either a GP practice or an
acute setting:
¢ In what proportion of patients who then receive a negative 12-lead ECG would you undertake
testing for paroxysmal AF?
Expert Response
1 This largely depends on whether or not they were having symptoms when they had the 12 lead ECG; if
symptomatic and NO AF on the 12 lead ECG then no further AF screening necessary. If asymptomatic during the
12 lead ECG but risk factors for AF (type 2 diabetes mellitus, hypertension, ischaemic heart disease, valvular heart
disease, obesity, alcohol, age, past history of cryptogenic stroke) then degree of suspicion is higher and a period
of prolonged ambulatory monitoring should be considered
2 50%
3 All
4 There is no fixed answer to this question. How far I go will depend on patient demographics (age group etc), my
own clinical suspicion, and the consequences to the patient if AF is missed. In someone with CHADS-VASc 0 and
a wishy-washy history, I will not go any further
5 Depends, if negative for AF but shows few ectopic may not need testing, but otherwise 100%
6 This is a very difficult question as it will depend very much on the individual clinician. If they are aware of the SAFE study,
then they will expect at least 8 in 10 people with an irregular pulse not to have AF and they may stop at this point
My advice when teaching GP colleagues is that they should undertake a CHADSVASc score (even though they are in
sinus rhythm) and if the score is high then this is actually a reasonable determinant as to those where you would expect
to find AF and maybe further investigation would be worth while. This is my practice. The problem is the next recording
which is often something as unhelpful as a 24hr ECG
Please note that this section refers to making decisions based on interpreting the trace produced by a
lead-I ECG and not on the results of the lead-I ECG algorithm.
2. For patients who present at a GP practice with signs or symptoms of AF and in whom MPP suggests AF
and who do have a lead-I ECG before being sent for a 12-lead ECG in either a GP practice or acute setting:
i. Patients with a negative lead-I ECG in a GP practice:
¢ Would you expect all patients with a negative lead-I ECG to be sent for a 12-lead ECG?
Expert Response
1 No, see earlier answer, if they were symptomatic at the time of the lead-I ECG and NO AF detected then further
12-lead testing may not be necessary in the context of low clinical suspicion and or the lead-I ECG has detected
ectopic; unless there were other reasons to do so, such as risk factors for AF or CVD as listed above, or heart
murmur detected on auscultation
2 No
3 Yes, unless alternative diagnosis made
4 Yes
5 Would ask for a 12-lead ECG if not had one recently. No protocol but probably 6 months
6 I would not suggest that those who have symptoms and signs of AF at the time of review and then have a negative
lead-I ECG should be referred for a 12-lead ECG. This is a sinus rhythm trace correlating to symptoms which excludes
AF. Clearly this is dependent on the clarity of the trace. I personally do not rely on the automated interpretation.
In the younger cohort who still have physiological sinus arrhythmia the algorithm could easily suggest AF
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¢ If not, what proportion of patients with a negative lead-I ECG would you expect to be sent for a
12-lead ECG?
Expert Response
1 I would expect the majority of patients to have a 12-lead ECG in this instance
2 70%
3 Not applicable (see response to the previous question)
4 Not applicable (see response to the previous question)
5 Probably 75%
6 Personally none, we have symptom trace correlation and no further ECG is warranted if the lead-I trace is of
sufficient quality
¢ In what proportion of patients with a negative lead-I ECG who are not sent for a 12-lead ECG
would you undertake testing for paroxysmal AF using a Holter ECG monitor or event recorder?
Expert Response
1 Every patient being referred for ambulatory ECG monitoring should have a 12-lead ECG as part of their
diagnostic assessment. In this instance if you suspect an underlying arrhythmia a lead-I ECG does not provide
enough information to look for other important causes of structural heart disease. i.e. a 12-lead ECG should be a
prerequisite for ambulatory Holter recording
2 10–20%
3 All, unless alternative diagnosis made (e.g. you might diagnose ectopic beats on lead I-ECG)
4 Hypothetical question. I expect everyone to be sent for a 12-lead ECG
5 Our protocol is if sent for testing for paroxysmal AF, all need a 12-lead ECG
6 See above. If symptomatic at the time of the trace and this shows sinus rhythm, then we have the wrong
diagnosis
ii. Patients with a positive lead-I ECG in a GP practice followed by a negative 12-lead ECG (done at a
later time point, i.e. between 48 hours and 14 days after the positive lead-I ECG):
¢ In what proportion of these patients would you diagnose AF with no further tests?
Expert Response
1 A diagnosis of AF can be made securely on a lead-I ECG, but further testing is still usually required with a 12
lead ECG, blood testing and usually an echocardiogram. The majority will require further testing
2 80–90% (assuming some will be false positives – if however, we take a positive ECG to be completely accurate
then 100% would be diagnosed)
3 Majority
4 If I have seen the tracing myself, and concur with the interpretation, then 100%
5 If lead-I ECG positive, then negative 12-lead ECG is not relevant. Diagnosis is paroxysmal AF
6 If I have an ECG trace showing AF (reviewed not algorithm driven) then this would be sufficient
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¢ In what proportion of these patients would you undertake testing for paroxysmal AF?
Expert Response
1 This depends on the quality and confidence of the clinical decision maker with their lead-I ECG device recording
2 By testing do you mean further ECG evidence or is there an assumption that the diagnosis of AF is confirmed,
and ‘testing’ means extra tests linked to AF such as an echocardiogram?
3 Depends on ongoing symptom burden and/or concerns regarding co-existing bradycardia
4 Depends on the need for symptom correlation
5 100% would get an ambulatory ECG
6 I have the diagnosis and do not need to work further. They now need working up as AF as per local protocol
iii. Patients with a negative lead-I ECG in a GP practice followed by negative 12-lead ECG (done at a
later time point, i.e. between 48 hours and 14 days after the positive lead-I ECG):
¢ In what proportion of these patients would you rule out a diagnosis of AF?
Expert Response
1 See earlier, this depends if they were symptomatic at the time of the recordings
2 70–80%
3 100% if symptoms/signs present at time of lead I-ECG
4 0%
5 Probably 90–95% rule out
6 I would accept the patient does not have AF at this time, they may have an atrialopathy but that is a slightly
different topic
¢ In what proportion of these patients would you undertake testing for paroxysmal AF?
Expert Response
1 In those with a high degree of suspicion of AF and risk factors as outlined earlier
2 20–30%
3 Only if subsequent clinical suspicion
4 See answer to question 1
5 Difficult to answer because either ECG may have given an alternative diagnosis. Possibly 10% have frequent
atrial ectopics and therefore I go on to investigate for paroxysmal AF, a further 5% to 10% I feel it was
paroxysmal AF but resolves before I can get lead-I ECG trace
6 Only if symptomatic
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3. For patients who present at a GP practice with signs or symptoms of AF and in whom MPP suggests AF,
who do have AF but who have had their AF ruled out after testing (with lead-I ECG and/or 12 lead ECG
and/or Holter and event monitoring):
¢ What proportion of patients would you expect to have their AF diagnosed, before having a CVE,
within 12 months of initially presenting at a GP practice?
Expert Response
1 Unknown: 20–30% of patients presenting with first stroke will either be known AF and not anticoagulated or
will be first presentation of AF (Southport district general hospital stroke admission data 2012–13)
2 20%
3 Difficult to answer but < 50%
4 I do not understand how anyone can rule out AF just because the tests are negative. Absence of proof is not the
same as proof of absence
5 Really difficult to tell because even with current array of testing we may still be missing paroxysmal AF. Only
better way is review of trials of patients with pacemakers or Implantable loop recorders
6 This is very difficult, you are suggesting the false negatives and I am unaware in a general population if this has
been examined. If you look in a high risk population (post embolic stroke of undetermined source) then we can
reference STOPSTROKE,77 EMBRACE109 and CRYSTAL.110 But this is a very high risk population
¢ What proportion of patients would you expect to have their AF diagnosed – before having a CVE –
within 5 years of initially presenting at a GP practice?
Expert Response




5 See response to the previous question
6 Would be interested to see if anyone has this data
4. Testing for paroxysmal AF:
¢ In the diagnosis of paroxysmal AF, would all patients use both a Holter ECG monitor and an event
recorder? If not, what proportion of patients would use (1) Holter ECG monitor or (2) event recorder
and what proportion would use both?
Expert Response
1 This will depend on frequency of symptoms: with daily or near daily symptoms a 24-hour Holter has a greater
chance of arrhythmia capture. In patients with less frequent symptoms an event recorder or prolonged period of
ambulatory monitoring will have a higher chance of arrhythmia capture
2 50/50 split: depending on access to which is available, only 20% we go on to use both
3 Either/or but not both
4 Depends on symptoms. I cannot put a number on this
5 For paroxysmal AF we always use an event recorder for 7 days (R test) unless patient getting symptoms
consistent with frequent AF more than once daily
6 Is this high risk or low risk cohorts? I feel it would be very different in different cohorts
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2 Depends on duration/frequency of symptoms. Holters are generally 24–48 hrs. Event recorders 5 days to 3 weeks
(e.g. hand-held cardio-memo recorder)
3 7–14 days
4 Depends on symptoms. There is no fixed answer
5 Usually 7 days. Can be up to 30 days with battery change on day 15 but rarely tolerated. We do also loan
AliveCor ECGs if patients happy to use them. Loan is up to 2 months
6 If post stroke the evidence would suggest 2–4 weeks (EMBRACE) but in CRYSTAL 30% were found to develop
AF at 3 years
¢ What is the diagnostic and treatment pathway for patients who have paroxysmal AF ruled out by
the results of a Holter ECG monitor and/or event recording?
Expert Response
1 To seek medical advice as soon as possible when symptomatic if no diagnosis yet made
2 If there is no diagnosis of AF after a search, then no further routine testing would take place unless the patient
re-presents or there is a change in their symptoms to warrant further investigation
3 Nil else unless ongoing clinical concern
4 I do not think you can rule out paroxysmal AF just because your Holter or event recorder is negative
5 Usually discharge back to GP. We are now loaning lead-I ECG devices to patients for up to 2 months. Very high
risk e.g. TIA/stroke with high probability owing to AF may be considered for implantable loop recorders
6 Never seen one
5. Diagnostic pathway for patients with signs or symptoms of AF and an irregular pulse who do not have AF:
¢ Do you think the introduction of lead-I ECGs into the diagnostic pathway for patients, with signs or
symptoms of AF and in whom MPP suggests AF but who do not have AF, will affect the diagnosis
and treatment of the other conditions causing symptoms in these patients? If yes, how?
Expert Response
1 Possibly, if the process stops after the Lead-I ECG recording. The clinical context and AF, CVD risk status must be
taken into consideration, as other cardiac conditions might be missed
2 Yes, an irregular pulse may feel like AF but be simple ectopic heart beats. This can mean that these patients are
not sent for further routine testing and could be treated with lifestyle advice (reduced caffeine/alcohol) or offered
drugs such as beta blockers
3 Alternative diagnoses might be made e.g. ectopic beats which will allow inform treatment/management decisions
4 Yes. It may correlate symptoms to another non-AF arrhythmia, which will require treatment in its own right
5 Yes. Lead-I ECG devices will pick up ectopics and pauses
6 This is probably ectopy (atrial or ventricular) as these are the commonest non-sustained dysrhythmias. Questions
around how much ectopy would make the diagnosis and what is the significance is hotly debated but unknown
This would be investigated as a palpitation and would have a varied pathway depending on local opinion and
protocol
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Appendix 12 Results (base cases 2–4)
Base case 2: 12-lead electrocardiogram in primary care, 14 days to 12-lead
electrocardiogram
Costs and QALYs generated in base case 2 are shown in Tables 43 and 44, respectively.
Pairwise cost-effectiveness results from the base case 2 analysis for each index test compared with the
standard diagnostic pathway are presented in Table 45 and the incremental analysis results are shown in
Table 46.





















Standard pathway 0 90,431 420,710 535 2741 514,416
Kardia Mobile 26 102,842 409,851 451 2239 515,408
imPulse 97 116,189 411,588 453 2263 530,590
MyDiagnostick 100 106,951 411,334 451 2245 521,080
Generic lead-I device 392 103,636 409,868 451 2240 516,587
Zenicor-ECG 624 104,824 410,181 451 2242 518,323
RhythmPad GPa 1110 100,198 414,279 445 2229 518,261
a Algorithm interpretation.
TABLE 44 Base case 2: QALYs and patient outcomes




positives Bleeds Total QALYs
Standard pathway 11.620 2.123 8.407 1.606 0.000 23.572 447.895
Kardia Mobile 11.451 1.996 8.358 0.144 1.378 23.743 449.220
imPulse 11.482 2.018 8.365 0.396 3.660 23.721 448.956
MyDiagnostick 11.477 2.015 8.364 0.360 2.153 23.711 448.994
Generic lead-I device 11.451 1.996 8.358 0.147 1.507 23.744 449.217
Zenicor-ECG 11.457 2.000 8.360 0.192 1.722 23.738 449.170
RhythmPad GPa 11.529 2.054 8.376 0.793 1.292 23.620 448.540
a Algorithm interpretation.
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Base case 3: 12-lead electrocardiogram in secondary care, 2 days to
12-lead electrocardiogram
Costs and QALYs generated in base case 3 are shown in Tables 47 and 48, respectively.
Pairwise cost-effectiveness results from the base case 3 analysis for each index test versus the standard
diagnostic pathway are presented in Table 49 and the incremental analyses are shown in Table 50.
Base case 4: 12-lead electrocardiogram in secondary care, 14 days to
12-lead electrocardiogram
Costs and QALYs generated in base case 4 are shown in Tables 51 and 52, respectively.
Pairwise cost-effectiveness results from the base case 4 analysis for each index test compared with the
standard diagnostic pathway are presented in Table 53 and the incremental analyses are shown in Table 54.
TABLE 45 Base case 2: pairwise cost-effectiveness analysis







Standard pathway 514,416 447.895
Kardia Mobile 515,408 449.220 1221 1.257 971
imPulse 530,590 448.956 16,403 0.994 16,506
MyDiagnostick 521,080 448.994 6892 1.031 6684
Generic lead-I device 516,587 449.217 2400 1.255 1912
Zenicor-ECG 518,323 449.170 4135 1.207 3426
RhythmPad GPa 518,261 448.540 4073 0.577 7055
a Algorithm interpretation.
TABLE 46 Base case 2: incremental cost-effectiveness analysis







Standard pathway 514,416 447.895
Kardia Mobile 515,408 449.220 992 1.324 £749
Generic lead-I device 516,587 449.217 1179 –0.002 Dominated
RhythmPad GPa 518,261 448.540 2853 –0.680 Dominated
Zenicor-ECG 518,323 449.170 2915 –0.050 Dominated
MyDiagnostick 521,080 448.994 5672 –0.226 Dominated
imPulse 530,590 448.956 15,182 –0.264 Dominated
a Algorithm interpretation.
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Standard pathway 0 90,630 420,279 2801 2743 516,453
Kardia Mobile 26 102,952 409,881 2361 2240 517,460
imPulse 97 116,317 411,612 2373 2265 532,663
MyDiagnostick 100 107,077 411,358 2359 2247 523,140
Generic lead-I device 392 103,746 409,898 2362 2242 518,640
Zenicor-ECG 624 104,938 410,210 2362 2244 520,378
RhythmPad GPa 1110 100,358 414,292 2330 2231 520,320
a Algorithm interpretation.
TABLE 48 Base case 3: QALYs and patient outcomes




positives Bleeds Total QALYs
Standard pathway 11.621 2.124 8.406 1.606 0.000 23.581 447.963
Kardia Mobile 11.452 1.996 8.359 0.144 1.379 23.751 449.249
imPulse 11.482 2.019 8.366 0.397 3.663 23.730 448.987
MyDiagnostick 11.478 2.015 8.365 0.361 2.155 23.720 449.024
Generic lead-I device 11.452 1.996 8.359 0.147 1.508 23.752 449.246
Zenicor-ECG 11.457 2.000 8.360 0.193 1.724 23.746 449.199
RhythmPad GPa 11.530 2.054 8.377 0.794 1.293 23.630 448.573
a Algorithm interpretation.
TABLE 49 Base case 3: pairwise cost-effectiveness analysis







Standard pathway 516,453 447.963
Kardia Mobile 517,460 449.249 3273 1.286 2544
imPulse 532,663 448.987 18,476 1.024 18,038
MyDiagnostick 523,140 449.024 8953 1.061 8435
Generic lead-I device 518,640 449.246 4453 1.284 3468
Zenicor-ECG 520,378 449.199 6191 1.236 5007
RhythmPad GPa 520,320 448.573 6133 0.610 10,048
a Algorithm interpretation.
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TABLE 50 Base case 3: incremental cost-effectiveness analysis
Strategy Costs (£) QALYs Incremental costs (£) Incremental QALYs ICER/QALY gained
Standard pathway 516,453 447.963
Kardia Mobile 517,460 449.249 1007 1.286 £783
imPulse 518,640 449.246 1180 –0.002 Dominated
MyDiagnostick 520,320 448.573 2860 –0.676 Dominated
Generic lead-I device 520,378 449.199 2918 –0.050 Dominated
Zenicor-ECG 523,140 449.024 5680 –0.225 Dominated
RhythmPad GPa 532,663 448.987 15,203 –0.262 Dominated
a Algorithm interpretation.




















Standard pathway 0 90,431 420,710 2797 2741 516,678
Kardia Mobile 26 102,842 409,851 2358 2239 517,315
imPulse 97 116,189 411,588 2370 2263 532,507
MyDiagnostick 100 106,951 411,334 2356 2245 522,985
Generic lead-I device 392 103,636 409,868 2359 2240 518,495
Zenicor-ECG 624 104,824 410,181 2359 2242 520,231
RhythmPad GPa 1110 100,198 414,279 2327 2229 520,142
a Algorithm interpretation.
TABLE 52 Base case 4: QALYs and patient outcomes




positives Bleeds Total QALYs
Standard pathway 11.620 2.123 8.407 1.606 0.000 23.572 447.895
Kardia Mobile 11.451 1.996 8.358 0.144 1.378 23.743 449.220
imPulse 11.482 2.018 8.365 0.396 3.660 23.721 448.956
MyDiagnostick 11.477 2.015 8.364 0.360 2.153 23.711 448.994
Generic lead-I device 11.451 1.996 8.358 0.147 1.507 23.744 449.217
Zenicor-ECG 11.457 2.000 8.360 0.192 1.722 23.738 449.170
RhythmPad GPa 11.529 2.054 8.376 0.793 1.292 23.620 448.540
a Algorithm interpretation.
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TABLE 53 Base case 4: pairwise cost-effectiveness analysis







Standard pathway 516,678 447.895
Kardia Mobile 517,315 449.220 3127 1.257 2487
imPulse 532,507 448.956 18,319 0.994 18,435
MyDiagnostick 522,985 448.994 8797 1.031 8532
Generic lead-I device 518,495 449.217 4307 1.255 3433
Zenicor-ECG 520,231 449.170 6043 1.207 5006
RhythmPad GPa 520,142 448.540 5955 0.577 10,314
a Algorithm interpretation.
TABLE 54 Base case 4: incremental cost-effectiveness analysis







Standard pathway 516,678 447.895
Kardia Mobile 517,315 449.220 637 1.324 £481
Generic lead-I device 518,495 449.217 1180 –0.002 Dominated
RhythmPad GPa 520,142 448.540 2828 –0.680 Dominated
Zenicor-ECG 520,231 449.170 2916 –0.050 Dominated
MyDiagnostick 522,985 448.994 5670 –0.226 Dominated
imPulse 532,507 448.956 15,192 –0.264 Dominated
a Algorithm interpretation.
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Appendix 13 Scenario analyses
Scenario A: unit cost associated with the lead-I electrocardiogram device
Incremental cost-effectiveness results from scenario A, which investigates the impact of removing the unit
cost of the lead-I ECG device from the analysis (using 12-lead ECG in primary care, 2 days to 12-lead
ECG), are presented in Table 55.
Scenario B: alternative sensitivity and specificity estimates for
MyDiagnostick
Pairwise cost-effectiveness results from scenario B, which investigates the impact of using the sensitivity
and specificity estimates based on the interpretation of the MyDiagnostick lead-I ECG trace by EP2 (using
12-lead ECG in primary care, 2 days to 12-lead ECG), are presented in Table 56.
TABLE 55 Scenario A: impact of removing the unit cost of the lead-I ECG device from the analysis, incremental
cost-effectiveness analysis







Standard pathway 514,187 447.963
Kardia Mobile 515,535 449.249 1347 1.286 £1047
Generic lead-I device 516,348 449.246 813 –0.002 Dominated
RhythmPad GPa 517,336 448.573 1802 –0.676 Dominated
Zenicor-ECG 517,854 449.199 2319 –0.050 Dominated
MyDiagnostick 521,143 449.024 5608 –0.225 Dominated
imPulse 530,657 448.987 15,123 –0.262 Dominated
a Algorithm interpretation.
TABLE 56 Scenario B: impact of using the sensitivity and specificity estimates based on interpretation of the
MyDiagnostick lead-I ECG trace by EP2, incremental cost-effectiveness analysis








Standard pathway 514,187 447.963 565 –0.9359 Dominated
Kardia Mobile 515,551 449.249 1928 0.3504 £5503
Generic lead-I device 516,730 449.246 1179 –0.0025 Dominated
RhythmPad GPa 518,436 448.573 2885 –0.6759 Dominated
Zenicor-ECG 518,468 449.199 2917 –0.0499 Dominated
imPulse 530,745 448.987 15,194 –0.2620 Dominated
a Algorithm interpretation.
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Scenario C: diagnosis without 12-lead electrocardiogram/Holter monitor
Incremental cost-effectiveness results from scenario C, which investigates the impact of removing the
12-lead ECG and Holter monitoring from the lead-I ECG diagnostic pathway (compared to using 12-lead
ECG in primary care, 2 days to 12-lead ECG), are presented in Table 57.
Scenario D: 5-year time horizon
Incremental cost-effectiveness results from scenario D investigating a 5-year time horizon as a proxy for all
undiagnosed patients being identified within 5 years (12-lead ECG in primary care, 2 days to 12-lead ECG)
are presented in Table 58.
Scenario E1 to E40: varying proportion of patients sent for Holter testing
after lead-I electrocardiogram and 12-lead electrocardiogram results
Incremental cost-effectiveness results from scenarios E1 to E40 exploring the uncertainty in the proportion
of people sent for paroxysmal testing following a negative 12-lead ECG result are presented in Table 59.
Given the complexity of the results, each scenario is shown for only the standard diagnostic pathway
compared with Kardia Mobile (the lead-I ECG test was found to be the most cost-effective option in the
base-case analyses) with 12-lead ECG undertaken in primary care and a 2-day wait for a 12-lead ECG.
TABLE 57 Scenario C: impact of removing 12-lead ECG and Holter monitoring from the lead-I ECG diagnostic
pathway, incremental analysis







Standard pathway 514,187 447.963
Kardia Mobile 515,356 448.896 1169 0.9335 £1252
Generic lead-I device 516,575 448.888 1218 –0.0085 Dominated
Zenicor-ECG 519,081 448.726 3725 –0.1697 Dominated
MyDiagnostick 524,667 448.131 9311 –0.7647 Dominated
RhythmPad GPa 529,083 446.597 13,727 –2.2991 Dominated
imPulse 534,767 448.004 19,411 –0.8924 Dominated
a Algorithm interpretation.
TABLE 58 Scenario D: impact of 5-year time horizon, incremental analysis







Standard pathway 101,668 173.979
Kardia Mobile 102,543 174.550 876 0.5706 £1534
Generic lead-I device 103,234 174.549 691 –0.0011 Dominated
Zenicor-ECG 104,051 174.527 1508 –0.0224 Dominated
RhythmPad GPa 104,073 174.247 1530 –0.3028 Dominated
MyDiagnostick 104,774 174.449 2231 –0.1008 Dominated
imPulse 108,573 174.432 6030 –0.1175 Dominated
a Algorithm interpretation.
APPENDIX 13
NIHR Journals Library www.journalslibrary.nihr.ac.uk
142
TABLE 59 Scenario E: varying the percentage of patients sent for Holter monitor testing for paroxysmal AF following a negative 12-lead ECG subsequent to the lead-I ECG
result, incremental analysis
Scenario
Proportion of patients being referred for Holter monitoring after
negative 12-lead ECG (%) Model results
Lead-I pathway
Standard pathway
Standard pathway Lead-I pathway Incremental
ICER per QALY
gainedLead-I ECG negative Lead-I ECG positive Costs (£) QALYs Costs (£) QALYs Costs (£) QALYs
E1 0 0 0 515,456 447.256 513,532 449.215 –1924 1.959 Dominates
E2 0 100 0 515,456 447.256 513,973 449.216 –1482 1.959 Dominates
E3 0 75 0 515,456 447.256 513,863 449.215 –1593 1.959 Dominates
E4 0 50 0 515,456 447.256 513,753 449.215 –1703 1.959 Dominates
E5 0 25 0 515,456 447.256 513,642 449.215 –1813 1.959 Dominates
E6 25 100 0 515,456 447.256 514,873 449.232 –583 1.976 Dominates
E7 25 75 0 515,456 447.256 514,762 449.232 –693 1.976 Dominates
E8 25 50 0 515,456 447.256 514,652 449.232 –804 1.976 Dominates
E9 25 25 0 515,456 447.256 514,541 449.232 –914 1.976 Dominates
E10 50 100 0 515,456 447.256 515,772 449.249 316 1.993 £159
E11 50 75 0 515,456 447.256 515,661 449.249 206 1.993 £103
E12 50 50 0 515,456 447.256 515,551 449.249 96 1.992 £48
E13 75 100 0 515,456 447.256 516,671 449.266 1215 2.010 £605
E14 75 75 0 515,456 447.256 516,561 449.266 1105 2.009 £550
E15 100 100 0 515,456 447.256 517,570 449.283 2114 2.026 £1043
E16 0 100 25 514,824 447.610 513,973 449.216 –851 1.606 Dominates
E17 0 75 25 514,824 447.610 513,863 449.215 –961 1.606 Dominates
E18 0 50 25 514,824 447.610 513,753 449.215 –1071 1.606 Dominates
E19 0 25 25 514,824 447.610 513,642 449.215 –1182 1.606 Dominates









































































































































































TABLE 59 Scenario E: varying the percentage of patients sent for Holter monitor testing for paroxysmal AF following a negative 12-lead ECG subsequent to the lead-I ECG
result, incremental analysis (continued )
Scenario
Proportion of patients being referred for Holter monitoring after
negative 12-lead ECG (%) Model results
Lead-I pathway
Standard pathway
Standard pathway Lead-I pathway Incremental
ICER per QALY
gainedLead-I ECG negative Lead-I ECG positive Costs (£) QALYs Costs (£) QALYs Costs (£) QALYs
E21 0 75 50 514,187 447.963 513,863 449.215 –324 1.253 Dominates
E22 0 50 50 514,187 447.963 513,753 449.215 –435 1.253 Dominates
E23 0 100 75 513,545 448.315 513,973 449.216 428 0.901 £476
E24 0 75 75 513,545 448.315 513,863 449.215 318 0.900 £353
E25 0 100 100 512,895 448.667 513,973 449.216 1078 0.549 £1966
E26 25 25 25 514,824 447.610 514,541 449.232 –282 1.622 Dominates
E27 50 50 50 514,187 447.963 515,551 449.249 1364 1.286 £1060
E28 50 50 25 514,824 447.610 515,551 449.249 727 1.639 £444
E29 75 75 25 514,824 447.610 516,561 449.266 1737 1.656 £1049
E30 75 75 50 514,187 447.963 516,561 449.266 2373 1.303 £1821
E31 75 75 75 513,545 448.315 516,561 449.266 3016 0.951 £3172
E32 100 100 25 514,824 447.610 517,570 449.283 2746 1.673 £1641
E33 100 100 50 514,187 447.963 517,570 449.283 3383 1.320 £2562
E34 100 100 75 513,545 448.315 517,570 449.283 4025 0.968 £4159
E35 25 50 50 514,187 447.963 514,652 449.232 464 1.270 £366
E36 50 50 75 513,545 448.315 515,551 449.249 2006 0.934 £2148
E37 25 75 75 513,545 448.315 514,762 449.232 1217 0.917 £1327
E38 25 75 75 513,545 448.315 514,762 449.232 1217 0.917 £1327
E39 50 75 75 513,545 448.315 515,661 449.249 2116 0.934 £2266
















Scenario F: cost of a smartphone or tablet added to the cost of the
Kardia Mobile device
In order to perform a lead-I ECG with the Kardia Mobile device, it is necessary to connect the device to
a smartphone or tablet. The EAG assumed in the base case that a GP would already have access to a
smartphone or tablet that could be used alongside the Kardia Mobile device and would incur no extra
cost. The cost of a supplementary smartphone or tablet for use alongside the Kardia Mobile device was
investigated in a scenario analysis.
The cost of purchasing a smartphone or tablet varies substantially depending on the type of device,
meaning that any estimate of the cost of such a device may not reflect reality for some or any GP
practices. The EAG considered it would be justified to perform a threshold analysis to estimate the level at
which the extra cost of a supplementary smartphone or tablet would result in Kardia Mobile no longer
dominating the other lead-I ECG devices or generating an ICER of £20,000 per QALY gained compared
with the standard pathway. The estimated minimum cost of a supplementary smartphone or tablet for
Kardia Mobile to no longer dominate ranged from £2885 compared with RhythmPad to £15,194
compared with the imPulse device. Provided a supplementary smartphone or tablet costs < £24,362, then
the ICER per QALY gained for Kardia Mobile compared with the standard pathway would be < £20,000.
The results of the threshold analysis from scenario F, which calculated the minimum cost of a
supplementary smartphone or tablet device that would result in Kardia Mobile no longer being dominant
over each of the alternative strategies (using 12-lead ECG in primary care, 2 days to 12-lead ECG) are
presented in Table 60.
Scenario G: extending the lifespan of the RhythmPad GP device from
1 year to 3 years
The manufacturer of the RhythmPad GP device advised that the minimum projected life of the device was
1 year, with the potential for it to last up to 3 years. Changing the lifespan of the RhythmPad GP device
from 1 year to 3 years reduces total costs; however, the RhythmPad GP device remains dominated by the
Kardia Mobile device.
Incremental cost-effectiveness results from scenario G, which investigates the impact of extending the
lifespan of the Rhythmpad GP device from 1 year to 3 years (using 12-lead ECG in primary care, 2 days to
12-lead ECG) are presented in Table 61.
TABLE 60 Scenario F: minimum cost per supplementary smartphone or tablet device for a non-dominant ICER per
QALY gained compared with Kardia Mobile (the cost to make the ICER £20,000 per QALY for Kardia Mobile
compared with the standard pathway)
Strategy Minimum cost per supplementary device (£)
Kardia Mobile ICER per QALY gained = £20,000
Standard pathway 24,362
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Scenario H: including a quality-adjusted life-year decrement for bleeds
In the base-case analysis, no disutility value for bleeds was assumed because robust estimates on utility
of bleeds could not be identified in the literature. As these are rare events of short duration, the impact
on QALYs was expected to be minor. To test the impact of the assumption of no QALY loss for bleeds,
a value for utility loss and duration of bleed was taken from the apixaban technology appraisal. Here
the company used a disutility value for major bleeds of 0.1070 from a standard gamble exercise of
patients with AF, valuing different health outcomes and AEs that could hypothetically occur while taking
anticoagulation treatment. The company in the apixaban appraisal assumed that major bleeds would last
for 14 days; this was a company assumption and no justification was provided. Applying the duration of
the bleed to the utility loss and assuming all bleeds are major, means each bleed results in a 0.004 QALY loss.
The impact of introducing a disutility value for bleeds in the model (using 12-lead ECG in primary care,
2 days to 12-lead ECG) are presented in Table 62. As can be seen, although the standard pathway and
lead-I devices all lose QALYs as expected, because the total lifetime number of bleeds for the cohort of
patients in the model was only 0.017 higher with Kardia Mobile compared with the standard pathway
and the QALY loss from bleeds was so small, the impact on incremental QALYs was almost zero; therefore,
the introduction of a disutility value for bleeds did not affect the ICER per QALY gained.
TABLE 61 Scenario G: impact of extending the lifespan of the Rhythmpad GP device from 1 year to 3 years,
incremental cost-effectiveness analysis







Standard pathway 514,187 447.963
Kardia Mobile 515,551 449.249 1364 1.2863 £1060
RhythmPad GPa 517,703 448.573 2152 –0.6759 Dominated
Zenicor-ECG 518,468 449.199 2917 –0.0499 Dominated
MyDiagnostick 521,233 449.024 5682 –0.2249 Dominated
imPulse 530,745 448.987 15,194 –0.262 Dominated
a Algorithm interpretation.
TABLE 62 Scenario H: impact of assuming a QALY loss from bleeds, incremental cost-effectiveness analysis







Standard pathway 514,187 447.901
Kardia Mobile 515,551 449.187 1364 1.286 £1060
RhythmPad GPa 518,436 448.511 2885 –0.676 Dominated
Zenicor-ECG 518,468 449.137 2917 –0.050 Dominated
MyDiagnostick 521,233 448.962 5682 –0.225 Dominated
imPulse 530,745 448.925 15,194 –0.262 Dominated
a Algorithm interpretation.
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Scenario I: using alternative sensitivity and specificity estimates for
Kardia Mobile from the pooled analysis with interpretation of the trace
by EP2
Incremental deterministic cost-effectiveness results from scenario I, which investigates the impact of using
the sensitivity and specificity estimates based on interpretation of the Kardia Mobile lead-I ECG trace by
EP2 (using 12-lead ECG in primary care, 2 days to 12-lead ECG) are presented in Table 63. Incremental
probabilistic cost-effectiveness results from scenario I are presented in Table 64. The CEAC for scenario I is
presented in Figure 27.
TABLE 63 Scenario I: impact of using the sensitivity and specificity estimates based on interpretation of the Kardia
Mobile lead-I ECG trace by EP2, incremental deterministic cost-effectiveness analysis







Kardia Mobile 514,177 449.181
Standard pathway 514,187 447.963 10 –1.219 Dominated
RhythmPad GPa 518,436 448.573 4259 –0.608 Dominated
Zenicor-ECG 518,468 449.199 4290 0.018 £242,994
MyDiagnostick 521,233 449.024 2765 –0.175 Dominated
imPulse 530,745 448.987 12,277 –0.212 Dominated
a Algorithm interpretation.
TABLE 64 Scenario I: impact of using the sensitivity and specificity estimates based on interpretation of the Kardia
Mobile lead-I ECG trace by EP2, incremental probabilistic cost-effectiveness analysis







Kardia Mobile 521,903 455.16065
Standard pathway 522,204 453.96612 301 –1.1945 Dominated
RhythmPad GPa 526,453 454.56963 1798 –0.5910 Dominated
Zenicor 526,518 455.17774 1864 0.0171 £109,012
MyDiagnostick 529,316 455.00675 4661 –0.1710 Dominated
imPulse 538,857 454.97117 14,203 –0.2066 Dominated
a Algorithm interpretation.
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Scenario J: assuming that the rates of haemorrhagic stroke for people
treated with NOACs who do not have atrial fibrillation are the same as
the rates of haemorrhagic stroke for people treated with NOACs who
have atrial fibrillation
Incremental cost-effectiveness results from scenario J, which investigates the impact of assuming that the
rates of HS for people treated with NOACs who do not have AF are the same as the rates of HS for people
treated with NOACs who have AF (using 12-lead ECG in primary care, 2 days to 12-lead ECG) are






































FIGURE 27 The CEAC for scenario I: all lead-I devices
TABLE 65 Scenario J: impact of assuming that rates of HS are the same for people treated with NOACs who do not
have AF as the rates of HS for people treated with NOACs who have AF, incremental cost-effectiveness analysis







Standard pathway 514,187 447.963
Kardia Mobile 516,109 448.697 1922 0.734 £2618
RhythmPad GPa 518,957 448.055 2848 –0.642 Dominated
Zenicor-ECG 519,177 448.511 3068 –0.186 Dominated
MyDiagnostick 522,133 448.166 6023 –0.530 Dominated
imPulse 532,320 447.537 16,211 –1.159 Dominated
a Algorithm interpretation.
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Appendix 14 Deterministic sensitivity analysis:
tornado diagrams
– £300,000 – £200,000 – £100,000 £100,000£0
AF prevalence by type: paroxysmal
% lead-I negative patients who have 12-lead
% lead-I positive patients who have 12-lead
% AF diagnosed after negative lead-I (no 12-lead)
% AF diagnosed after negative lead-I and
negative 12-lead and negative paroxysmal test
% standard pathway patients who have 12-lead
% AF ruled out after positive lead-I        negative 12-lead
Specificity
Sensitivity
% AF ruled out after MPP only (standard pathway)      
negative 12-lead
FIGURE 28 Tornado diagram: base case 1, imPulse.
– £50,000 0 £50,000 £250,000£150,000 £200,000£100,000
AF prevalence by type: paroxysmal
Specificity
% AF ruled out after negative lead-I       negative 12-lead
% lead-I positive patients who have 12-lead
Costs: 5-year cost IS
Event rate: IS AF NOAC (Sterne HR under 80)
% AF diagnosed after positive lead-I and
negative 12-lead and negative paroxysmal test
% symptomatic with AF: male
% AF ruled out after MPP only (standard pathway)      
negative 12-lead
Event rate: IS AF untreated (Sterne HR)
FIGURE 29 Tornado diagram: base case 1, Kardia Mobile.
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– £160,000 – £120,000 – £80,000 – £40,000 £40,000£0
AF prevalence by type: paroxysmal
% AF ruled out after MPP only (standard pathway)      
negative 12-lead
% lead-I positive patients who have 12-lead
% AF diagnosed after negative lead-I and
negative 12-lead and negative paroxysmal test
% AF diagnosed after negative lead-I (no 12-lead)
Specificity
% standard pathway patients who have 12-lead
% AF ruled out after positive lead-I       negative 12-lead
Sensitivity
% lead-I negative patients who have 12-lead
FIGURE 30 Tornado diagram: base case 1, MyDiagnostick.
– £100,000 – £50,000 £50,000£0
% lead-I negative patients who have 12-lead
% AF patients with CHA2DS2-VASc ≥ 2 on OACs
% AF patients with CHA2DS2-VASc ≥ 2
Sensitivity
% AF ruled out after MPP only (standard pathway)      
negative 12-lead
% lead-I positive patients who have 12-lead
% AF ruled out after negative lead-I (no 12-lead)
% AF diagnosed after negative lead-I and
negative 12-lead and negative paroxysmal test
AF prevalence by type: paroxysmal
Specificity
FIGURE 31 Tornado diagram: base case 1, RhythmPad GP.
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– £1,000,000 £0 £2,000,000£1,000,000
AF prevalence by type: paroxysmal
% AF ruled out after MPP only (standard pathway)      
negative 12-lead
% symptomatic with AF: male
Event rate: IS AF untreated (Sterne HR)
% AF diagnosed after positive lead-I and
negative 12-lead and negative paroxysmal test
Specificity
% AF diagnosed after negative lead-I and
negative 12-lead and negative paroxysmal test
Sensitivity
Event rate: IS AF NOAC (Sterne HR under 80)
% lead-I positive patients who have 12-lead
FIGURE 32 Tornado diagram: base case 1, Zenicor ECG.
– £100,000 £0 £100,000 £300,000£200,000
AF prevalence by type: paroxysmal
Specificity
% lead-I positive patients who have 12-lead
% AF ruled out after negative lead-I       negative 12-lead
% symptomatic with AF: male
% AF ruled out after MPP only (standard pathway)      
negative 12-lead
% AF diagnosed after positive lead-I and
negative 12-lead and negative paroxysmal test
Costs: 5-year cost IS
Event rate: IS AF NOAC (Sterne HR under 80)
Event rate: IS AF untreated (Sterne HR)
FIGURE 33 Tornado diagram: base case 1, Generic lead-I device.
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FIGURE 35 The CEAC for base case 1: Kardia Mobile.
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FIGURE 38 The CEAC for base case 1: Zenicor ECG.
APPENDIX 15
































0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 40 42 44 46 48 50
Standard pathway
Generic lead-I device
FIGURE 39 The CEAC for base case 1: generic lead-I ECG device.
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value LB UB SD Alpha Beta Distribution
Event rate: bleeds
HR compared with Warfarin: AF treated with NOACs > 80 years (Sterne 201785) 0.630 0.473 0.788 0.155 Log-normal
HR compared with Warfarin: AF treated with NOACs ≤ 80 years (Sterne 201785) 0.820 0.615 1.025 0.155 Log-normal
HR compared with Warfarin: AF untreated (Sterne, 201785) 0.543 0.511 0.575 0.036 Log-normal
AF treated with Warfarin (Sterne, 201785) 0.066 0.050 0.083 0.008 59.710 844.987 Beta
No AF untreated (NHS Reference Costs98) 0.011 0.008 0.014 0.001 63.270 5573.516 Beta
Event rate: ICH
HR compared with Warfarin: AF treated with NOACs > 80 years (Sterne, 201785) 2.780 2.085 3.475 0.155 Log-normal
HR compared with Warfarin: AF treated with NOACs ≤ 80 years (Sterne, 201785) 0.460 0.345 0.575 0.155 Log-normal
AF treated with Warfarin (Sterne, 201785) 0.009 0.007 0.012 0.001 63.389 6680.122 Beta
HR compared with Warfarin:AF untreated (Sterne, 201785) 2.777 3.113 2.509 0.066 Log-normal
No AF untreated (NHS Reference Costs98) 0.000 0.000 0.000 0.000 63.979 195,185.287 Beta
AF untreated, female 50 years (Rothwell, 200590) 0.022 0.017 0.028 Binomial
AF untreated, female 60 years (Rothwell, 200590) 0.189 0.142 0.236 Binomial
AF untreated, female 70 years (Rothwell, 200590) 0.343 0.257 0.428 Binomial
AF untreated, female 80 years (Rothwell, 200590) 1.003 0.752 1.254 Binomial
AF untreated, female 90 years (Rothwell, 200590) 1.041 0.781 1.302 Binomial
AF untreated, male 50 years (Rothwell, 200590) 0.022 0.017 0.028 Binomial
AF untreated, male 60 years (Rothwell, 200590) 0.189 0.142 0.236 Binomial
AF untreated, male 70 years (Rothwell, 200590) 0.261 0.196 0.327 Binomial
AF untreated, male 80 years (Rothwell, 200590) 1.706 1.279 2.132 Binomial


















value LB UB SD Alpha Beta Distribution
Event rate: IS
HR compared with Warfarin:AF treated with NOACs > 80 years (Sterne, 201785) 0.740 0.555 0.925 0.155 Log-normal
HR compared with Warfarin: AF treated with NOACs ≤ 80 years (Sterne, 201785) 0.900 0.675 1.125 0.155 Log-normal
HR compared with Warfarin: AF untreated (Sterne, 201785) 2.777 3.113 2.509 0.066 Log-normal
AF untreated, female 50 years (PHE, 201888) 0.729 0.546 0.911 Binomial
AF untreated, female 60 years (PHE, 201888) 1.347 1.010 1.683 Binomial
AF untreated, female 70 years (PHE, 201888) 2.968 2.226 3.710 Binomial
AF untreated, female 80 years (PHE, 201888) 6.044 4.533 7.555 Binomial
AF untreated, female 90 years (PHE, 201888) 10.770 8.077 13.462 Binomial
AF untreated, male 50 years (PHE, 201888) 1.246 0.935 1.558 Binomial
AF untreated, male 60 years (PHE, 201888) 2.285 1.714 2.856 Binomial
AF untreated, male 70 years (PHE, 201888) 4.423 3.317 5.529 Binomial
AF untreated, male 80 years (PHE, 201888) 6.400 4.800 8.000 Binomial
AF untreated, male 90 years (PHE, 201888) 9.897 7.422 12.371 Binomial
Event rate: TIA
HR compared with Warfarin: AF treated with NOACs > 80 years (Sterne, 201785) 0.760 0.570 0.950 0.155 Log-normal
HR compared with Warfarin: AF treated with NOACs ≤ 80 years (Sterne, 201785) 0.740 0.555 0.925 0.155 Log-normal
HR compared with Warfarin: AF untreated (Sterne, 201785) 1.617 1.935 1.434 0.091 Log-normal
AF untreated, female 50 years (Rothwell, 200590) 0.287 0.215 0.359 Binomial
AF untreated, female 60 years (Rothwell, 200590) 1.098 0.824 1.373 Binomial
AF untreated, female 70 years (Rothwell, 200590) 2.213 1.660 2.766 Binomial
AF untreated, female 80 years (Rothwell, 200590) 5.706 4.279 7.132 Binomial
AF untreated, female 90 years (Rothwell, 200590) 9.321 6.991 11.651 Binomial
AF untreated, male 50 years (Rothwell, 200590) 0.165 0.124 0.207 Binomial










































































































































































value LB UB SD Alpha Beta Distribution
AF untreated, male 70 years (Rothwell, 200590) 1.359 1.019 1.699 Binomial
AF untreated, male 80 years (Rothwell, 200590) 3.389 2.542 4.236 Binomial
AF untreated, male 90 years (Rothwell, 200590) 8.041 6.031 10.051 Binomial
Event rate: stroke
AF treated with Warfarin (Sterne, 201785) 0.012 0.009 0.015 0.002 63.220 5205.113 Beta
AF untreated, female 65 years (Lowres, 201461) 0.026 0.019 0.032 0.003 62.317 2343.726 Beta
AF untreated, female 75 years (Lowres, 201461) 0.050 0.038 0.063 0.006 60.737 1149.163 Beta
AF untreated, male 65 years (Lowres, 201461) 0.019 0.014 0.024 0.002 62.746 3188.317 Beta
AF untreated, male 75 years (Lowres, 201461) 0.050 0.038 0.063 0.006 60.737 1149.163 Beta
Characteristics
Proportion of patients contraindicated for lead-I device use (%) 0.060 0.045 0.075 0.008 60.100 941.567 Beta
Cycle length 3.000 3.000 3.000 Fixed
Discount costs 0.035 0.000 0.060 Fixed
Discount benefits 0.035 0.000 0.060 Fixed
Include cost of extra anticoagulation discussion? No Yes Yes Fixed
Include cost of 12-lead device? Yes No Yes Fixed
Include cost of 12-lead test? Yes Yes Yes Fixed
Include cost of lead-I device Yes No Yes Fixed
Include dispensing cost? Yes No Yes Fixed
Use different NOAC dose and event rate for > 80 years? No No Yes Fixed
Number of lead-I ECG devices per practice 1.000 0.170 1.000 Fixed
Proportion of 12-lead ECGs interpreted by: cardiologist 0.100 0.000 0.200 0.050 3.500 31.500 Beta
Proportion of symptoms: angina pectoris symptoms 0.287 0.215 0.359 0.036 45.351 112.719 Beta
Proportion of symptoms: shortness of breath 0.618 0.463 0.772 0.077 23.846 14.755 Beta


















value LB UB SD Alpha Beta Distribution
Proportion of symptoms: fatigue 0.704 0.528 0.881 0.088 18.213 7.643 Beta
Proportion of lead-I tests interpreted by: cardiologist 0.100 0.000 0.200 0.050 3.500 31.500 Beta
AF prevalence by type: paroxysmal 1.000 0.000 1.000 Fixed
Proportion of lead-I negative or standard pathway patients given rate control (%) 0.000 0.000 0.000 Uniform
Cost per use: 12-lead 3.377 2.533 4.221 0.138 Log-normal
Sensitivity: algorithm #N/A #N/A #N/A #N/A #N/A #N/A Beta
Sensitivity 0.939 0.862 0.974 0.028 67.664 4.396 Beta
Specificity: algorithm #N/A #N/A #N/A #N/A #N/A #N/A Beta
Specificity 0.965 0.904 0.988 0.021 72.942 2.646 Beta
Proportion female (%) 0.516 0.258 0.775 0.129 7.221 6.761 Beta
Proportion of symptoms: Other symptoms 0.517 0.388 0.647 0.065 30.374 28.340 Beta
Mean GPs per practice 5.898 5.805 5.991 Fixed
Mean GP list size 8187.121 1591.795 1630.954 Fixed
Proportion of untreated lead-I positive patients given rate control (%) 1.000 1.000 1.000 Fixed
Utility: symptom decrements
Bleed 0.000 0.000 0.000 Log-normal
HS 0.272 0.345 0.198 0.169 Log-normal
IS 0.272 0.345 0.198 0.169 Log-normal










































































































































































value LB UB SD Alpha Beta Distribution
Costs
Bleed 704.049 592.435 782.475 0.085 Log-normal
TIA 729.616 570.081 837.648 0.117 Log-normal
IS: 1-year cost 15,387.635 11,540.727 17,695.781 0.130 Log-normal
IS: 5-year cost 31,315.530 23,486.647 36,012.859 0.130 Log-normal
HS: 1-year cost 17,833.307 13,374.980 20,508.303 0.130 Log-normal
HS: 5-year cost 37,907.660 28,430.745 43,593.809 0.130 Log-normal
AF occurrence
AF prevalence: female (%) 0.034 0.026 0.043 0.004 61.774 1741.839 Beta
AF prevalence: male (%) 0.067 0.050 0.083 0.008 59.659 833.711 Beta
AF undiagnosed: female (%) 0.157 0.118 0.196 0.020 53.795 288.848 Beta
AF undiagnosed: male (%) 0.120 0.090 0.150 0.015 56.200 412.133 Beta
AF symptomatic: female (%) 0.679 0.509 0.849 0.085 19.865 9.391 Beta
AF symptomatic: male (%) 0.575 0.431 0.719 0.072 26.625 19.679 Beta
Symptomatic with AF: female (%) 0.200 0.150 0.250 0.025 51.000 204.000 Beta
Symptomatic with AF: male (%) 0.200 0.150 0.250 0.025 51.000 204.000 Beta
AF patients with CHA2DS2-VASc ≥ 2 (%) 0.824 0.618 1.000 0.096 12.278 2.624 Beta
AF patients with CHA2DS2-VASc ≥ 2 on OACs (%) 0.812 0.609 1.000 0.098 12.157 2.821 Beta
Treatment characteristics
OACs that are NOACs (%) 1.000 1.000 1.000 Fixed
Time taken to administer lead-I test 0.000 0.000 7.000 Fixed
Standard pathway patients who have 12-lead (%) 1.000 0.500 1.000 Fixed
Patients with paroxysmal AF NOT in AF at 12-lead (%) 0.475 0.356 0.594 0.059 33.125 36.612 Beta
Lead-I positive patients who have 12-lead (%) 1.000 0.000 1.000 Fixed


















value LB UB SD Alpha Beta Distribution
AF diagnosed after MPP only (standard pathway) -> negative 12-lead (%) 0.000 0.000 1.000 Fixed
AF ruled out after MPP only (standard pathway) -> negative 12-lead (%) 0.500 0.000 1.000 Fixed
Patients sent for paroxysmal testing after MPP only (standard pathway) -> negative 12-lead (%) 0.500 0.000 1.000 Fixed
AF diagnosed after MPP only (standard pathway) (no 12-lead) (%) 0.000 0.000 1.000 Fixed
AF ruled out after MPP only (standard pathway) (no 12-lead) (%) 0.500 0.000 1.000 Fixed
Patients sent for paroxysmal testing after MPP only (standard pathway) (no 12-lead) (%) 0.500 0.000 1.000 Fixed
AF diagnosed after negative lead-I -> negative 12-lead (%) 0.000 0.000 1.000 Fixed
AF ruled out after negative lead-I -> negative 12-lead (%) 0.500 0.000 1.000 Fixed
Patients sent for paroxysmal testing after negative lead-I -> negative 12-lead (%) 0.500 0.000 1.000 Fixed
AF diagnosed after negative lead-I (no 12-lead) (%) 0.000 0.000 1.000 Fixed
AF ruled out after negative lead-I (no 12-lead) (%) 0.500 0.000 1.000 Fixed
Patients sent for paroxysmal testing after negative lead-I (no 12-lead) (%) 0.500 0.000 1.000 Fixed
AF diagnosed after positive lead-I -> negative 12-lead (%) 0.500 0.000 1.000 Fixed
AF ruled out after positive lead-I -> negative 12-lead (%) 0.000 0.000 1.000 Fixed
Patients sent for paroxysmal testing after positive lead-I -> negative 12-lead (%) 0.500 0.000 1.000 Fixed
AF diagnosed after positive lead-I (no 12-lead) (%) 0.000 0.000 1.000 Fixed
AF ruled out after positive lead-I (no 12-lead) (%) 0.500 0.000 0.000 Fixed
Patients sent for paroxysmal testing after positive lead-I (no 12-lead) (%) 0.500 0.000 1.000 Fixed
Patients with paroxysmal AF NOT in AF at paroxysmal test (%) 0.300 0.225 0.375 0.038 44.500 103.833 Beta
AF diagnosed after MPP & negative 12-lead & negative paroxysmal test (%) 0.000 0.000 1.000 Fixed
AF ruled out after MPP & negative 12-lead & negative paroxysmal test (%) 1.000 Fixed
AF diagnosed after negative lead-I & negative 12-lead & negative paroxysmal test (%) 0.000 0.000 1.000 Fixed
AF ruled out after negative lead-I & negative 12-lead & negative paroxysmal test (%) 1.000 Fixed
AF diagnosed after positive lead-I & negative 12-lead & negative paroxysmal test (%) 1.000 0.000 1.000 Fixed










































































































































































value LB UB SD Alpha Beta Distribution
Risk ratio for mortality
Previous CVE: AF, NOAC 2.600 2.600 2.600 Fixed
Previous CVE: AF, Warfarin 2.600 2.600 2.600 Fixed
Previous CVE: AF, untreated 2.600 2.600 2.600 Fixed
Previous CVE: no AF 2.600 2.600 2.600 Fixed
Proportion of subsequent stroke types (%)
HS 0.057 0.042 0.071 0.007 60.324 1006.196 Dirichlet
IS 0.640 0.626 0.654 0.007 2949.534 1657.159 Dirichlet
TIA 0.303 0.289 0.317 0.007 1280.959 2944.294 Dirichlet
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